<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36321381</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0463</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>APMIS : acta pathologica, microbiologica, et immunologica Scandinavica</Title><ISOAbbreviation>APMIS</ISOAbbreviation></Journal><ArticleTitle>Altered Gut Microbiota in Hepatocellular Carcinoma: Insights into the Pathogenic Mechanism and Preclinical to Clinical Findings.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/apm.13282</ELocationID><Abstract><AbstractText>Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. It is usually the result of pre-existing liver damage caused by hepatitis B and/or C virus infection, alcohol consumption, non-alcoholic steatohepatitis (NASH), aflatoxin exposure, liver cirrhosis, obesity, and diabetes. A growing body of evidence suggests that gut microbes have a role in cancer genesis. More research into the microbiome gut-liver axis has recently contributed to understanding how the gut microbiome facilitates liver disease or even HCC progression. This review focuses on the preclinical results of gut-related hepatocarcinogenesis and probiotics, prebiotics, and antibiotics as therapeutic interventions to maintain gut microbial flora and minimize HCC-associated symptoms. Understanding the mechanistic link between the gut microbiota, host, and cancer progression could aid us in elucidating the cancer-related pathways and drive us toward preventing HCC-associated gut microbiota dysbiosis.</AbstractText><CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Bhrigu Kumar</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Girijananda Chowdhury Institute of Pharmaceutical Science (Assam Science and Technology University), Azara, Guwahati, 781 017, Assam, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>APMIS</MedlineTA><NlmUniqueID>8803400</NlmUniqueID><ISSNLinking>0903-4641</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hepatocellular carcinoma</Keyword><Keyword MajorTopicYN="N">dysbiosis</Keyword><Keyword MajorTopicYN="N">gut microbiome</Keyword><Keyword MajorTopicYN="N">gut-liver axis</Keyword><Keyword MajorTopicYN="N">human microbiome</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321381</ArticleId><ArticleId IdType="doi">10.1111/apm.13282</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321379</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2474-9842</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>11</Month><Day>02</Day></PubDate></JournalIssue><Title>BJS open</Title><ISOAbbreviation>BJS Open</ISOAbbreviation></Journal><ArticleTitle>Impact of long-course neoadjuvant radiation on postoperative low anterior resection syndrome and stoma status in rectal cancer: long-term functional follow-up of a randomized clinical trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">zrac127</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/bjsopen/zrac127</ELocationID><Abstract><AbstractText Label="BACKGROUND">Neoadjuvant radiation has been increasingly associated with postoperative bowel dysfunction, including low anterior resection syndrome (LARS). Although permanent stoma often results from severe bowel dysfunction and significantly impacts quality of life, the presence of stoma paradoxically excludes patients from functional follow-up. Hence, stoma status is rarely reported along with LARS, while assessment of both is essential for the comprehensive evaluation of bowel dysfunction in long-term survivors of rectal cancer.</AbstractText><AbstractText Label="METHOD">Patients enrolled into the Neoadjuvant FOLFOX6 Chemotherapy with or without Radiation in Rectal Cancer (FOWARC) multicentre randomized clinical trial were randomized to receive long-course neoadjuvant chemoradiotherapy (nCRT) or chemotherapy (nCT) followed by sphincter-saving proctectomy and longitudinal follow-up. The primary outcome of the trial was disease-free survival. LARS score and stoma status were assessed secondarily for postoperative bowel function in the largest single-centre cohort of the trial.</AbstractText><AbstractText Label="RESULTS">Overall, 327 patients with locally advanced rectal cancer were enrolled in the original trial and 203 responded after a median follow-up of 83.4 months, of whom 24 (11.8 per cent) had persistent stoma, and 48 patients (23.6 per cent) reported major LARS. Compared with the nCT group, the nCRT group reported more persistent stomas (16.5 per cent versus 4.9 per cent, P = 0.014), and more major LARS in patients without persistent stoma (34.7 per cent versus 16.7 per cent, P = 0.003). The combined prevalence of persistent stoma and major LARS was significantly higher in the nCRT group (45.5 per cent versus 20.7 per cent, P &lt; 0.001). Long-course neoadjuvant radiation (OR 2.20, 95 per cent c.i. 1.10 to 4.40, P = 0.027), height of anastomosis (OR 0.74, 95 per cent c.i. 0.61 to 0.91, P = 0.004), and anastomotic leak (OR 4.97, 95 per cent c.i. 2.24 to 11.05, P &lt; 0.001) were associated with persistent stoma and major LARS in multivariate analysis.</AbstractText><AbstractText Label="CONCLUSION">More than one-third of patients receiving sphincter-saving proctectomy reported major LARS or persistent stoma at long-term follow-up. Long-course neoadjuvant radiation, low anastomosis, and postoperative leak are independent risk factors for persistent stoma and major LARS.</AbstractText><CopyrightInformation>© The Author(s) 2022. Published by Oxford University Press on behalf of BJS Society Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Siqi</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8285-7715</Identifier><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, P. R. China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jinquan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Runxian</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pelvic Floor Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Lishuo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Research Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Donglin</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Pelvic Floor Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jianping</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Yanhong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dou</LastName><ForeName>Ruoxu</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, P. R. China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BJS Open</MedlineTA><NlmUniqueID>101722685</NlmUniqueID><ISSNLinking>2474-9842</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012007" MajorTopicYN="N">Rectum</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>08</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321379</ArticleId><ArticleId IdType="pii">6793731</ArticleId><ArticleId IdType="doi">10.1093/bjsopen/zrac127</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36321378</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2184</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Cell proliferation</Title><ISOAbbreviation>Cell Prolif</ISOAbbreviation></Journal><ArticleTitle>A NR2E1-interacting peptide of LSD1 inhibits the proliferation of brain tumour initiating cells.</ArticleTitle><Pagination><MedlinePgn>e13350</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/cpr.13350</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Elimination of brain tumour initiating cells (BTICs) is important for the good prognosis of malignant brain tumour treatment. To develop a novel strategy targeting BTICs, we studied NR2E1(TLX) involved self-renewal mechanism of BTICs and explored the intervention means.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">NR2E1 and its interacting protein-LSD1 in BTICs were studied by gene interference combined with cell growth, tumour sphere formation, co-immunoprecipitation and chromatin immunoprecipitation assays. NR2E1 interacting peptide of LSD1 was identified by Amide Hydrogen/Deuterium Exchange and Mass Spectrometry (HDX-MS) and analysed by in vitro functional assays. The in vivo function of the peptide was examined with intracranial mouse model by transplanting patient-derived BTICs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found NR2E1 recruits LSD1, a lysine demethylase, to demethylate mono- and di-methylated histone 3 Lys4 (H3K4me/me2) at the Pten promoter and repress its expression, thereby promoting BTIC proliferation. Using Amide Hydrogen/Deuterium Exchange and Mass Spectrometry (HDX-MS) method, we identified four LSD1 peptides that may interact with NR2E1. One of the peptides, LSD1-197-211 that locates at the LSD1 SWIRM domain, strongly inhibited BTIC proliferation by promoting Pten expression through interfering NR2E1 and LSD1 function. Furthermore, overexpression of this peptide in human BTICs can inhibit intracranial tumour formation.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Peptide LSD1-197-211 can repress BTICs by interfering the synergistic function of NR2E1 and LSD1 and may be a promising lead peptide for brain tumour therapy in future.</AbstractText><CopyrightInformation>© 2022 The Authors. Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Rong</ForeName><Initials>R</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-2352-2744</Identifier><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hameed</LastName><ForeName>Umar Farook Shahul</ForeName><Initials>UFS</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Stem Cell Biology and Tissue Engineering, Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moorthy</LastName><ForeName>Balakrishnan Shenbaga</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeffrey</LastName><ForeName>Philip D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Fangjin</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Center for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pei</LastName><ForeName>Jianfeng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giri</LastName><ForeName>Pankaj K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Faculty of Life Sciences and Biotechnology, South Asian University, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mou</LastName><ForeName>Yonggao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery/Neuro-oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swaminathan</LastName><ForeName>Kunchithapadam</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Ping</ForeName><Initials>P</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-7243-3487</Identifier><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81773156</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>81872324</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><Agency>Ministry of Education of Singapore Academic Research Fund</Agency><Country/></Grant><Grant><Agency>German Cancer Research Center</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cell Prolif</MedlineTA><NlmUniqueID>9105195</NlmUniqueID><ISSNLinking>0960-7722</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>09</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>4</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321378</ArticleId><ArticleId IdType="doi">10.1111/cpr.13350</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Mrugala MM. Advances and challenges in the treatment of glioblastoma: a clinician's perspective. Discov Med. 2013;15(83):221-230.</Citation></Reference><Reference><Citation>Houshyari M, Hajalikhani F, Rakhsha A, Hajian P. A comparative study of survival rate in high grade glioma tumors being treated by radiotherapy alone versus chemoradiation with nitrosourea. Global J Health Sci. 2015;7(6):43702.</Citation></Reference><Reference><Citation>Zhu Z, Khan MA, Weiler M, et al. Targeting self-renewal in high-grade brain tumors leads to loss of brain tumor stem cells and prolonged survival. Cell Stem Cell. 2014;15(2):185-198.</Citation></Reference><Reference><Citation>Lin S, Shen H, Li JL, et al. Proteomic and functional analyses reveal the role of chromatin reader SFMBT1 in regulating epigenetic silencing and the myogenic gene program. J Biol Chem. 2013;288(9):6238-6247.</Citation></Reference><Reference><Citation>Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18):5821-5828.</Citation></Reference><Reference><Citation>Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396-401.</Citation></Reference><Reference><Citation>Venkataramani V, Yang Y, Schubert MC, et al. Glioblastoma hijacks neuronal mechanisms for brain invasion. Cell. 2022;185(16):2899-2917 e2831.</Citation></Reference><Reference><Citation>Chen J, Li Y, Yu TS, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012;488(7412):522-526.</Citation></Reference><Reference><Citation>Shi Y, Chichung Lie D, Taupin P, et al. Expression and function of orphan nuclear receptor TLX in adult neural stem cells. Nature. 2004;427(6969):78-83.</Citation></Reference><Reference><Citation>Yokoyama A, Takezawa S, Schule R, Kitagawa H, Kato S. Transrepressive function of TLX requires the histone demethylase LSD1. Mol Cell Biol. 2008;28(12):3995-4003.</Citation></Reference><Reference><Citation>Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119(7):941-953.</Citation></Reference><Reference><Citation>Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol. 2006;13(6):563-567.</Citation></Reference><Reference><Citation>Metzger E, Wissmann M, Yin N, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005;437(7057):436-439.</Citation></Reference><Reference><Citation>Shi YJ, Matson C, Lan F, Iwase S, Baba T, Shi Y. Regulation of LSD1 histone demethylase activity by its associated factors. Mol Cell. 2005;19(6):857-864.</Citation></Reference><Reference><Citation>Singh MM, Manton CA, Bhat KP, et al. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. Neuro Oncol. 2011;13(8):894-903.</Citation></Reference><Reference><Citation>Li P, Ma X, Adams IR, Yuan P. A tight control of Rif1 by Oct4 and Smad3 is critical for mouse embryonic stem cell stability. Cell Death Dis. 2015;6:e1588.</Citation></Reference><Reference><Citation>Li P, Chen Y, Meng X, et al. Suppression of malignancy by Smad3 in mouse embryonic stem cell formed teratoma. Stem Cell Rev. 2013;9(5):709-720.</Citation></Reference><Reference><Citation>Sun G, Alzayady K, Stewart R, et al. Histone demethylase LSD1 regulates neural stem cell proliferation. Mol Cell Biol. 2010;30(8):1997-2005.</Citation></Reference><Reference><Citation>Li P, Chen Y, Mak KK, Wong CK, Wang CC, Yuan P. Functional role of mst1/mst2 in embryonic stem cell differentiation. PLoS One. 2013;8(11):e79867.</Citation></Reference><Reference><Citation>Steinschneider A, Santos V. Parental reports of apnea and bradycardia: temporal characteristics and accuracy. Pediatrics. 1991;88(6):1100-1105.</Citation></Reference><Reference><Citation>Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009;347(1-2):70-78.</Citation></Reference><Reference><Citation>Zhang S, Zhao BS, Zhou A, et al. m(6)A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. Cancer Cell. 2017;31(4):591-606 e596.</Citation></Reference><Reference><Citation>Mandell JG, Falick AM, Komives EA. Measurement of amide hydrogen exchange by MALDI-TOF mass spectrometry. Anal Chem. 1998;70(19):3987-3995.</Citation></Reference><Reference><Citation>Yuan P, Jedd G, Kumaran D, et al. A HEX-1 crystal lattice required for Woronin body function in Neurospora crassa. Nat Struct Biol. 2003;10(4):264-270.</Citation></Reference><Reference><Citation>Brunger AT, Adams PD, Clore GM, et al. Crystallography &amp; NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr. 1998;54(Pt 5):905-921.</Citation></Reference><Reference><Citation>Chen R, Li L, Weng Z. ZDOCK: an initial-stage protein-docking algorithm. Proteins. 2003;52(1):80-87.</Citation></Reference><Reference><Citation>Feig M, Karanicolas J, Brooks CL 3rd. MMTSB tool set: enhanced sampling and multiscale modeling methods for applications in structural biology. J Mol Graph Model. 2004;22(5):377-395.</Citation></Reference><Reference><Citation>Hubbard SJ, Thornton JM. NACCESS, Computer Program. Department of Biochemistry Molecular Biology, University College London; 1993.</Citation></Reference><Reference><Citation>Zhi X, Zhou XE, He Y, et al. Structural basis for corepressor assembly by the orphan nuclear receptor TLX. Genes Dev. 2015;29(4):440-450.</Citation></Reference><Reference><Citation>Da G, Lenkart J, Zhao K, Shiekhattar R, Cairns BR, Marmorstein R. Structure and function of the SWIRM domain, a conserved protein module found in chromatin regulatory complexes. Proc Natl Acad Sci U S A. 2006;103(7):2057-2062.</Citation></Reference><Reference><Citation>Chen Y, Yang Y, Wang F, et al. Crystal structure of human histone lysine-specific demethylase 1 (LSD1). Proc Natl Acad Sci U S A. 2006;103(38):13956-13961.</Citation></Reference><Reference><Citation>Zhang M, Song T, Yang L, et al. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res. 2008;27:85.</Citation></Reference><Reference><Citation>Yang XR, Xu Y, Yu B, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut. 2010;59(7):953-962.</Citation></Reference><Reference><Citation>Sun JC, Pan K, Chen MS, et al. Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells. Cancer Biol Ther. 2010;10(4):368-375.</Citation></Reference><Reference><Citation>Song Y, Pan G, Chen L, et al. Loss of ATOH8 increases stem cell features of hepatocellular carcinoma cells. Gastroenterology. 2015;149(4):1068-1081 e1065.</Citation></Reference><Reference><Citation>Weller M, Gorlia T, Cairncross JG, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 2011;77(12):1156-1164.</Citation></Reference><Reference><Citation>Thotala D, Karvas RM, Engelbach JA, et al. Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells. Oncotarget. 2015;6:35004-35022.</Citation></Reference><Reference><Citation>Kashyap V, Ahmad S, Nilsson EM, et al. The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer. Mol Oncol. 2013;7(3):555-566.</Citation></Reference><Reference><Citation>Liang Y, Quenelle D, Vogel JL, Mascaro C, Ortega A, Kristie TM. A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. MBio. 2013;4(1):e00558-e00512.</Citation></Reference><Reference><Citation>Lynch JT, Harris WJ, Somervaille TC. LSD1 inhibition: a therapeutic strategy in cancer? Expert Opin Ther Targets. 2012;16(12):1239-1249.</Citation></Reference><Reference><Citation>Schenk T, Chen WC, Gollner S, et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med. 2012;18(4):605-611.</Citation></Reference><Reference><Citation>Willmann D, Lim S, Wetzel S, et al. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Int J Cancer. 2012;131(11):2704-2709.</Citation></Reference><Reference><Citation>Schmidt DM, McCafferty DG. Trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry. 2007;46(14):4408-4416.</Citation></Reference><Reference><Citation>Tortorici M, Borrello MT, Tardugno M, et al. Protein recognition by short peptide reversible inhibitors of the chromatin-modifying LSD1/CoREST lysine demethylase. ACS Chem Biol. 2013;8(8):1677-1682.</Citation></Reference><Reference><Citation>Baron R, Vellore NA. LSD1/CoREST is an allosteric nanoscale clamp regulated by H3-histone-tail molecular recognition. Proc Natl Acad Sci U S A. 2012;109(31):12509-12514.</Citation></Reference><Reference><Citation>Guidotti G, Brambilla L, Rossi D. Peptides in clinical development for the treatment of brain tumors. Curr Opin Pharmacol. 2019;47:102-109.</Citation></Reference><Reference><Citation>Ueda Y, Wei FY, Hide T, et al. Induction of autophagic cell death of glioma-initiating cells by cell-penetrating D-isomer peptides consisting of Pas and the p53 C-terminus. Biomaterials. 2012;33(35):9061-9069.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36321363</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1789</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Neuropathology : official journal of the Japanese Society of Neuropathology</Title><ISOAbbreviation>Neuropathology</ISOAbbreviation></Journal><ArticleTitle>Severe cerebrovascular pathology of the first supercentenarian to be autopsied in the world.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/neup.12874</ELocationID><Abstract><AbstractText>We report on a 116-year-old Japanese woman who was the first officially documented supercentenarian to be autopsied in the world. She lived a remarkably healthy life until suffering cerebral infarction at 109 years of age. She became Japan's oldest person at 113 years and died in 1995 from colon cancer at 116 years 175 days. Her medical records show the delayed onset of stroke, cancer, dementia, and heart disease and the importance of appropriate medical treatment and intensive dedicated care provided during the last stage of her life. She was the longest-lived person in Japan for 21 years from 1993 until 2014. The neuropathological findings of her autopsied brain were briefly reported in the Japanese literature in 1997. In this study, we reinvestigated her brain and spinal cord in more detail. Severe cerebrovascular lesions and cervical spondylotic myelopathy were found to be the main causes of her disability. Although the density of senile plaques was relatively high, the distribution of neurofibrillary tangles was limited. Ghost tangles and argyrophilic grains were mild. The mildness of tau pathological changes in her neurons, in other words the resistance of neurons to tau pathology, may be a factor responsible for her longevity.</AbstractText><CopyrightInformation>© 2022 Japanese Society of Neuropathology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iwase</LastName><ForeName>Tamaki</ForeName><Initials>T</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-0797-4129</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Nagoya City Koseiin Medical Welfare Center, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Mari</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-8520-6184</Identifier><AffiliationInfo><Affiliation>Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashizume</LastName><ForeName>Yoshio</ForeName><Initials>Y</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-8389-5860</Identifier><AffiliationInfo><Affiliation>Institute for Neuropathology, Fukushimura Hospital, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inagaki</LastName><ForeName>Toshiaki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation, Tosei General Hospital, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwasaki</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-0059-3104</Identifier><AffiliationInfo><Affiliation>Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JP19dm0107105</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country/></Grant><Grant><GrantID>JP20dm0107105</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country/></Grant><Grant><GrantID>JP20ek0109391</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country/></Grant><Grant><GrantID>JP20ek0109392</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country/></Grant><Grant><GrantID>the Research Committee of CNS Degenerative Disease</GrantID><Agency>Ministry of Health, Labour and Welfare</Agency><Country/></Grant><Grant><GrantID>Intramural Research Grant (30-8) for the Neurologi</GrantID><Agency>National Center of Neurology and Psychiatry</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Neuropathology</MedlineTA><NlmUniqueID>9606526</NlmUniqueID><ISSNLinking>0919-6544</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">centenarians</Keyword><Keyword MajorTopicYN="N">myelopathy</Keyword><Keyword MajorTopicYN="N">tauopathy</Keyword><Keyword MajorTopicYN="N">vascular dementia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>4</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321363</ArticleId><ArticleId IdType="doi">10.1111/neup.12874</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Dong X, Milholland B, Vijg J. Evidence for a limit to human lifespan. Nature 2016; 538: 257-259.</Citation></Reference><Reference><Citation>Inagaki T, Imaida K, Niimi T, Yamamoto T, Shinagawa N. An autopsy case report on clinical and pathological findings of the oldest 116-year-old woman in present Japan (in Japanese). In: Tauchi H, Sato T, Watanabe T, (eds). Nippon no Hyakujusha. Centenarians in Japan. Tokyo: Nakayama Shoten, 1997; 296-304.</Citation></Reference><Reference><Citation>Robine JM, Allard M. The oldest human. Science 1998; 279: 1834-1835.</Citation></Reference><Reference><Citation>Inagaki T, Yamamoto T, Niimi T et al. A 115-year-old woman: The oldest individual in Japan (in Japanese with English abstract). Nihon Ronen Igakkai Zasshi Jpn J Geriatr 1995; 32: 172-177.</Citation></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: A practical approach. Acta Neuropathol 2012; 123: 1-11.</Citation></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012; 8: 1-13.</Citation></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.</Citation></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-486.</Citation></Reference><Reference><Citation>Thal DR, Rüb U, Orantes M, Braak H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-1800.</Citation></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112: 389-404.</Citation></Reference><Reference><Citation>Saito Y, Ruberu NN, Sawabe M et al. Staging of argyrophilic grains: An age-associated tauopathy. J Neuropathol Exp Neurol 2004; 63: 911-918.</Citation></Reference><Reference><Citation>Kovacs GG, Ferrer I, Grinberg LT et al. Aging-related tau astrogliopathy (ARTAG): Harmonized evaluation strategy. Acta Neuropathol 2016; 131: 87-102.</Citation></Reference><Reference><Citation>Nelson PT, Trojanowski JQ, Abner EL et al. New old pathologies: AD, PART, and cerebral age-related TDP-43 with sclerosis (CARTS). J Neuropathol Exp Neurol 2016; 75: 482-498.</Citation></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): Consensus working group report. Brain 2019; 142: 1503-1527.</Citation></Reference><Reference><Citation>Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP Jr. Cerebral amyloid angiopathy without and with cerebral hemorrhages: A comparative histological study. Ann Neurol 1991; 30: 637-639.</Citation></Reference><Reference><Citation>Fries JF. Aging, natural death, and the compression of morbidity. N Engl J Med 1980; 303: 130-135.</Citation></Reference><Reference><Citation>Andersen SL, Sebastiani P, Dworkis DA, Feldman L, Perls T. Health span approximates life span among many supercentenarians: Compression of morbidity at the approximate limit of life span. J Gerontol A Biol Sci Med Sci 2012; 67: 395-405.</Citation></Reference><Reference><Citation>Sebastiani P, Perls TT. The genetics of extreme longevity: Lessons from the new England centenarian study. Front Genet 2012; 3: 277.</Citation></Reference><Reference><Citation>Maeda K. Older persons in a special elderly nursing home (in Japanese). Koshu Eisei J Public Health Pract 1972; 36: 173-177.</Citation></Reference><Reference><Citation>Walker JM, Richardson TE, Farrell K et al. Early selective vulnerability of the CA2 hippocampal subfield in primary age-related tauopathy. J Neuropathol Exp Neurol 2021; 80: 102-111.</Citation></Reference><Reference><Citation>Braak H, Braak E. Argyrophilic grain disease: Frequency of occurrence in different age categories and neuropathological diagnostic criteria. J Neural Transm 1998; 105: 801-819.</Citation></Reference><Reference><Citation>Yamada M. Senile dementia of the neurofibrillary tangle type (tangle-only dementia): Neuropathological criteria and clinical guidelines for diagnosis. Neuropathology 2003; 23: 311-317.</Citation></Reference><Reference><Citation>Jellinger KA, Attems J. Neurofibrillary tangle-predominant dementia: Comparison with classical Alzheimer disease. Acta Neuropathol 2007; 113: 107-117.</Citation></Reference><Reference><Citation>Crary JF, Trojanowski JQ, Schneider JA et al. Primary age-related tauopathy (PART): A common pathology associated with human aging. Acta Neuropathol 2014; 128: 755-766.</Citation></Reference><Reference><Citation>Braak H, Del Tredici K, Schultz C, Braak E. Vulnerability of select neuronal types to Alzheimer's disease. Ann N Y Acad Sci 2000; 924: 53-61.</Citation></Reference><Reference><Citation>Braak H, Rüb U, Schultz C, Del Tredici K. Vulnerability of cortical neurons to Alzheimer's and Parkinson's diseases. J Alzheimers Dis 2006; 9: 35-44.</Citation></Reference><Reference><Citation>Kovacs GG, Xie SX, Robinson JL et al. Sequential stages and distribution patterns of aging-related tau astrogliopathy (ARTAG) in the human brain. Acta Neuropathol Commun 2018; 6: 50.</Citation></Reference><Reference><Citation>Kovacs GG. Astroglia and tau: New perspectives. Front Aging Neurosci 2020; 12: 96.</Citation></Reference><Reference><Citation>Tomé SO, Vandenberghe R, Ospitalieri S et al. Distinct molecular patterns of TDP-43 pathology in Alzheimer's disease: Relationship with clinical phenotypes. Acta Neuropathol Commun 2020; 8: 61.</Citation></Reference><Reference><Citation>Kadokura A, Yamazaki T, Kakuda S et al. Phosphorylation-dependent TDP-43 antibody detects intraneuronal dot-like structures showing morphological characters of granulovacuolar degeneration. Neurosci Lett 2009; 463: 87-92.</Citation></Reference><Reference><Citation>Thal DR, Del Tredici K, Ludolph AC et al. Stages of granulovacuolar degeneration: Their relation to Alzheimer's disease and chronic stress response. Acta Neuropathol 2011; 122: 577-589.</Citation></Reference><Reference><Citation>Amador-Ortiz C, Lin WL, Ahmed Z et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol 2007; 61: 435-445.</Citation></Reference><Reference><Citation>Josephs KA, Murray ME, Whitwell JL et al. Updated TDP-43 in Alzheimer's disease staging scheme. Acta Neuropathol 2016; 131: 571-585.</Citation></Reference><Reference><Citation>Fujishiro H, Uchikado H, Arai T et al. Accumulation of phosphorylated TDP-43 in brains of patients with argyrophilic grain disease. Acta Neuropathol 2009; 117: 151-158.</Citation></Reference><Reference><Citation>Yokota O, Davidson Y, Bigio EH et al. Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. Acta Neuropathol 2010; 120: 55-66.</Citation></Reference><Reference><Citation>Uryu K, Nakashima-Yasuda H, Forman MS et al. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 2008; 67: 555-564.</Citation></Reference><Reference><Citation>Nakashima-Yasuda H, Uryu K, Robinson J et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 2007; 114: 221-229.</Citation></Reference><Reference><Citation>Freis ED, Wanko A, Wilson IM, Parrish AE. Treatment of essential hypertension with chlorothiazide (Diuril). JAMA 1958; 166: 137-140.</Citation></Reference><Reference><Citation>Veterans administration cooperative study group on antihypertensive agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967; 202: 1028-1034.</Citation></Reference><Reference><Citation>Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-1898.</Citation></Reference><Reference><Citation>Takao M, Hirose N, Arai Y, Mihara B, Mimura M. Neuropathology of supercentenarians - four autopsy case studies. Acta Neuropathol Commun 2016; 4: 97.</Citation></Reference><Reference><Citation>Wang Y, Hashizume Y, Yoshida M, Inagaki T, Kameyama T. Pathological changes of the spinal cord in centenarians. Pathol Int 1999; 49: 118-124.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36321342</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2005-6648</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>The Korean journal of internal medicine</Title><ISOAbbreviation>Korean J Intern Med</ISOAbbreviation></Journal><ArticleTitle>Stumbling across transthyretin amyloid cardiomyopathy during diagnostic work-up forstomach cancer.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.3904/kjim.2022.280</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hyun-Ki</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Yun-Seok</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Eun Ji</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine, Department of Radiology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>Yeoun Eun</ForeName><Initials>YE</Initials><AffiliationInfo><Affiliation>Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Youn</LastName><ForeName>Jong-Chan</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Korean J Intern Med</MedlineTA><NlmUniqueID>8712418</NlmUniqueID><ISSNLinking>1226-3303</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>09</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321342</ArticleId><ArticleId IdType="pii">kjim.2022.280</ArticleId><ArticleId IdType="doi">10.3904/kjim.2022.280</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321336</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2001-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Clinical and translational medicine</Title><ISOAbbreviation>Clin Transl Med</ISOAbbreviation></Journal><ArticleTitle>RNASeq profiling of COVID19-infected patients identified an EIF2AK2 inhibitor as a potent SARS-CoV-2 antiviral.</ArticleTitle><Pagination><MedlinePgn>e1098</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ctm2.1098</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Sidharth</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, District of Columbia, 20057, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Georgetown College, Georgetown University, Washington DC, District of Columbia, 20057, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rego</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Georgetown College, Georgetown University, Washington DC, District of Columbia, 20057, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Discovery and Innovation, Hackensack Meridian Health, New Jersey, 07110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yiran</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biochemistry &amp; Molecular Biology, Georgetown University Medical Center, Washington DC, District of Columbia, 20057, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parn</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>College of Arts &amp; Science, University of the District of Columbia, Washington DC, District of Columbia, 20008, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savsani</LastName><ForeName>Kush</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>College of Humanities and Sciences, Virginia Commonwealth University, Richmond, Virginia, 23284, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perlin</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Center for Discovery and Innovation, Hackensack Meridian Health, New Jersey, 07110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dakshanamurthy</LastName><ForeName>Sivanesan</ForeName><Initials>S</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-3681-4121</Identifier><AffiliationInfo><Affiliation>Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, District of Columbia, 20057, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Transl Med</MedlineTA><NlmUniqueID>101597971</NlmUniqueID><ISSNLinking>2001-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C000602769">EIF2AK2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D019892">eIF-2 Kinase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019892" MajorTopicYN="N">eIF-2 Kinase</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321336</ArticleId><ArticleId IdType="doi">10.1002/ctm2.1098</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36321332</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-4095</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Advanced materials (Deerfield Beach, Fla.)</Title><ISOAbbreviation>Adv Mater</ISOAbbreviation></Journal><ArticleTitle>Actively-Triggerable Metals via Liquid Metal Embrittlement for Biomedical Applications.</ArticleTitle><Pagination><MedlinePgn>e2208227</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/adma.202208227</ELocationID><Abstract><AbstractText>Actively-triggerable materials, which break down upon introduction of an exogenous stimulus, enable precise control over the lifetime of biomedical technologies as well as adaptation to unforeseen circumstances, such as changes to an established treatment plan. Yet most actively-triggerable materials are low-strength polymers and hydrogels with limited long-term durability. By contrast, metals possess advantageous functional properties, including high mechanical strength and conductivity, that are desirable across several applications within biomedicine. To realize actively-triggerable metals, we leveraged a mechanism called liquid metal embrittlement, in which certain liquid metals penetrate the grain boundaries of certain solid metals and cause them to dramatically weaken or disintegrate. In this work, we demonstrate that eutectic gallium indium (EGaIn), a biocompatible alloy of gallium, can be formulated to reproducibly trigger the breakdown of aluminum within different physiologically-relevant environments. The breakdown behavior of aluminum after triggering can further be readily controlled by manipulating its grain structure. Finally, we demonstrate three possible use cases of biomedical devices constructed from actively-triggerable metals. This article is protected by copyright. All rights reserved.</AbstractText><CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feig</LastName><ForeName>Vivian</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Remlova</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Sciences and Technology, Eidgenössische Technische Hochschule Zürich, Universitätstrasse 2, Zurich, 8092, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muller</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuosmanen</LastName><ForeName>Johannes L P</ForeName><Initials>JLP</Initials><AffiliationInfo><Affiliation>Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lal</LastName><ForeName>Nikhil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ginzburg</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell/Cellular and Molecular Biology, Northeastern University, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nan</LastName><ForeName>Kewang</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Ashka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Bioengineering, Northeastern University, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jebran</LastName><ForeName>Ahmad Mujtaba</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bantwal</LastName><ForeName>Meghana Prabhu</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biotechnology, Northeastern University, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabian</LastName><ForeName>Niora</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishida</LastName><ForeName>Keiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jenkins</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenboom</LastName><ForeName>Jan-Georg</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sanghyun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madani</LastName><ForeName>Wiam</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayward</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traverso</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-7851-4077</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Adv Mater</MedlineTA><NlmUniqueID>9885358</NlmUniqueID><ISSNLinking>0935-9648</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Stimuli-responsive materials</Keyword><Keyword MajorTopicYN="N">embrittlement</Keyword><Keyword MajorTopicYN="N">liquid metals</Keyword><Keyword MajorTopicYN="N">triggerable materials</Keyword><Keyword MajorTopicYN="N">triggerable metals</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>09</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321332</ArticleId><ArticleId IdType="doi">10.1002/adma.202208227</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36321310</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2159-8290</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Cancer discovery</Title><ISOAbbreviation>Cancer Discov</ISOAbbreviation></Journal><ArticleTitle>Correction: Belly Fat Weakens Immune Fitness.</ArticleTitle><Pagination><MedlinePgn>2710</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/2159-8290.CD-22-1073</ELocationID><Language>eng</Language><PublicationTypeList><PublicationType UI="D016425">Published Erratum</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Discov</MedlineTA><NlmUniqueID>101561693</NlmUniqueID><ISSNLinking>2159-8274</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumFor"><RefSource>Cancer Discov. 2022 Aug 5;12(8):1841-1843</RefSource><PMID Version="1">35929132</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>09</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321310</ArticleId><ArticleId IdType="pii">710005</ArticleId><ArticleId IdType="doi">10.1158/2159-8290.CD-22-1073</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321309</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2159-8290</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Cancer discovery</Title><ISOAbbreviation>Cancer Discov</ISOAbbreviation></Journal><ArticleTitle>Race and Ancestry in Immune Response to Breast Cancer.</ArticleTitle><Pagination><MedlinePgn>2496-2497</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/2159-8290.CD-22-0852</ELocationID><Abstract><AbstractText>Martini and colleagues performed genetic ancestry estimation on a unique international triple-negative breast cancer (TNBC) study enriched for participants with African ancestry. They identified gene signatures indicative of ancestry in race-associated TNBC and found ancestry-associated immunologic differences that may contribute to racial disparities in breast cancer. See related article by Martini et al., p. 2530 (5).</AbstractText><CopyrightInformation>©2022 American Association for Cancer Research.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Alina M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0001-9121-7114</Identifier><AffiliationInfo><Affiliation>Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoadley</LastName><ForeName>Katherine A</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0002-1216-477X</Identifier><AffiliationInfo><Affiliation>Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troester</LastName><ForeName>Melissa A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-9506-6624</Identifier><AffiliationInfo><Affiliation>Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Discov</MedlineTA><NlmUniqueID>101561693</NlmUniqueID><ISSNLinking>2159-8274</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Cancer Discov. 2022 Nov 2;12(11):2530-2551</RefSource><PMID Version="1">36121736</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064726" MajorTopicYN="Y">Triple Negative Breast Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007109" MajorTopicYN="N">Immunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001695" MajorTopicYN="N">Biology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321309</ArticleId><ArticleId IdType="pii">710004</ArticleId><ArticleId IdType="doi">10.1158/2159-8290.CD-22-0852</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321308</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2159-8290</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Cancer discovery</Title><ISOAbbreviation>Cancer Discov</ISOAbbreviation></Journal><ArticleTitle>Developmental Deconvolution Suggests New Tumor Biology and a Tool for Predicting Cancer Origin.</ArticleTitle><Pagination><MedlinePgn>2498-2500</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/2159-8290.CD-22-0943</ELocationID><Abstract><AbstractText Label="SUMMARY" NlmCategory="UNASSIGNED">Defining the developmental origins of cancer can help uncover cellular mechanisms of cancer development and progression and identify effective treatments, but it has been challenging. In this issue of Cancer Discovery, Moiso and colleagues constructed a developmental map of 33 cancer types, based on which they deconvoluted tumors into developmental components and constructed a deep learning classifier capable of high- accuracy tumor type prediction. See related article by Moiso et al., p. 2566 (4) .</AbstractText><CopyrightInformation>©2022 American Association for Cancer Research.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Linghua</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-9380-0266</Identifier><AffiliationInfo><Affiliation>Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, Texas.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Discov</MedlineTA><NlmUniqueID>101561693</NlmUniqueID><ISSNLinking>2159-8274</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Cancer Discov. 2022 Nov 2;12(11):2566-2585</RefSource><PMID Version="1">36041084</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009857" MajorTopicYN="Y">Oncogenes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001695" MajorTopicYN="N">Biology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321308</ArticleId><ArticleId IdType="pii">709997</ArticleId><ArticleId IdType="doi">10.1158/2159-8290.CD-22-0943</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321307</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2159-8290</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Cancer discovery</Title><ISOAbbreviation>Cancer Discov</ISOAbbreviation></Journal><ArticleTitle>Lung CAFs Show T Cells the Velvet Rope.</ArticleTitle><Pagination><MedlinePgn>2501-2503</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/2159-8290.CD-22-0944</ELocationID><Abstract><AbstractText>Cancer-associated fibroblasts share defined features with fibroblasts in secondary lymphoid organs, including the ability to regulate immune cell localization. In this issue of Cancer Discovery, Grout and colleagues perform multimodal analysis of human lung cancer specimens and identify two distinct fibroblast populations associated with spatial exclusion of T cells from tumor cell nests. See related article by Grout et al., p. 2606 (3).</AbstractText><CopyrightInformation>©2022 American Association for Cancer Research.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sherman</LastName><ForeName>Mara H</ForeName><Initials>MH</Initials><Identifier Source="ORCID">0000-0001-7826-3888</Identifier><AffiliationInfo><Affiliation>Department of Cell, Developmental and Cancer Biology, Oregon Health &amp; Science University, Portland, Oregon.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Cancer Institute, Oregon Health &amp; Science University, Portland, Oregon.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Discov</MedlineTA><NlmUniqueID>101561693</NlmUniqueID><ISSNLinking>2159-8274</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Cancer Discov. 2022 Nov 2;12(11):2606-2625</RefSource><PMID Version="1">36027053</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072645" MajorTopicYN="Y">Cancer-Associated Fibroblasts</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321307</ArticleId><ArticleId IdType="pii">709990</ArticleId><ArticleId IdType="doi">10.1158/2159-8290.CD-22-0944</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321306</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2159-8290</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Cancer discovery</Title><ISOAbbreviation>Cancer Discov</ISOAbbreviation></Journal><ArticleTitle>The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.</ArticleTitle><Pagination><MedlinePgn>2475-2481</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/2159-8290.CD-22-1105</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Kenneth C</ForeName><Initials>KC</Initials><Identifier Source="ORCID">0000-0002-6418-0886</Identifier></Author><Author ValidYN="Y"><LastName>Cantley</LastName><ForeName>Lewis C</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000-0002-1298-7653</Identifier></Author><Author ValidYN="Y"><LastName>Dalla-Favera</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3502-8826</Identifier></Author><Author ValidYN="Y"><LastName>Dang</LastName><ForeName>Chi Van</ForeName><Initials>CV</Initials><Identifier Source="ORCID">0000-0002-4031-2522</Identifier></Author><Author ValidYN="Y"><LastName>Diaz</LastName><ForeName>Luis A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0002-7079-8914</Identifier></Author><Author ValidYN="Y"><LastName>DuBois</LastName><ForeName>Raymond N</ForeName><Initials>RN</Initials><Identifier Source="ORCID">0000-0002-6385-7154</Identifier></Author><Author ValidYN="Y"><LastName>Flaherty</LastName><ForeName>Keith T</ForeName><Initials>KT</Initials><Identifier Source="ORCID">0000-0002-3402-0478</Identifier></Author><Author ValidYN="Y"><LastName>Greenberg</LastName><ForeName>Philip D</ForeName><Initials>PD</Initials><Identifier Source="ORCID">0000-0003-3812-647X</Identifier></Author><Author ValidYN="Y"><LastName>Loda</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9674-8379</Identifier></Author><Author ValidYN="Y"><LastName>Mardis</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials><Identifier Source="ORCID">0000-0002-5892-1553</Identifier></Author><Author ValidYN="Y"><LastName>Platz</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0003-3676-8954</Identifier></Author><Author ValidYN="Y"><LastName>Pollak</LastName><ForeName>Michael N</ForeName><Initials>MN</Initials><Identifier Source="ORCID">0000-0003-3047-0604</Identifier></Author><Author ValidYN="Y"><LastName>Schreiber</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials><Identifier Source="ORCID">0000-0003-1590-2341</Identifier></Author><Author ValidYN="Y"><LastName>Siu</LastName><ForeName>Lillian L</ForeName><Initials>LL</Initials><Identifier Source="ORCID">0000-0002-3500-0540</Identifier></Author><Author ValidYN="Y"><LastName>Teicher</LastName><ForeName>Beverly A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0003-1535-7304</Identifier></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Discov</MedlineTA><NlmUniqueID>101561693</NlmUniqueID><ISSNLinking>2159-8274</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010506" MajorTopicYN="Y">Periodicals as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321306</ArticleId><ArticleId IdType="pii">710009</ArticleId><ArticleId IdType="doi">10.1158/2159-8290.CD-22-1105</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321305</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2159-8290</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Cancer discovery</Title><ISOAbbreviation>Cancer Discov</ISOAbbreviation></Journal><ArticleTitle>C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan.</ArticleTitle><Pagination><MedlinePgn>2509-2515</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/2159-8290.CD-22-0417</ELocationID><Abstract><AbstractText Label="SUMMARY" NlmCategory="UNASSIGNED">Since June 2019, under the umbrella of the national health insurance system, Japan has started cancer genomic medicine (CGM) with comprehensive genomic profiling (CGP) tests. The Ministry of Health, Labour and Welfare (MHLW) of Japan constructed a network of CGM hospitals (a total of 233 institutes as of July 1, 2022) and established the Center for Cancer Genomics and Advanced Therapeutics (C-CAT), the national datacenter for CGM. Clinical information and genomic data from the CGP tests are securely transferred to C-CAT, which then generates "C-CAT Findings" reports containing information of clinical annotation and matched clinical trials based on the CGP data. As of June 30, 2022, a total of 36,340 datapoints of clinical/genomic information are aggregated in C-CAT, and the number is expected to increase swiftly. The data are now open for sharing with not only the CGM hospitals but also other academic institutions and industries.</AbstractText><CopyrightInformation>©2022 The Authors; Published by the American Association for Cancer Research.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kohno</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-5371-706X</Identifier><AffiliationInfo><Affiliation>Center for Cancer Genomics and Advanced Therapeutics (C-CAT), National Cancer Center, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Mamoru</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8485-8316</Identifier><AffiliationInfo><Affiliation>Center for Cancer Genomics and Advanced Therapeutics (C-CAT), National Cancer Center, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohsaka</LastName><ForeName>Shinji</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8651-6136</Identifier><AffiliationInfo><Affiliation>Center for Cancer Genomics and Advanced Therapeutics (C-CAT), National Cancer Center, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sudo</LastName><ForeName>Tomohisa</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-0798-9176</Identifier><AffiliationInfo><Affiliation>Center for Cancer Genomics and Advanced Therapeutics (C-CAT), National Cancer Center, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamai</LastName><ForeName>Ikuo</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-8750-3097</Identifier><AffiliationInfo><Affiliation>Center for Cancer Genomics and Advanced Therapeutics (C-CAT), National Cancer Center, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shiraishi</LastName><ForeName>Yuichi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-6144-5845</Identifier><AffiliationInfo><Affiliation>Center for Cancer Genomics and Advanced Therapeutics (C-CAT), National Cancer Center, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okuma</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-5743-0149</Identifier><AffiliationInfo><Affiliation>Center for Cancer Genomics and Advanced Therapeutics (C-CAT), National Cancer Center, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogasawara</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-8773-6763</Identifier><AffiliationInfo><Affiliation>Center for Cancer Genomics and Advanced Therapeutics (C-CAT), National Cancer Center, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Tatsuya</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-0100-9678</Identifier><AffiliationInfo><Affiliation>Center for Cancer Genomics and Advanced Therapeutics (C-CAT), National Cancer Center, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Teruhiko</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1607-3899</Identifier><AffiliationInfo><Affiliation>Center for Cancer Genomics and Advanced Therapeutics (C-CAT), National Cancer Center, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mano</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-4645-0181</Identifier><AffiliationInfo><Affiliation>Center for Cancer Genomics and Advanced Therapeutics (C-CAT), National Cancer Center, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Our Center is directly governed and funded by the Ministry</GrantID><Agency>Ministry of Health, Labour and Welfare (MHLW)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Discov</MedlineTA><NlmUniqueID>101561693</NlmUniqueID><ISSNLinking>2159-8274</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000088744" MajorTopicYN="Y">Genomic Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321305</ArticleId><ArticleId IdType="pii">709981</ArticleId><ArticleId IdType="doi">10.1158/2159-8290.CD-22-0417</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36321303</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-7755</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</Title><ISOAbbreviation>Cancer Epidemiol Biomarkers Prev</ISOAbbreviation></Journal><ArticleTitle>Correction: Cognitive Impairment in Patients with Breast Cancer before Surgery: Results from a CANTO Cohort Subgroup.</ArticleTitle><Pagination><MedlinePgn>2092</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/1055-9965.EPI-22-0922</ELocationID><Language>eng</Language><PublicationTypeList><PublicationType UI="D016425">Published Erratum</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Epidemiol Biomarkers Prev</MedlineTA><NlmUniqueID>9200608</NlmUniqueID><ISSNLinking>1055-9965</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumFor"><RefSource>Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1759-1766</RefSource><PMID Version="1">32611581</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321303</ArticleId><ArticleId IdType="pii">710027</ArticleId><ArticleId IdType="doi">10.1158/1055-9965.EPI-22-0922</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321302</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-7755</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</Title><ISOAbbreviation>Cancer Epidemiol Biomarkers Prev</ISOAbbreviation></Journal><ArticleTitle>Predicting Postallogeneic Hematopoietic Cell Transplant Glucose Intolerance: The Role of CT-based Body Composition.</ArticleTitle><Pagination><MedlinePgn>2002-2003</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/1055-9965.EPI-22-0619</ELocationID><Abstract><AbstractText>The description of methodologic approaches to quantifying skeletal muscle and adipose tissue compartments using routinely obtained CT images among patients with cancer have reinvigorated the field of body composition research in this population. In the accompanying article, Bhandari and colleagues demonstrate yet another application of body composition measurement in oncology; identification of glucose intolerance shortly after undergoing allogenic hematopoietic stem cell transplantation among adults with myeloid neoplasms. The authors were able to show that skeletal muscle mass and visceral adipose tissue were associated with an increased risk of incident dysglycemia within 30 days of transplantation. This article further supports the growing evidence that body composition measures can provide clinically meaningful information in oncology allowing identification of individuals at risk of a variety of adverse events during cancer therapy. See related article by Bhandari et al., p. 2004.</AbstractText><CopyrightInformation>©2022 American Association for Cancer Research.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giri</LastName><ForeName>Smith</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1827-5032</Identifier><AffiliationInfo><Affiliation>Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Alabama.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Grant R</ForeName><Initials>GR</Initials><Identifier Source="ORCID">0000-0003-4294-5232</Identifier><AffiliationInfo><Affiliation>Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Alabama.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Epidemiol Biomarkers Prev</MedlineTA><NlmUniqueID>9200608</NlmUniqueID><ISSNLinking>1055-9965</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Cancer Epidemiol Biomarkers Prev. 2022 Nov 2;31(11):2004-2010</RefSource><PMID Version="1">35797113</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018149" MajorTopicYN="Y">Glucose Intolerance</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018380" MajorTopicYN="Y">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001823" MajorTopicYN="N">Body Composition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000273" MajorTopicYN="N">Adipose Tissue</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>07</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321302</ArticleId><ArticleId IdType="pii">710024</ArticleId><ArticleId IdType="doi">10.1158/1055-9965.EPI-22-0619</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321301</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-7755</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</Title><ISOAbbreviation>Cancer Epidemiol Biomarkers Prev</ISOAbbreviation></Journal><ArticleTitle>The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.</ArticleTitle><Pagination><MedlinePgn>1995-2001</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/1055-9965.EPI-22-0852</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Kenneth C</ForeName><Initials>KC</Initials><Identifier Source="ORCID">0000-0002-6418-0886</Identifier></Author><Author ValidYN="Y"><LastName>Cantley</LastName><ForeName>Lewis C</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000-0002-1298-7653</Identifier></Author><Author ValidYN="Y"><LastName>Dalla-Favera</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3502-8826</Identifier></Author><Author ValidYN="Y"><LastName>Dang</LastName><ForeName>Chi Van</ForeName><Initials>CV</Initials><Identifier Source="ORCID">0000-0002-4031-2522</Identifier></Author><Author ValidYN="Y"><LastName>Diaz</LastName><ForeName>Luis A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0002-7079-8914</Identifier></Author><Author ValidYN="Y"><LastName>DuBois</LastName><ForeName>Raymond N</ForeName><Initials>RN</Initials><Identifier Source="ORCID">0000-0002-6385-7154</Identifier></Author><Author ValidYN="Y"><LastName>Flaherty</LastName><ForeName>Keith T</ForeName><Initials>KT</Initials><Identifier Source="ORCID">0000-0002-3402-0478</Identifier></Author><Author ValidYN="Y"><LastName>Greenberg</LastName><ForeName>Philip D</ForeName><Initials>PD</Initials><Identifier Source="ORCID">0000-0003-3812-647X</Identifier></Author><Author ValidYN="Y"><LastName>Loda</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9674-8379</Identifier></Author><Author ValidYN="Y"><LastName>Mardis</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials><Identifier Source="ORCID">0000-0002-5892-1553</Identifier></Author><Author ValidYN="Y"><LastName>Platz</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0003-3676-8954</Identifier></Author><Author ValidYN="Y"><LastName>Pollak</LastName><ForeName>Michael N</ForeName><Initials>MN</Initials><Identifier Source="ORCID">0000-0003-3047-0604</Identifier></Author><Author ValidYN="Y"><LastName>Schreiber</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials><Identifier Source="ORCID">0000-0003-1590-2341</Identifier></Author><Author ValidYN="Y"><LastName>Siu</LastName><ForeName>Lillian L</ForeName><Initials>LL</Initials><Identifier Source="ORCID">0000-0002-3500-0540</Identifier></Author><Author ValidYN="Y"><LastName>Teicher</LastName><ForeName>Beverly A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0003-1535-7304</Identifier></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Epidemiol Biomarkers Prev</MedlineTA><NlmUniqueID>9200608</NlmUniqueID><ISSNLinking>1055-9965</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010506" MajorTopicYN="Y">Periodicals as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321301</ArticleId><ArticleId IdType="pii">710035</ArticleId><ArticleId IdType="doi">10.1158/1055-9965.EPI-22-0852</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321299</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2326-6074</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Cancer immunology research</Title><ISOAbbreviation>Cancer Immunol Res</ISOAbbreviation></Journal><ArticleTitle>About the Rising Star.</ArticleTitle><Pagination><MedlinePgn>1291</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/2326-6066.CIR-22-0741</ELocationID><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Immunol Res</MedlineTA><NlmUniqueID>101614637</NlmUniqueID><ISSNLinking>2326-6066</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Cancer Immunol Res. 2022 Nov 2;10(11):1292-1298</RefSource><PMID Version="1">36166399</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005770" MajorTopicYN="Y">Gastrointestinal Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064307" MajorTopicYN="Y">Microbiota</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321299</ArticleId><ArticleId IdType="pii">709875</ArticleId><ArticleId IdType="doi">10.1158/2326-6066.CIR-22-0741</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321298</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2326-6074</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Cancer immunology research</Title><ISOAbbreviation>Cancer Immunol Res</ISOAbbreviation></Journal><ArticleTitle>The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.</ArticleTitle><Pagination><MedlinePgn>1282-1288</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/2326-6066.CIR-22-0782</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Kenneth C</ForeName><Initials>KC</Initials><Identifier Source="ORCID">0000-0002-6418-0886</Identifier></Author><Author ValidYN="Y"><LastName>Cantley</LastName><ForeName>Lewis C</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000-0002-1298-7653</Identifier></Author><Author ValidYN="Y"><LastName>Dalla-Favera</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3502-8826</Identifier></Author><Author ValidYN="Y"><LastName>Dang</LastName><ForeName>Chi Van</ForeName><Initials>CV</Initials><Identifier Source="ORCID">0000-0002-4031-2522</Identifier></Author><Author ValidYN="Y"><LastName>Diaz</LastName><ForeName>Luis A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0002-7079-8914</Identifier></Author><Author ValidYN="Y"><LastName>DuBois</LastName><ForeName>Raymond N</ForeName><Initials>RN</Initials><Identifier Source="ORCID">0000-0002-6385-7154</Identifier></Author><Author ValidYN="Y"><LastName>Flaherty</LastName><ForeName>Keith T</ForeName><Initials>KT</Initials><Identifier Source="ORCID">0000-0002-3402-0478</Identifier></Author><Author ValidYN="Y"><LastName>Greenberg</LastName><ForeName>Philip D</ForeName><Initials>PD</Initials><Identifier Source="ORCID">0000-0003-3812-647X</Identifier></Author><Author ValidYN="Y"><LastName>Loda</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9674-8379</Identifier></Author><Author ValidYN="Y"><LastName>Mardis</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials><Identifier Source="ORCID">0000-0002-5892-1553</Identifier></Author><Author ValidYN="Y"><LastName>Platz</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0003-3676-8954</Identifier></Author><Author ValidYN="Y"><LastName>Pollak</LastName><ForeName>Michael N</ForeName><Initials>MN</Initials><Identifier Source="ORCID">0000-0003-3047-0604</Identifier></Author><Author ValidYN="Y"><LastName>Schreiber</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials><Identifier Source="ORCID">0000-0003-1590-2341</Identifier></Author><Author ValidYN="Y"><LastName>Siu</LastName><ForeName>Lillian L</ForeName><Initials>LL</Initials><Identifier Source="ORCID">0000-0002-3500-0540</Identifier></Author><Author ValidYN="Y"><LastName>Teicher</LastName><ForeName>Beverly A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0003-1535-7304</Identifier></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Immunol Res</MedlineTA><NlmUniqueID>101614637</NlmUniqueID><ISSNLinking>2326-6066</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D010506" MajorTopicYN="Y">Periodicals as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321298</ArticleId><ArticleId IdType="pii">709880</ArticleId><ArticleId IdType="doi">10.1158/2326-6066.CIR-22-0782</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321297</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2326-6074</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Cancer immunology research</Title><ISOAbbreviation>Cancer Immunol Res</ISOAbbreviation></Journal><ArticleTitle>A Sampling of Highlights from the Literature.</ArticleTitle><Pagination><MedlinePgn>1281</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/2326-6066.CIR-10-11-WWR</ELocationID><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Immunol Res</MedlineTA><NlmUniqueID>101614637</NlmUniqueID><ISSNLinking>2326-6066</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321297</ArticleId><ArticleId IdType="pii">709877</ArticleId><ArticleId IdType="doi">10.1158/2326-6066.CIR-10-11-WWR</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321294</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2643-3249</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>11</Month><Day>02</Day></PubDate></JournalIssue><Title>Blood cancer discovery</Title><ISOAbbreviation>Blood Cancer Discov</ISOAbbreviation></Journal><ArticleTitle>The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.</ArticleTitle><Pagination><MedlinePgn>469-475</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/2643-3230.BCD-22-0165</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Kenneth C</ForeName><Initials>KC</Initials><Identifier Source="ORCID">0000-0002-6418-0886</Identifier></Author><Author ValidYN="Y"><LastName>Cantley</LastName><ForeName>Lewis C</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000-0002-1298-7653</Identifier></Author><Author ValidYN="Y"><LastName>Dalla-Favera</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3502-8826</Identifier></Author><Author ValidYN="Y"><LastName>Dang</LastName><ForeName>Chi Van</ForeName><Initials>CV</Initials><Identifier Source="ORCID">0000-0002-4031-2522</Identifier></Author><Author ValidYN="Y"><LastName>Diaz</LastName><ForeName>Luis A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0002-7079-8914</Identifier></Author><Author ValidYN="Y"><LastName>DuBois</LastName><ForeName>Raymond N</ForeName><Initials>RN</Initials><Identifier Source="ORCID">0000-0002-6385-7154</Identifier></Author><Author ValidYN="Y"><LastName>Flaherty</LastName><ForeName>Keith T</ForeName><Initials>KT</Initials><Identifier Source="ORCID">0000-0002-3402-0478</Identifier></Author><Author ValidYN="Y"><LastName>Greenberg</LastName><ForeName>Philip D</ForeName><Initials>PD</Initials><Identifier Source="ORCID">0000-0003-3812-647X</Identifier></Author><Author ValidYN="Y"><LastName>Loda</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9674-8379</Identifier></Author><Author ValidYN="Y"><LastName>Mardis</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials><Identifier Source="ORCID">0000-0002-5892-1553</Identifier></Author><Author ValidYN="Y"><LastName>Platz</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0003-3676-8954</Identifier></Author><Author ValidYN="Y"><LastName>Pollak</LastName><ForeName>Michael N</ForeName><Initials>MN</Initials><Identifier Source="ORCID">0000-0003-3047-0604</Identifier></Author><Author ValidYN="Y"><LastName>Schreiber</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials><Identifier Source="ORCID">0000-0003-1590-2341</Identifier></Author><Author ValidYN="Y"><LastName>Siu</LastName><ForeName>Lillian L</ForeName><Initials>LL</Initials><Identifier Source="ORCID">0000-0002-3500-0540</Identifier></Author><Author ValidYN="Y"><LastName>Teicher</LastName><ForeName>Beverly A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0003-1535-7304</Identifier></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood Cancer Discov</MedlineTA><NlmUniqueID>101764786</NlmUniqueID><ISSNLinking>2643-3230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D010506" MajorTopicYN="Y">Periodicals as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008921" MajorTopicYN="Y">Religious Missions</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321294</ArticleId><ArticleId IdType="pii">709899</ArticleId><ArticleId IdType="doi">10.1158/2643-3230.BCD-22-0165</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321293</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1092-0684</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurosurgical focus</Title><ISOAbbreviation>Neurosurg Focus</ISOAbbreviation></Journal><ArticleTitle>Stereotactic radiosurgery and resection for treatment of multiple brain metastases: a systematic review and analysis.</ArticleTitle><Pagination><MedlinePgn>E9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3171/2022.8.FOCUS22369</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Stereotactic radiosurgery (SRS) has recently emerged as a minimally invasive alternative to resection for treating multiple brain metastases. Given the lack of consensus regarding the application of SRS versus resection for multiple brain metastases, the authors aimed to conduct a systematic literature review of all published work on the topic.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The PubMed, OVID, Cochrane, Web of Science, and Scopus databases were used to identify studies that examined clinical outcomes after resection or SRS was performed in patients with multiple brain metastases. Radiological studies, case series with fewer than 3 patients, pediatric studies, or national database studies were excluded. Data extracted included patient demographics and mean overall survival (OS). Weighted t-tests and ANOVA were performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1300 abstracts were screened, 450 articles underwent full-text review, and 129 studies met inclusion criteria, encompassing 20,177 patients (18,852 treated with SRS and 1325 who underwent resection). The OS for the SRS group was 10.2 ± 6 months, and for the resection group it was 6.5 ± 3.8 months. A weighted ANOVA test comparing OS with covariates of age, sex, and publication year revealed that the treatment group (p = 0.045), age (p = 0.034), and publication year (0.0078) were all independently associated with OS (with SRS, younger age, and later publication year being associated with longer survival), whereas sex (p = 0.95) was not.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">For patients with multiple brain metastases, SRS and resection are effective treatments to prolong OS, with published data suggesting that SRS may have a trend toward lengthened survival outcomes. The authors encourage additional work examining outcomes of treatments for multiple brain metastases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mahajan</LastName><ForeName>Uma V</ForeName><Initials>UV</Initials><AffiliationInfo><Affiliation>1Case Western Reserve University School of Medicine, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Ansh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1Case Western Reserve University School of Medicine, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shost</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>1Case Western Reserve University School of Medicine, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>1Case Western Reserve University School of Medicine, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anthony</LastName><ForeName>Austin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>2University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labak</LastName><ForeName>Collin M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>3Department of Neurological Surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herring</LastName><ForeName>Eric Z</ForeName><Initials>EZ</Initials><AffiliationInfo><Affiliation>3Department of Neurological Surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wijesekera</LastName><ForeName>Olindi</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>3Department of Neurological Surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukherjee</LastName><ForeName>Debraj</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>4Department of Neurosurgery, The Johns Hopkins Hospital, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sloan</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>3Department of Neurological Surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodges</LastName><ForeName>Tiffany R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>3Department of Neurological Surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio; and.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurosurg Focus</MedlineTA><NlmUniqueID>100896471</NlmUniqueID><ISSNLinking>1092-0684</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016634" MajorTopicYN="Y">Radiosurgery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001932" MajorTopicYN="Y">Brain Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016371" MajorTopicYN="N">Cranial Irradiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">multiple cerebral metastases</Keyword><Keyword MajorTopicYN="N">neurosurgery</Keyword><Keyword MajorTopicYN="N">resection</Keyword><Keyword MajorTopicYN="N">stereotactic radiosurgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321293</ArticleId><ArticleId IdType="doi">10.3171/2022.8.FOCUS22369</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321292</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1092-0684</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurosurgical focus</Title><ISOAbbreviation>Neurosurg Focus</ISOAbbreviation></Journal><ArticleTitle>Risk factors for peritumoral edema after radiosurgery for intracranial benign meningiomas: a long-term follow-up in a single institution.</ArticleTitle><Pagination><MedlinePgn>E7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3171/2022.8.FOCUS22377</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Peritumoral edema (PTE) is recognized as a complication following stereotactic radiosurgery (SRS). The aim of this paper was to evaluate the risk of post-SRS PTE for intracranial benign meningiomas and determine the predictive factors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Between 2006 and 2021, 227 patients with 237 WHO grade I meningiomas were treated with Novalis linear accelerator SRS. All patients were treated with a single-fraction dose of 11-20 Gy (median 14 Gy). The median tumor volume was 3.32 cm3 (range 0.24-51.7 cm3).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median follow-up was 52 months (range 12-178 months). The actuarial local tumor control rates at 2, 5, and 10 years after SRS were 99.0%, 96.7%, and 86.3%, respectively. Twenty-seven (11.9%) patients developed new or worsened post-SRS PTE, with a median onset time of 5.2 months (range 1.2-50 months). Only 2 patients developed post-SRS PTE after 24 months. The authors evaluated factors related to new-onset or worsened PTE after SRS. In univariate analysis, initial tumor volume &gt; 10 cm3 (p = 0.03), total marginal dose &gt; 14 Gy (p &lt; 0.001), preexisting edema (p &lt; 0.0001), tumor location (p &lt; 0.001), parasagittal location (p &lt; 0.0001), superior sagittal sinus (SSS) involvement (p &lt; 0.0001), and SSS invasion (p &lt; 0.015) were found to be significant risk factors. In multivariate analysis, total marginal dose &gt; 14 Gy (HR 3.38, 95% CI 1.37-8.33, p = 0.008), preexisting SRS edema (HR 12.86, 95% CI 1.09-4.15, p &lt; 0.0001), tumor location (HR 2.13, 95% CI 1.04-3.72, p = 0.027), parasagittal location (HR 8.84, 95% CI 1.48-52.76, p = 0.017), and SSS invasion (HR 0.34, 95% CI 0.13-0.89, p = 0.027) were significant risk factors. Twelve (5.3%) patients were symptomatic. Ten of 27 patients had complete resolution of neurological symptoms and edema improvement with steroid treatment. Steroid treatment failed in 2 patients, who subsequently required resection for PTE.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Radiosurgery is a safe and effective method of treating benign intracranial meningiomas according to long-term follow-up. We also identified total marginal dose &gt; 14 Gy, preexisting PTE, parasagittal location, and SSS invasion as predictors of post-SRS PTE. Risk factors for post-SRS PTE should be considered in meningioma treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Sheng-Han</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>1Department of Neurosurgery, Chang Gung Memorial Hospital at Linkou, Chang Gung University, Taoyuan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Chi-Cheng</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>1Department of Neurosurgery, Chang Gung Memorial Hospital at Linkou, Chang Gung University, Taoyuan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chun-Chieh</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>2Department of Radiation Oncology, Chang Gung Memorial Hospital at Linkou, Chang Gung University, Taoyuan; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Kuo-Chen</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>1Department of Neurosurgery, Chang Gung Memorial Hospital at Linkou, Chang Gung University, Taoyuan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hsien-Chih</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>3Department of Neurosurgery, Chang Gung Memorial Hospital at Keelung, Chang Gung University, Keelung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Peng-Wei</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>1Department of Neurosurgery, Chang Gung Memorial Hospital at Linkou, Chang Gung University, Taoyuan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurosurg Focus</MedlineTA><NlmUniqueID>100896471</NlmUniqueID><ISSNLinking>1092-0684</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013256">Steroids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008579" MajorTopicYN="Y">Meningioma</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016634" MajorTopicYN="Y">Radiosurgery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008577" MajorTopicYN="Y">Meningeal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013256" MajorTopicYN="N">Steroids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">meningioma</Keyword><Keyword MajorTopicYN="N">peritumoral edema</Keyword><Keyword MajorTopicYN="N">stereotactic radiosurgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321292</ArticleId><ArticleId IdType="doi">10.3171/2022.8.FOCUS22377</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321291</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1092-0684</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurosurgical focus</Title><ISOAbbreviation>Neurosurg Focus</ISOAbbreviation></Journal><ArticleTitle>Neoadjuvant stereotactic radiosurgery for brain metastases: a new paradigm.</ArticleTitle><Pagination><MedlinePgn>E8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3171/2022.8.FOCUS22367</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">For patients with surgically accessible solitary metastases or oligometastatic disease, treatment often involves resection followed by postoperative stereotactic radiosurgery (SRS). This strategy has several potential drawbacks, including irregular target delineation for SRS and potential tumor "seeding" away from the resection cavity during surgery. A neoadjuvant (preoperative) approach to radiation therapy avoids these limitations and offers improved patient convenience. This study assessed the efficacy of neoadjuvant SRS as a new treatment paradigm for patients with brain metastases.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective review was performed at a single institution to identify patients who had undergone neoadjuvant SRS (specifically, Gamma Knife radiosurgery) followed by resection of a brain metastasis. Kaplan-Meier survival and log-rank analyses were used to evaluate risks of progression and death. Assessments were made of local recurrence and leptomeningeal spread. Additionally, an analysis of the contemporary literature of postoperative and neoadjuvant SRS for metastatic disease was performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-four patients who had undergone neoadjuvant SRS followed by resection of a brain metastasis were identified in the single-institution cohort. The median age was 64 years (range 32-84 years), and the median follow-up time was 16.5 months (range 1 month to 5.7 years). The median radiation dose was 17 Gy prescribed to the 50% isodose. Rates of local disease control were 100% at 6 months, 87.6% at 12 months, and 73.5% at 24 months. In 4 patients who had local treatment failure, salvage therapy included repeat resection, laser interstitial thermal therapy, or repeat SRS. One hundred thirty patients (including the current cohort) were identified in the literature who had been treated with neoadjuvant SRS prior to resection. Overall rates of local control at 1 year after neoadjuvant SRS treatment ranged from 49% to 91%, and rates of leptomeningeal dissemination from 0% to 16%. In comparison, rates of local control 1 year after postoperative SRS ranged from 27% to 91%, with 7% to 28% developing leptomeningeal disease.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Neoadjuvant SRS for the treatment of brain metastases is a novel approach that mitigates the shortcomings of postoperative SRS. While additional prospective studies are needed, the current study of 130 patients including the summary of 106 previously published cases supports the safety and potential efficacy of preoperative SRS with potential for improved outcomes compared with postoperative SRS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuping Derek</ForeName><Initials>YD</Initials><AffiliationInfo><Affiliation>1Department of Neurosurgery, Washington University School of Medicine, St. Louis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coxon</LastName><ForeName>Andrew T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>1Department of Neurosurgery, Washington University School of Medicine, St. Louis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jiayi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>2Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>4The Brain Tumor Center, Siteman Cancer Center, Washington University School of Medicine, St. Louis; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>Christopher D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>2Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>4The Brain Tumor Center, Siteman Cancer Center, Washington University School of Medicine, St. Louis; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dowling</LastName><ForeName>Joshua L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>1Department of Neurosurgery, Washington University School of Medicine, St. Louis.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>4The Brain Tumor Center, Siteman Cancer Center, Washington University School of Medicine, St. Louis; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leuthardt</LastName><ForeName>Eric C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>1Department of Neurosurgery, Washington University School of Medicine, St. Louis.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>4The Brain Tumor Center, Siteman Cancer Center, Washington University School of Medicine, St. Louis; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunn</LastName><ForeName>Gavin P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>3Department of Neurosurgery, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Albert H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>1Department of Neurosurgery, Washington University School of Medicine, St. Louis.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>4The Brain Tumor Center, Siteman Cancer Center, Washington University School of Medicine, St. Louis; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dacey</LastName><ForeName>Ralph G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>1Department of Neurosurgery, Washington University School of Medicine, St. Louis.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>4The Brain Tumor Center, Siteman Cancer Center, Washington University School of Medicine, St. Louis; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zipfel</LastName><ForeName>Gregory J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>1Department of Neurosurgery, Washington University School of Medicine, St. Louis.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>4The Brain Tumor Center, Siteman Cancer Center, Washington University School of Medicine, St. Louis; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1Department of Neurosurgery, Washington University School of Medicine, St. Louis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filiput</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>1Department of Neurosurgery, Washington University School of Medicine, St. Louis.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chicoine</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>1Department of Neurosurgery, Washington University School of Medicine, St. Louis.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>4The Brain Tumor Center, Siteman Cancer Center, Washington University School of Medicine, St. Louis; and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>5Department of Neurosurgery, University of Missouri, Columbia, Missouri.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurosurg Focus</MedlineTA><NlmUniqueID>100896471</NlmUniqueID><ISSNLinking>1092-0684</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016634" MajorTopicYN="Y">Radiosurgery</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001932" MajorTopicYN="Y">Brain Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008577" MajorTopicYN="Y">Meningeal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016879" MajorTopicYN="N">Salvage Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">brain metastasis</Keyword><Keyword MajorTopicYN="N">neoadjuvant stereotactic radiosurgery</Keyword><Keyword MajorTopicYN="N">preoperative</Keyword><Keyword MajorTopicYN="N">resection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321291</ArticleId><ArticleId IdType="doi">10.3171/2022.8.FOCUS22367</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321290</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1092-0684</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurosurgical focus</Title><ISOAbbreviation>Neurosurg Focus</ISOAbbreviation></Journal><ArticleTitle>A quantitative and comparative evaluation of stereotactic spine radiosurgery local control: proposing a consistent measurement methodology.</ArticleTitle><Pagination><MedlinePgn>E10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3171/2022.8.FOCUS22363</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Stereotactic body radiotherapy (SBRT) is a precise and conformal treatment modality used in the management of metastatic spine tumors. Multiple studies have demonstrated its safety and efficacy for pain and tumor control. However, no uniform quantitative imaging methodology exists to evaluate response to treatment in these patients. This study presents radiographic local control rates post-SBRT, systematically compares measurements acquired according to WHO and Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and explores the relationship to patient outcome.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The authors performed a retrospective review of prospectively obtained data from a cohort of 59 consecutive patients (81 metastatic isocenters) treated with SBRT and followed with serial MRI scans. Measurements were performed by a neuroradiologist blinded to the patients' clinical course. Local control status was determined according to both WHO and RECIST measurements, and agreement between the measuring methodologies was calculated and reported.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighty-one isocenters (111 vertebral bodies) were treated with SBRT. The mean treatment dose was 13.96 Gy and the median follow-up duration was 10.8 months, during which 408 MRI scans were evaluated with both WHO and RECIST criteria for each scan point. Imaging demonstrated a mean unidimensional size decrease of 0.2 cm (p = 0.14) and a mean area size decrease of 0.99 cm2 (p = 0.03). Although 88% of the case classifications were concordant and the agreement was significant, WHO criteria were found to be more sensitive to tumor size change. The local control rates according to WHO and RECIST were 95% and 98%, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although WHO volumetric measurements are admittedly superior for tumor size measurement, RECIST is simpler, reproducible, and for the first time is shown here to be comparable to WHO criteria. Thus, the application of RECIST methodology appears to be a suitable standard for evaluating post-SBRT treatment response. Moreover, using comprehensive and consistent measuring approaches, this study substantiates the efficacy of SBRT in the treatment of spine metastases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harel</LastName><ForeName>Ran</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>1Department of Neurosurgery, Sheba Medical Center Affiliated to Tel-Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaisman-Elbaz</LastName><ForeName>Tehila</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>2Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3Department of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emch</LastName><ForeName>Todd</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>4Imaging Institute, Cleveland Clinic, Cleveland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elson</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>5Quantitative Health Sciences, Cleveland Clinic, Cleveland; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Samuel T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>2Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>6Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suh</LastName><ForeName>John H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>2Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>6Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angelov</LastName><ForeName>Lilyana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>2Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3Department of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurosurg Focus</MedlineTA><NlmUniqueID>100896471</NlmUniqueID><ISSNLinking>1092-0684</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016634" MajorTopicYN="Y">Radiosurgery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013125" MajorTopicYN="Y">Spinal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013131" MajorTopicYN="N">Spine</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">RECIST</Keyword><Keyword MajorTopicYN="N">Response Evaluation Criteria in Solid Tumors</Keyword><Keyword MajorTopicYN="N">WHO</Keyword><Keyword MajorTopicYN="N">local control</Keyword><Keyword MajorTopicYN="N">spinal metastases</Keyword><Keyword MajorTopicYN="N">spine radiosurgery</Keyword><Keyword MajorTopicYN="N">stereotactic body radiation therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321290</ArticleId><ArticleId IdType="doi">10.3171/2022.8.FOCUS22363</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321288</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1092-0684</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurosurgical focus</Title><ISOAbbreviation>Neurosurg Focus</ISOAbbreviation></Journal><ArticleTitle>Editorial. Assessing treatment response following stereotactic body radiotherapy for spinal metastases.</ArticleTitle><Pagination><MedlinePgn>E11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3171/2022.8.FOCUS22438</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roth</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Chambless</LastName><ForeName>Lola B</ForeName><Initials>LB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurosurg Focus</MedlineTA><NlmUniqueID>100896471</NlmUniqueID><ISSNLinking>1092-0684</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016634" MajorTopicYN="Y">Radiosurgery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013125" MajorTopicYN="Y">Spinal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321288</ArticleId><ArticleId IdType="doi">10.3171/2022.8.FOCUS22438</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321287</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1092-0684</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurosurgical focus</Title><ISOAbbreviation>Neurosurg Focus</ISOAbbreviation></Journal><ArticleTitle>Introduction. Evolution of radiation therapy techniques.</ArticleTitle><Pagination><MedlinePgn>E1</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3171/2022.8.FOCUS22436</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sahgal</LastName><ForeName>Arjun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheehan</LastName><ForeName>Jason P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>2Department of Neurosurgery, University of Virginia, Charlottesville, Virginia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niranjan</LastName><ForeName>Ajay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>3Department of Neurosurgery, University of Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chambless</LastName><ForeName>Lola B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>4Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Lijun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>5Department of Clinical Radiation Oncology, Keck School of Medicine of USC, Los Angeles, California; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trifiletti</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>6Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurosurg Focus</MedlineTA><NlmUniqueID>100896471</NlmUniqueID><ISSNLinking>1092-0684</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321287</ArticleId><ArticleId IdType="doi">10.3171/2022.8.FOCUS22436</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321286</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1092-0684</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurosurgical focus</Title><ISOAbbreviation>Neurosurg Focus</ISOAbbreviation></Journal><ArticleTitle>The role of radiation therapy in the treatment of spine metastases from hepatocellular carcinoma: a systematic review and meta-analysis.</ArticleTitle><Pagination><MedlinePgn>E12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3171/2022.8.FOCUS2255</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Spine hepatocellular carcinoma (HCC) metastases severely worsen quality of life and prognosis, with the role of radiotherapy being controversial. The authors systematically reviewed the literature on radiotherapy for spine metastatic HCCs.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The PubMed, Scopus, Web of Science, and Cochrane databases were searched according to the PRISMA guidelines to include studies of radiotherapy for spine metastatic HCCs. Outcomes, complications, and local control were analyzed with indirect random-effect meta-analyses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The authors included 12 studies comprising 713 patients. The median time interval from diagnosis of HCC to spine metastases was 12 months (range 0-105 months). Most lesions were thoracic (35.9%) or lumbar (24.7%). Radiotherapy was delivered with conventional external-beam (67.3%) or stereotactic (31.7%) techniques. The median dose was 30.3 Gy (range 12.5-52 Gy) in a median of 5 fractions (range 1-20 fractions). The median biologically effective dose was 44.8 Gy10 (range 14.4-112.5 Gy10). Actuarial rates of postradiotherapy pain relief and radiological response were 87% (95% CI 84%-90%) and 70% (95% CI 65%-75%), respectively. Radiation-related adverse events and vertebral fractures had actuarial rates of 8% (95% CI 5%-11%) and 16% (95% CI 10%-23%), respectively, with fracture rates significantly higher after stereotactic radiotherapy (p = 0.033). Fifty-eight patients (27.6%) had local recurrences after a median of 6.8 months (range 0.1-59 months), with pooled local control rates of 61.6% at 6 months and 40.8% at 12 months, and there were no significant differences based on radiotherapy type (p = 0.068). The median survival was 6 months (range 0.1-62 months), with pooled rates of 52.5% at 6 months and 23.4% at 12 months.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Radiotherapy in spine metastatic HCCs shows favorable rates of pain relief, radiological responses, and local control. Rates of postradiotherapy vertebral fractures are higher after high-dose stereotactic radiotherapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferini</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1Department of Radiation Oncology, REM Radioterapia srl, Viagrande, Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmisciano</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>2Department of Neurosurgery, University of Cincinnati, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scalia</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>3Department of Neurosurgery, Highly Specialized Hospital of National Importance "Garibaldi," Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haider</LastName><ForeName>Ali S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>4Texas A&amp;M University College of Medicine, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bin-Alamer</LastName><ForeName>Othman</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>5King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagoo</LastName><ForeName>Navraj S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>6Department of Orthopaedic Surgery, University of Texas Southwestern Medical Center, Dallas, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bozkurt</LastName><ForeName>Ismail</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>7Department of Neurosurgery, Cankiri State Hospital, Cankiri, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deora</LastName><ForeName>Harsh</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>8Department of Neurosurgery, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Priola</LastName><ForeName>Stefano M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>9Division of Neurosurgery, Health Sciences North, Northern Ontario School of Medicine, Sudbury, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aoun</LastName><ForeName>Salah G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>10Department of Neurosurgery, University of Texas Southwestern Medical Center, Dallas, Texas; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umana</LastName><ForeName>Giuseppe E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>11Department of Neurosurgery, Trauma Center, Gamma Knife Center, Cannizzaro Hospital, Catania, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurosurg Focus</MedlineTA><NlmUniqueID>100896471</NlmUniqueID><ISSNLinking>1092-0684</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006528" MajorTopicYN="Y">Carcinoma, Hepatocellular</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013125" MajorTopicYN="Y">Spinal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016634" MajorTopicYN="Y">Radiosurgery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016103" MajorTopicYN="Y">Spinal Fractures</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">hepatocellular carcinoma</Keyword><Keyword MajorTopicYN="N">radiation-induced complications</Keyword><Keyword MajorTopicYN="N">spine metastases</Keyword><Keyword MajorTopicYN="N">spine radiotherapy</Keyword><Keyword MajorTopicYN="N">stereotactic radiotherapy</Keyword><Keyword MajorTopicYN="N">vertebral fractures</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>02</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321286</ArticleId><ArticleId IdType="doi">10.3171/2022.8.FOCUS2255</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321285</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1092-0684</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurosurgical focus</Title><ISOAbbreviation>Neurosurg Focus</ISOAbbreviation></Journal><ArticleTitle>Stereotactic radiosurgery for recurrent pediatric brain tumors: clinical outcomes and toxicity.</ArticleTitle><Pagination><MedlinePgn>E2</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3171/2022.8.FOCUS22361</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Recurrence of brain tumors in children after the initial course of treatment remains a problem. This study evaluated the efficacy and safety of reirradiation using stereotactic radiosurgery (SRS) in patients with recurrent pediatric primary brain tumors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This IRB-approved retrospective review included pediatric patients with recurrent primary brain tumors treated at Stanford University from 2000 to 2019 using frameless SRS. Time to local failure (LF) and distant intracranial failure (DIF) were measured from the date of SRS and analyzed using competing risk analysis. Overall survival (OS) and progression-free survival (PFS) were analyzed with the Kaplan-Meier method.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 37 patients aged 2-24 years (median age 11 years at recurrence) were treated for 48 intracranial tumors. Ependymoma (38%) and medulloblastoma (22%) were the most common tumor types. The median (range) single fraction equivalent dose of SRS was 16.4 (12-24) Gy. The median (range) follow-up time was 22.9 (1.5-190) months. The median OS of all patients was 36.8 months. Eight of 40 (20%) lesions with follow-up imaging locally recurred. The 2-year cumulative incidence of LF after reirradiation with SRS was 12.8% (95% CI 4.6%-25.4%). The 2-year cumulative incidence of DIF was 25.3% (95% CI 12.9%-39.8%). The median PFS was 18 months (95% CI 8.9-44). Five (10.4%) patients developed toxicities potentially attributed to SRS, including cognitive effects and necrosis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Reirradiation using SRS for recurrent pediatric brain tumors appears safe with good local control. Innovations that improve overall disease control should continue because survival outcomes after relapse remain poor.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Elyn</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>1Department of Radiation Oncology, Stanford University, Stanford.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gutkin</LastName><ForeName>Paulina M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>1Department of Radiation Oncology, Stanford University, Stanford.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1Department of Radiation Oncology, Stanford University, Stanford.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pollom</LastName><ForeName>Erqi</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>1Department of Radiation Oncology, Stanford University, Stanford.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soltys</LastName><ForeName>Scott G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>1Department of Radiation Oncology, Stanford University, Stanford.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>Gerald A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>2Department of Neurosurgery, Stanford University, Stanford; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prolo</LastName><ForeName>Laura M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>2Department of Neurosurgery, Stanford University, Stanford; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>2Department of Neurosurgery, Stanford University, Stanford; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>2Department of Neurosurgery, Stanford University, Stanford; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>Paul G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>3Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Partap</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>3Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campen</LastName><ForeName>Cynthia J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>3Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibbs</LastName><ForeName>Iris C</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>1Department of Radiation Oncology, Stanford University, Stanford.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiniker</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>1Department of Radiation Oncology, Stanford University, Stanford.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurosurg Focus</MedlineTA><NlmUniqueID>100896471</NlmUniqueID><ISSNLinking>1092-0684</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016634" MajorTopicYN="Y">Radiosurgery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001932" MajorTopicYN="Y">Brain Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002528" MajorTopicYN="Y">Cerebellar Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">oncology</Keyword><Keyword MajorTopicYN="N">pediatric brain tumors</Keyword><Keyword MajorTopicYN="N">stereotactic radiosurgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321285</ArticleId><ArticleId IdType="doi">10.3171/2022.8.FOCUS22361</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321284</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1092-0684</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurosurgical focus</Title><ISOAbbreviation>Neurosurg Focus</ISOAbbreviation></Journal><ArticleTitle>Stereotactic radiosurgery for trigeminal neuralgia secondary to tumor: a single-institution retrospective series.</ArticleTitle><Pagination><MedlinePgn>E3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3171/2022.8.FOCUS22381</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Trigeminal neuralgia (TN) secondary to tumor represents a rare and diverse entity, and treatment for secondary TN remains controversial. This report reviews a single institution's experience in treating secondary TN with stereotactic radiosurgery (SRS) and focuses on the durability of pain relief with respect to various treatment targets, i.e., the trigeminal nerve, offending tumor, or both.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Between the years 2009 and 2021, 21 patients with TN secondary to benign (n = 13) or malignant (n = 8) tumors underwent SRS. Barrow Neurological Institute (BNI) pain intensity scale scores were collected from patient electronic medical records at baseline, initial follow-up, and 1 and 3 years post-SRS. The interval change in BNI scale score (ΔBNI) at the various follow-up time points was also calculated to assess the durability of pain relief following SRS.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median follow-up period was 24 (range 0.5-155) months. Five patients (24%) received treatment to the trigeminal nerve only, 10 (48%) received treatment to the tumor only, and 6 (29%) had treatment to both the nerve and tumor. The overall radiation dosage ranged from 14 to 60 Gy delivered in 1-5 fractions, with a median overall dose of 26 Gy. The median dose to the tumor was 22.5 (range 14-35) Gy, delivered in 1-5 fractions. Of the treatments targeting the tumor, 25% were delivered in a single fraction with doses ranging from 14 to 20 Gy, 60% were delivered in 3 fractions with doses ranging from 18 to 27 Gy, and 15% were delivered in 5 fractions with doses ranging from 25 to 35 Gy. The most common dose regimen for tumor treatment was 24 Gy in 3 fractions. The median biologically effective dose (with an assumed alpha/beta ratio of 10 [BED10]) for tumor treatments was 43.1 (range 13.3-60.0) Gy. There was a significant difference in the proportion of patients with recurrent pain (ΔBNI score ≥ 0) at the time of last follow-up across the differing SRS treatment targets: trigeminal nerve only, tumor only, or both (p = 0.04). At the time of last follow-up, the median ΔBNI score after SRS to the nerve only was -1, 0 after SRS to tumor only, and -2 after SRS to both targets.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">SRS offers clinical symptomatic benefit to patients with TN secondary to tumor. For optimal pain relief and response durability, treatment targeting both the tumor and the trigeminal nerve appears to be most advantageous.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Jennifer C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Departments of1Radiation Oncology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ung</LastName><ForeName>Timothy H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>2Neurosurgery, Stanford University, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCleary</LastName><ForeName>Tamra-Lee</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>2Neurosurgery, Stanford University, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Departments of1Radiation Oncology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibbs</LastName><ForeName>Iris C</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Departments of1Radiation Oncology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soltys</LastName><ForeName>Scott G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Departments of1Radiation Oncology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayden Gephart</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>2Neurosurgery, Stanford University, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>2Neurosurgery, Stanford University, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pollom</LastName><ForeName>Erqi L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Departments of1Radiation Oncology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Steven D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>2Neurosurgery, Stanford University, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meola</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>2Neurosurgery, Stanford University, Palo Alto, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurosurg Focus</MedlineTA><NlmUniqueID>100896471</NlmUniqueID><ISSNLinking>1092-0684</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014277" MajorTopicYN="Y">Trigeminal Neuralgia</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016634" MajorTopicYN="Y">Radiosurgery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">facial pain syndromes</Keyword><Keyword MajorTopicYN="N">secondary trigeminal neuralgia</Keyword><Keyword MajorTopicYN="N">stereotactic radiosurgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>07</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321284</ArticleId><ArticleId IdType="doi">10.3171/2022.8.FOCUS22381</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321282</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1092-0684</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurosurgical focus</Title><ISOAbbreviation>Neurosurg Focus</ISOAbbreviation></Journal><ArticleTitle>Outcomes following stereotactic radiosurgery for foramen magnum meningiomas: a single-center experience and systematic review of the literature.</ArticleTitle><Pagination><MedlinePgn>E6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3171/2022.8.FOCUS22299</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Foramen magnum meningiomas (FMMs) pose a unique challenge given their intimate anatomical relationship with the craniovertebral junction. While resection has been studied extensively, much less has been reported about the use of stereotactic radiosurgery (SRS) for FMMs. This study includes what is to the authors' knowledge the first systematic review in the literature that summarizes patient and treatment characteristics and synthesizes outcomes following SRS for FMMs.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective chart review was conducted at a single major academic institution, and a systematic review was performed according to PRISMA guidelines. The initial search on the PubMed and Scopus databases yielded 530 results. Key data extracted from both databases included Karnofsky Performance Status (KPS) score and neurological deficits at presentation, tumor location, treatment indication, target volume, single versus multiple fractions, marginal and maximum doses, isodose line, clinical and radiographic follow-up times, and primary (clinical stability and local control at last follow-up) and secondary (mortality, adverse radiation events, time to regression, progression-free survival) outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study patients included 9 patients from the authors' institution and 165 patients across 4 studies who received SRS for FMMs. The weighted median age at treatment was 60.2 years, and 73.9% of patients were female. Common presenting symptoms included headache (33.9%), dizziness/ataxia (29.7%), cranial nerve deficit(s) (27.9%), numbness (22.4%), weakness (15.2%), and hydrocephalus (4.2%). Lateral/ventrolateral (64.2%) was the most common tumor location. SRS was utilized as the primary therapy in 63.6% of patients and as salvage (21.8%) or adjuvant (14.5%) therapy for the rest of the patients. Most patients (91.5%) were treated with a single fraction. A tumor with a weighted median target volume of 2.9 cm3 was treated with a weighted median marginal dose, maximum dose, and isodose line of 12.9 Gy, 22.8 Gy, and 58%, respectively. Clinical stability and local control at last follow-up were achieved in 98.8% and 97.0% of patients, respectively. Only one possible adverse radiation event occurred, and no mortality directly related to the tumor or SRS was reported.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this retrospective analysis and systematic review, the authors demonstrate SRS to be an effective and safe treatment option for carefully selected patients with FMMs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karras</LastName><ForeName>Constantine L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>1Department of Neurological Surgery, Northwestern University, Chicago.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Texakalidis</LastName><ForeName>Pavlos</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>1Department of Neurological Surgery, Northwestern University, Chicago.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Jeffrey Z</ForeName><Initials>JZ</Initials><AffiliationInfo><Affiliation>2School of Medicine, Southern Illinois University, Springfield; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trybula</LastName><ForeName>S Joy</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>1Department of Neurological Surgery, Northwestern University, Chicago.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Youngblood</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>1Department of Neurological Surgery, Northwestern University, Chicago.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sachdev</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>3Department of Radiation Oncology, Northwestern University, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Tarita O</ForeName><Initials>TO</Initials><AffiliationInfo><Affiliation>3Department of Radiation Oncology, Northwestern University, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalapurakal</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>3Department of Radiation Oncology, Northwestern University, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandler</LastName><ForeName>James P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>1Department of Neurological Surgery, Northwestern University, Chicago.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magill</LastName><ForeName>Stephen T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>1Department of Neurological Surgery, Northwestern University, Chicago.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurosurg Focus</MedlineTA><NlmUniqueID>100896471</NlmUniqueID><ISSNLinking>1092-0684</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008579" MajorTopicYN="Y">Meningioma</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016634" MajorTopicYN="Y">Radiosurgery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005539" MajorTopicYN="N">Foramen Magnum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019292" MajorTopicYN="Y">Skull Base Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008577" MajorTopicYN="Y">Meningeal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">brain</Keyword><Keyword MajorTopicYN="N">foramen magnum</Keyword><Keyword MajorTopicYN="N">meningioma</Keyword><Keyword MajorTopicYN="N">stereotactic radiosurgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321282</ArticleId><ArticleId IdType="doi">10.3171/2022.8.FOCUS22299</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321281</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1092-0684</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurosurgical focus</Title><ISOAbbreviation>Neurosurg Focus</ISOAbbreviation></Journal><ArticleTitle>Adjuvant stereotactic radiosurgery with or without postoperative fractionated radiation therapy in adults with skull base chordomas: a systematic review.</ArticleTitle><Pagination><MedlinePgn>E5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3171/2022.8.FOCUS22239</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this retrospective study was to compare the survival of patients with biopsy-proven skull base chordoma who had undergone stereotactic radiosurgery (SRS) with versus without prior fractionated radiation therapy (RT).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Relevant articles from database inception to September 2021 were retrieved from the PubMed, Scopus, Web of Science, and Cochrane databases for a systematic review of treatment protocols. Studies were included if they 1) involved adult patients (age ≥ 18 years) with histologically and radiologically confirmed chordomas located within the clival skull base region and treated with SRS; 2) reported data on clinical features, SRS protocols, and outcomes; and 3) were written in the English language. Studies were excluded if they 1) were literature reviews, case reports, technical notes, abstracts, or autopsy reports; 2) did not clearly differentiate the data of patients with chordomas from the data of patients with different tumors or the data of patients with chordomas in locations other than the skull base; or 3) lacked histological confirmation or treatment and outcome data. Extracted data included the following: study author and publication year, patient age and sex, symptoms, cranial nerve involvement, invaded structures, lesion size, treatment modality, surgical details, histopathological type, RT modality, SRS parameters, complications, postradiosurgery outcomes, complications, and survival outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After the selection process, 15 articles describing 130 patients met the study eligibility criteria, including 94 patients who had undergone postresection SRS (NoRT group) and 36 who had undergone postresection fractionated RT and subsequent SRS (RT group). The NoRT and RT groups were comparable in age (51.3 vs 47.4 years, respectively), sex (57.1% vs 58.3% male), tumor volume (9.5 vs 11.2 cm3), SRS treatment parameters (maximum dose: 35.4 vs 42.2 Gy, marginal dose: 19.6 vs 20.6 Gy, treatment isodose line: 60.2% vs 65.2%), and SRS adverse effects (10.9% vs 17.6%). For the entire cohort, the 3-, 5-, and 10-year progression-free survival (PFS) rates were 23%, 9%, and 3%, respectively, and the overall survival (OS) rates were 94%, 82%, and 76%, respectively. In the NoRT group, SRS was adjuvant treatment after resection in 38 patients (40.4%), salvage treatment for recurrent tumor treated with resection alone in 10 (10.6%), and not specified in 46 (48.9%). In the RT group, SRS was boost treatment in 9 patients (25.0%), salvage treatment after recurrence in 22 (61.1%), and not specified in 5 (13.9%). There was no difference between the two groups in terms of median PFS (24.0 months [Q1 34.0, Q3 15.0] vs 23.8 months [34.0, 18.0], respectively; p = 0.8) or median OS (293.0 months [not reached, 137.4] vs not reached [not reached, 48.0], respectively; p = 0.36). The adverse radiation effect rates were comparable between the groups (10.9% vs 17.6%, respectively; p = 0.4).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The role of SRS in the management of skull base chordomas is still evolving. This systematic literature review of biopsy-proven chordoma revealed that tumor control and survival rates for SRS alone after chordoma surgery were not inferior to those encountered after SRS plus fractionated RT.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bin-Alamer</LastName><ForeName>Othman</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>1Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallela</LastName><ForeName>Arka N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>1Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmisciano</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>2Department of Neurosurgery, University of Cincinnati College of Medicine, Cincinnati, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gersey</LastName><ForeName>Zachary C</ForeName><Initials>ZC</Initials><AffiliationInfo><Affiliation>1Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elarjani</LastName><ForeName>Turki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>3Department of Neurosurgery, University of Miami Miller School of Medicine, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labib</LastName><ForeName>Mohamed A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>4Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zenonos</LastName><ForeName>Georgios A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>1Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dehdashti</LastName><ForeName>Amir R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>5Department of Neurosurgery, Zucker School of Medicine at Hofstra/Northwell, Manhasset, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheehan</LastName><ForeName>Jason P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>6Department of Neurosurgery, University of Virginia Health System, Charlottesville, Virginia; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couldwell</LastName><ForeName>William T</ForeName><Initials>WT</Initials><AffiliationInfo><Affiliation>7Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunsford</LastName><ForeName>L Dade</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>1Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abou-Al-Shaar</LastName><ForeName>Hussam</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>1Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurosurg Focus</MedlineTA><NlmUniqueID>100896471</NlmUniqueID><ISSNLinking>1092-0684</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002817" MajorTopicYN="Y">Chordoma</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016634" MajorTopicYN="Y">Radiosurgery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019292" MajorTopicYN="Y">Skull Base Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CyberKnife</Keyword><Keyword MajorTopicYN="N">Gamma Knife</Keyword><Keyword MajorTopicYN="N">chordoma</Keyword><Keyword MajorTopicYN="N">endoscopic endonasal approach</Keyword><Keyword MajorTopicYN="N">linear accelerator</Keyword><Keyword MajorTopicYN="N">microsurgery</Keyword><Keyword MajorTopicYN="N">radiosurgery</Keyword><Keyword MajorTopicYN="N">skull base</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>04</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321281</ArticleId><ArticleId IdType="doi">10.3171/2022.8.FOCUS22239</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321266</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-7445</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>21</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Cancer research</Title><ISOAbbreviation>Cancer Res</ISOAbbreviation></Journal><ArticleTitle>Accidentals of the DNA Symphony.</ArticleTitle><Pagination><MedlinePgn>3880-3881</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/0008-5472.CAN-22-2750</ELocationID><Abstract><AbstractText>Cancer epigenome profiling such as DNA methylation (5mC) and DNA hydroxymethylation (5hmC) is emerging as a sensitive approach for cancer detection and risk stratification. 5mC modification has been widely described in many cancer types including prostate cancer; however, the 5hmC landscape is yet to be explored. In this issue of Cancer Research, Sjöström and colleagues have comprehensively incorporated genomic, transcriptomic, and epigenomic, including 5hmC, data to interrogate the molecular evolution of prostate cancer. See related article by Sjöström et al., p. 3888.</AbstractText><CopyrightInformation>©2022 American Association for Cancer Research.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Anjui</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1167-7071</Identifier><AffiliationInfo><Affiliation>University College London Cancer Institute, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attard</LastName><ForeName>Gerhardt</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-4811-7983</Identifier><AffiliationInfo><Affiliation>University College London Cancer Institute, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Res</MedlineTA><NlmUniqueID>2984705R</NlmUniqueID><ISSNLinking>0008-5472</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1123-95-1</RegistryNumber><NameOfSubstance UI="C011865">5-hydroxymethylcytosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Cancer Res. 2022 Nov 2;82(21):3888-3902</RefSource><PMID Version="1">36251389</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="Y">Prostatic Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>08</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321266</ArticleId><ArticleId IdType="pii">709949</ArticleId><ArticleId IdType="doi">10.1158/0008-5472.CAN-22-2750</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321265</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-7445</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>21</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Cancer research</Title><ISOAbbreviation>Cancer Res</ISOAbbreviation></Journal><ArticleTitle>The Heat Is On: 20-HETE Instructs an Immunosuppressive Phenotype in Cancer-Associated Fibroblasts.</ArticleTitle><Pagination><MedlinePgn>3882-3883</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/0008-5472.CAN-22-2774</ELocationID><Abstract><AbstractText>Immunotherapy of cancer is a burgeoning field of research since the realization that our immune system intrinsically has the capacity to restrict tumor occurrence and progression. Though strategies to maximize antitumor T-cell activation are well established, the efficacy of these therapies is limited by an insufficient knowledge of the intricate tumor microenvironment and its capacity to thwart antitumor immunity. Chen and colleagues now uncover a novel immunosuppressive pathway in non-small cell lung carcinoma. Overexpression of cytochrome P450F2 in cancer cells increases production of 20-hydroxyeicosatetraenoic acid, which instructs the expression of immunosuppressive molecules in cancer-associated fibroblasts by binding the GPR75 receptor and activating STAT3/c-Jun signaling. This work proposes several innovative therapeutic anchor points that may improve the efficacy of existing immunotherapies. See related article by Chen et al., p. 4016.</AbstractText><CopyrightInformation>©2022 American Association for Cancer Research.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Van Ginderachter</LastName><ForeName>Jo A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-4442-7474</Identifier><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Res</MedlineTA><NlmUniqueID>2984705R</NlmUniqueID><ISSNLinking>0008-5472</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>79551-86-3</RegistryNumber><NameOfSubstance UI="C055987">20-hydroxy-5,8,11,14-eicosatetraenoic acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>27YG812J1I</RegistryNumber><NameOfSubstance UI="D016718">Arachidonic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>59985-28-3</RegistryNumber><NameOfSubstance UI="D019377">12-Hydroxy-5,8,10,14-eicosatetraenoic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.14.78</RegistryNumber><NameOfSubstance UI="C117480">CYP4F2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C120151">GPR75 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Cancer Res. 2022 Nov 2;82(21):4016-4030</RefSource><PMID Version="1">36006988</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016718" MajorTopicYN="N">Arachidonic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072645" MajorTopicYN="Y">Cancer-Associated Fibroblasts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="Y">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006358" MajorTopicYN="N">Hot Temperature</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019377" MajorTopicYN="N">12-Hydroxy-5,8,10,14-eicosatetraenoic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017154" MajorTopicYN="N">Stromal Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002384" MajorTopicYN="N">Catalysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>08</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321265</ArticleId><ArticleId IdType="pii">709948</ArticleId><ArticleId IdType="doi">10.1158/0008-5472.CAN-22-2774</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321264</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-7445</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>21</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Cancer research</Title><ISOAbbreviation>Cancer Res</ISOAbbreviation></Journal><ArticleTitle>The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.</ArticleTitle><Pagination><MedlinePgn>3861-3867</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/0008-5472.CAN-22-2453</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Kenneth C</ForeName><Initials>KC</Initials><Identifier Source="ORCID">0000-0002-6418-0886</Identifier></Author><Author ValidYN="Y"><LastName>Cantley</LastName><ForeName>Lewis C</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000-0002-1298-7653</Identifier></Author><Author ValidYN="Y"><LastName>Dalla-Favera</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3502-8826</Identifier></Author><Author ValidYN="Y"><LastName>Dang</LastName><ForeName>Chi Van</ForeName><Initials>CV</Initials><Identifier Source="ORCID">0000-0002-4031-2522</Identifier></Author><Author ValidYN="Y"><LastName>Diaz</LastName><ForeName>Luis A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0002-7079-8914</Identifier></Author><Author ValidYN="Y"><LastName>DuBois</LastName><ForeName>Raymond N</ForeName><Initials>RN</Initials><Identifier Source="ORCID">0000-0002-6385-7154</Identifier></Author><Author ValidYN="Y"><LastName>Flaherty</LastName><ForeName>Keith T</ForeName><Initials>KT</Initials><Identifier Source="ORCID">0000-0002-3402-0478</Identifier></Author><Author ValidYN="Y"><LastName>Greenberg</LastName><ForeName>Philip D</ForeName><Initials>PD</Initials><Identifier Source="ORCID">0000-0003-3812-647X</Identifier></Author><Author ValidYN="Y"><LastName>Loda</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9674-8379</Identifier></Author><Author ValidYN="Y"><LastName>Mardis</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials><Identifier Source="ORCID">0000-0002-5892-1553</Identifier></Author><Author ValidYN="Y"><LastName>Platz</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0003-3676-8954</Identifier></Author><Author ValidYN="Y"><LastName>Pollak</LastName><ForeName>Michael N</ForeName><Initials>MN</Initials><Identifier Source="ORCID">0000-0003-3047-0604</Identifier></Author><Author ValidYN="Y"><LastName>Schreiber</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials><Identifier Source="ORCID">0000-0003-1590-2341</Identifier></Author><Author ValidYN="Y"><LastName>Siu</LastName><ForeName>Lillian L</ForeName><Initials>LL</Initials><Identifier Source="ORCID">0000-0002-3500-0540</Identifier></Author><Author ValidYN="Y"><LastName>Teicher</LastName><ForeName>Beverly A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0003-1535-7304</Identifier></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Res</MedlineTA><NlmUniqueID>2984705R</NlmUniqueID><ISSNLinking>0008-5472</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010506" MajorTopicYN="Y">Periodicals as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321264</ArticleId><ArticleId IdType="pii">709966</ArticleId><ArticleId IdType="doi">10.1158/0008-5472.CAN-22-2453</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321262</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-7445</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>21</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Cancer research</Title><ISOAbbreviation>Cancer Res</ISOAbbreviation></Journal><ArticleTitle>Challenges and Emerging Opportunities for Targeting mTOR in Cancer.</ArticleTitle><Pagination><MedlinePgn>3884-3887</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/0008-5472.CAN-22-0602</ELocationID><Abstract><AbstractText>The mechanistic target of rapamycin (mTOR) plays a key role in normal and malignant cell growth. However, pharmacologic targeting of mTOR in cancer has shown little clinical benefit, in spite of aberrant hyperactivation of mTOR in most solid tumors. Here, we discuss possible reasons for the reduced clinical efficacy of mTOR inhibition and highlight lessons learned from recent combination clinical trials and approved indications of mTOR inhibitors in cancer. We also discuss how the emerging systems level understanding of mTOR signaling in cancer can be exploited for the clinical development of novel multimodal precision targeted therapies and immunotherapies aimed at achieving tumor remission.</AbstractText><CopyrightInformation>©2022 American Association for Cancer Research.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Kris C</ForeName><Initials>KC</Initials><Identifier Source="ORCID">0000-0002-5887-2253</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gutkind</LastName><ForeName>J Silvio</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0002-5150-4482</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Moores Cancer Center, University of California, La Jolla, San Diego, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CA247551</GrantID><Agency>National Cancer Institute (NCI)</Agency><Country/></Grant><Grant><GrantID>DE026644</GrantID><Agency>National Institute of Dental and Craniofacial Research (NIDCR)</Agency><Country/></Grant><Grant><GrantID>DE026870</GrantID><Agency>National Institute of Dental and Craniofacial Research (NIDCR)</Agency><Country/></Grant><Grant><GrantID>CA263593</GrantID><Agency>National Cancer Institute (NCI)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Res</MedlineTA><NlmUniqueID>2984705R</NlmUniqueID><ISSNLinking>0008-5472</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber><NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="Y">Sirolimus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>07</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321262</ArticleId><ArticleId IdType="pii">709952</ArticleId><ArticleId IdType="doi">10.1158/0008-5472.CAN-22-0602</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321254</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1758-5090</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Biofabrication</Title><ISOAbbreviation>Biofabrication</ISOAbbreviation></Journal><ArticleTitle>A rapid high throughput bioprinted colorectal cancer spheroid platform for<i>in vitro</i>drug- and radiation-response.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1088/1758-5090/ac999f</ELocationID><Abstract><AbstractText>We describe the development of a high-throughput bioprinted colorectal cancer (CRC) spheroid platform with high levels of automation, information content, and low cell number requirement. This is achieved via the formulation of a hydrogel bioink with a compressive Young's modulus that is commensurate with that of colonic tissue (1-3 kPa), which supports exponential growth of spheroids from a wide range of CRC cell lines. The resulting spheroids display tight cell-cell junctions, bioink matrix-cell interactions and necrotic hypoxic cores. By combining high content light microscopy imaging and processing with rapid multiwell plate bioprinting, dose-response profiles are generated from CRC spheroids challenged with oxaliplatin (OX) and fluorouracil (5FU), as well as radiotherapy. Bioprinted CRC spheroids are shown to exhibit high levels of chemoresistance relative to cell monolayers, and OX was found to be significantly less effective against tumour spheroids than in monolayer culture, when compared to 5FU.</AbstractText><CopyrightInformation>Creative Commons Attribution license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Oxford, Oxford OX1 3TA, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menegatti</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chambers</LastName><ForeName>Adam C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>School of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alibhai</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Wolfson Bioimaging Facility, University of Bristol, Bristol BS8 1TD, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collard</LastName><ForeName>Tracey J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>School of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Ann C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>School of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bayley</LastName><ForeName>Hagan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Oxford, Oxford OX1 3TA, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perriman</LastName><ForeName>Adam W</ForeName><Initials>AW</Initials><Identifier Source="ORCID">0000-0003-2205-9364</Identifier><AffiliationInfo><Affiliation>School of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Biofabrication</MedlineTA><NlmUniqueID>101521964</NlmUniqueID><ISSNLinking>1758-5082</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>U3P01618RT</RegistryNumber><NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance></Chemical><Chemical><RegistryNumber>04ZR38536J</RegistryNumber><NameOfSubstance UI="D000077150">Oxaliplatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018874" MajorTopicYN="N">Spheroids, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062028" MajorTopicYN="Y">Bioprinting</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077150" MajorTopicYN="N">Oxaliplatin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bioprinting</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">colorectal</Keyword><Keyword MajorTopicYN="N">spheroid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>03</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321254</ArticleId><ArticleId IdType="doi">10.1088/1758-5090/ac999f</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36321246</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4209</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Medical physics</Title><ISOAbbreviation>Med Phys</ISOAbbreviation></Journal><ArticleTitle>Transfer learning framework for low-dose CT reconstruction based on marginal distribution adaptation in multi-scale.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/mp.16027</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">With the increasing use of CT in clinical practice, limiting CT radiation exposure to reduce potential cancer risks has become one of the important directions of medical imaging research. As the dose decreases, the reconstructed CT image will be severely degraded by projection noise.</AbstractText><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">As an important method of image processing, supervised deep learning has been widely used in the restoration of low-dose CT(LDCT) in recent years. However, the normal-dose CT (NDCT) corresponding to a specific LDCT (it is regareded as the label of the LDCT, which is necessary for supervised learning) are very difficult to obtain. So that the application of supervised learning methods in LDCT reconstruction is limited. It is necessary to construct a unsupervised deep learning framework for LDCT reconstruction that does not depend on paired LDCT-NDCT datasets.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We presented an unsupervised learning framework for the transferring from the identity mapping to the low-dose recontruction task, called Marginal Distribution Adaptation in Multi-scale (MDAM). For NDCTs as source domain data, MDAM is an identity map with two parts: firstly, it establishes a dimensionality reduction mapping, which can obtain the same feature distribution from NDCTs and LDCTs; and then NDCTs is retrieved by reconstructing the image overview and details from the low-dimensional features. For the purpose of the feature transfer between source domain and target domain (LDCTs), we introduce the multi-scale feature extraction in the MDAM, and then eliminate differences in probability distributions of these multi-scale features between NDCTs and LDCTs through wavelet decomposition and domain adaptation learning.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Image quality evaluation metrics and subjective quality scores show that, as an unsupervised method, the performance of the MDAM approaches or even surpasses some state-of-the-art supervised methods. Especially, MDAM has been favorably evaluated in terms of noise suppression, structural preservation, and lesion detection.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We demonstrated that, the MDAM framework can reconstruct corresponding NDCTs from LDCTs with high accuracy, and without relying on any labeles. Moreover, it is more suitable for clinical application compared with supervised learning methods. This article is protected by copyright. All rights reserved.</AbstractText><CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Minghan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hefei Institutes of Physical Science, Chinese Academy of Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jianye</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hefei Institutes of Physical Science, Chinese Academy of Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ziheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Hefei Institutes of Physical Science, Chinese Academy of Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hefei Institutes of Physical Science, Chinese Academy of Sciences.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hefei Cancer Hospital, Chinese Academy of Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lingling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hefei Institutes of Physical Science, Chinese Academy of Sciences.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hefei Cancer Hospital, Chinese Academy of Sciences.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Phys</MedlineTA><NlmUniqueID>0425746</NlmUniqueID><ISSNLinking>0094-2405</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">low-dose CT</Keyword><Keyword MajorTopicYN="N">reconstruction</Keyword><Keyword MajorTopicYN="N">transfer learning</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>09</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>3</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321246</ArticleId><ArticleId IdType="doi">10.1002/mp.16027</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36321239</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2589-9783</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Current drug research reviews</Title><ISOAbbreviation>Curr Drug Res Rev</ISOAbbreviation></Journal><ArticleTitle>Synergistic Effect of Piperine and its Derivatives: A Comprehensive Review.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.2174/2589977515666221101153730</ELocationID><Abstract><AbstractText>Piperine is a fascinating substance since it can be used as a biomarker in combination with other bioactive compounds or their analogues, as well as therapeutic molecules used for the healing of a variety of diseases. It displays a plentiful therapeutic potential and various health benefits when administered alone or in combination with several other drugs and/or phytochemicals. It has also been used to enhance the pharmacokinetic profile of many nutraceutical compounds like curcumin, resveratrol, quercetin, beta-carotene, barbiturates, propranolol, metformin, theophylline etc. The present review discloses the synergistic effect of piperine and its derivatives, clinical studies, and patent studies of piperine.</AbstractText><CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saini</LastName><ForeName>Neha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Guru Gobind Singh College of Pharmacy, Yamuna Nagar-135001, Haryana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chopra</LastName><ForeName>Bhawna</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Guru Gobind Singh College of Pharmacy, Yamuna Nagar-135001, Haryana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhingra</LastName><ForeName>Ashwani K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Guru Gobind Singh College of Pharmacy, Yamuna Nagar-135001, Haryana, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Drug Res Rev</MedlineTA><NlmUniqueID>101735701</NlmUniqueID><ISSNLinking>2589-9775</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Piperine</Keyword><Keyword MajorTopicYN="N">anti-cancer</Keyword><Keyword MajorTopicYN="N">clinical studies</Keyword><Keyword MajorTopicYN="N">neuroprotective</Keyword><Keyword MajorTopicYN="N">synergistic effect</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321239</ArticleId><ArticleId IdType="pii">CDRR-EPUB-127327</ArticleId><ArticleId IdType="doi">10.2174/2589977515666221101153730</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36321238</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-6220</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Oct</Month><Day>31</Day></PubDate></JournalIssue><Title>Current drug discovery technologies</Title><ISOAbbreviation>Curr Drug Discov Technol</ISOAbbreviation></Journal><ArticleTitle>PROTAC: A Novel drug delivery technology for targeting proteins in cancer cells.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.2174/1570163820666221031124612</ELocationID><Abstract><AbstractText>The treatment measures of malignant carcinomas are most important for the progress of human health. In recent years the use of targeted therapy based on small molecules compounds and identical immunoglobulin are the most frequently used tools to combat cancerous cells. But there are still several limitations in their clinical development and applications of these technologies comprising their ability to bind multiple molecular target sites including both cell surface receptors and intracellular proteins and therefore promoting greater risk of toxicity. PROTAC a novel technology that work on maintaining balance between protein synthesis and degradation and make use of molecules instead of conventional enzyme inhibitor, containing two active domains and a linker to destroy unwanted selective protein (like kinase, skeleton protein and regulatory protein). PROTACs are the heterobifunctional nano molecules with size range of about 10 nanometres find application to eliminate the protein complexes formed by protein-protein interaction through large and flat surface generally defined as "undruggable" in conventional drug delivery system, which include around 85 % of proteins present in humans, suggesting their wide application in the field of drug development. Such peptide-based PROTACs have shown the destruction of targets in cultured cells successfully (e.g., MetAP-2, and FKBP12F36V, receptors for estrogens and androgen). However, some obstacles prevent this technology from transferring from the laboratory to its actual clinical utility, such as delivery system and bioavailability. The scope of the presented review is to gives an overview of novel PROTAC technology with its limitations, advantages , mechanism of action, development of photo-controlled PROTACs and to summarize its futuristic approach in targeting proteins in cancer cells.</AbstractText><CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bala</LastName><ForeName>Rajni</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Chitkara College of Pharmacy, Chitkara University, Punjab, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sindhu</LastName><ForeName>Rakesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Sharda University, Greater Noida, Gautam Buddha Nagar 201310, Uttar Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madaan</LastName><ForeName>Reecha</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Chitkara College of Pharmacy, Chitkara University, Punjab, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shantanu</LastName><AffiliationInfo><Affiliation>Chitkara College of Pharmacy, Chitkara University, Punjab, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Drug Discov Technol</MedlineTA><NlmUniqueID>101157212</NlmUniqueID><ISSNLinking>1570-1638</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Carcinoma</Keyword><Keyword MajorTopicYN="N">PROTACs</Keyword><Keyword MajorTopicYN="N">Proteins</Keyword><Keyword MajorTopicYN="N">Small molecules</Keyword><Keyword MajorTopicYN="N">Undruggable.</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>09</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321238</ArticleId><ArticleId IdType="pii">CDDT-EPUB-127297</ArticleId><ArticleId IdType="doi">10.2174/1570163820666221031124612</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36321237</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-5992</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Oct</Month><Day>31</Day></PubDate></JournalIssue><Title>Anti-cancer agents in medicinal chemistry</Title><ISOAbbreviation>Anticancer Agents Med Chem</ISOAbbreviation></Journal><ArticleTitle>Development of Antibody-Drug Conjugates: Future Perspective towards Solid Tumor Treatment.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.2174/1871520623666221031105432</ELocationID><Abstract><AbstractText>Antibody-Drug Conjugates (ADCs) are basically a targeted drug delivery system where tumour antigen-specific antibodies are used for targeting particular tumor cells and cytotoxic materials are conjugated with it by a linker molecule. Till now, twelve ADCs have been approved by FDA for clinical use. Majority of the approved ADCs are against hematological cancer. Here in this review we will discuss the combinations of targeted ligands (antigen) specific antibodies, different types of cytotoxic drugs (payload/warheads) and linker moieties which are being used towards the development of successful FDA approved ADCs. We will discuss new ADC formulations which completed clinical trials or undergo advance phases of clinical trials against different types of solid tumours. New ADC formulation or recently developed its prototypes against solid tumour models in preclinical studies will be discussed precisely in this review article.</AbstractText><CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pramanik</LastName><ForeName>Dipankar</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Postgraduate Department of Chemistry, Haldia Government College, Debhog, Haldia, West Bengal, India 721657.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Anticancer Agents Med Chem</MedlineTA><NlmUniqueID>101265649</NlmUniqueID><ISSNLinking>1871-5206</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ADC</Keyword><Keyword MajorTopicYN="N">antibody</Keyword><Keyword MajorTopicYN="N">chemotherapy</Keyword><Keyword MajorTopicYN="N">cytotoxicity</Keyword><Keyword MajorTopicYN="N">tumour</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321237</ArticleId><ArticleId IdType="pii">ACAMC-EPUB-127285</ArticleId><ArticleId IdType="doi">10.2174/1871520623666221031105432</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36321230</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-5402</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Oct</Month><Day>31</Day></PubDate></JournalIssue><Title>Combinatorial chemistry &amp; high throughput screening</Title><ISOAbbreviation>Comb Chem High Throughput Screen</ISOAbbreviation></Journal><ArticleTitle>Acteoside (Verbascoside): A prospective therapeutic alternative against Hepatocellular Carcinoma by inhibiting the expression of AXL, FGFR, BRAF, TIE2 and RAF1 targets.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.2174/1386207326666221031121426</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">Hepatocellular carcinoma (HCC) is the world's second leading cause of cancer-related mortality and the fifth most prevalent cancer overall. To treat diverse liver disorders, several synthetic and plant-based remedies are in practice. Because of their minimal side effects and protective characteristics, plant phenolics have the potential to become alternative therapeutics, replacing currently existing HCC medications. The present study identifies the plant phenolics as having the capacity to inhibit HCC with low side effects and cost efficiency.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hepatocellular carcinoma (HCC) is the leading cause of cancer-related mortality, despite the proven effectiveness of screening programs for at-risk individuals, the majority of patients have disease progression or tumor characteristics that preclude curative therapies at the time of diagnosis. Acteoside (Verbascoside) is a naturally occurring phenylethanoid glycoside found throughout the plant kingdom. Acteoside is a physiologically active chemical with number of pharmacological and protective effects against various liver illnesses.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Currently used HCC medications have a variety of side effects. Plant-based chemicals offer the possibility of treating HCC with minimal side effects. The work is targeted to find the best phytochemical (plant phenolic) lead molecule for future drug development research against Hepatocellular carcinoma.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The targets were selected based on an analysis of relevant literature, and the 3D structures of the selected receptors were obtained in.pdb format from the RCSB-Protein data bank (PDB, http://www.rscb.org/pdb). Based on a review of the literature, sixty plant secondary metabolites, or plant phenolics, were selected. The ligand structures were obtained and downloaded in.sdf format from the NCBI PubChem chemicals database (https://pubchem.ncbi.nlm.nih.gov/). Molecular docking between the receptor and ligands was accomplished using the Molegro Virtual Docker 6.0 (MVD) software.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The target RAF1, BRAF chain 1, TIE2 chain 2 FGFR1, FGFR2, AXL, and FGFR4 showed the best binding effectiveness with acteoside compared to their respective positive control. RET chain 1 and BRAF chain 2 acteoside showed prominent binding efficacy after Curcumin, and Epigallocatechingallate respectively against positive control. Present findings clearly pointing towards the potentiality of acteoside in inhibiting various HCC targets.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Acteoside, may be used as a prominent lead molecule in the future treatment of hepatic cancer with its multifaceted binding efficiencies against various target proteins.</AbstractText><CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kityania</LastName><ForeName>Sibashish</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Life Science and Bioinformatics, Assam University, Silchar, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nath</LastName><ForeName>Rajat</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Life Science and Bioinformatics, Assam University, Silchar, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nath</LastName><ForeName>Deepa</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Botany, Guru Charan College, Silchar, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patra</LastName><ForeName>Jayanta Kumar</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Research Institute Integrative Life Sciences, Dongguk University-Seoul, Goyangsi, 10326, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talukdar</LastName><ForeName>Anupam Das</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Life Science and Bioinformatics, Assam University, Silchar, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Comb Chem High Throughput Screen</MedlineTA><NlmUniqueID>9810948</NlmUniqueID><ISSNLinking>1386-2073</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acteoside</Keyword><Keyword MajorTopicYN="N">Hepatocellular carcinoma (HCC)</Keyword><Keyword MajorTopicYN="N">In-silico</Keyword><Keyword MajorTopicYN="N">Molecular Docking</Keyword><Keyword MajorTopicYN="N">Natural phenolics</Keyword><Keyword MajorTopicYN="N">drug lead.</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>09</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321230</ArticleId><ArticleId IdType="pii">CCHTS-EPUB-127292</ArticleId><ArticleId IdType="doi">10.2174/1386207326666221031121426</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36321227</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-6697</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Oct</Month><Day>31</Day></PubDate></JournalIssue><Title>Current computer-aided drug design</Title><ISOAbbreviation>Curr Comput Aided Drug Des</ISOAbbreviation></Journal><ArticleTitle>The Determination of Molecular and Toxicological Mechanisms of Cucurbitacine E in Model Organism Drosophila melanogaster and Various Cancer Cell Lines: Molecular modelling, docking and dynamic simulation studies.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.2174/1573409919666221031112223</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Cucurbitacins are one of the most important components of Ecballium elaterium. Among the cucurbitacins, Cucurbitacin E was the first to be isolated. This study focused on screening the anticancer and insecticidal potential of Cucurbitacin E by the in-vitro, in-vivo, and in-silico methods.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In the study, toxicity analysis of Cucurbitacin E were determined on HeLa, Caco 2 cancer cell lines and D. melanogaster. While the expression levels of the BAD, BCL-2, AKT-1 and H-purine genes of cancer cell lines were determined, the CG15530, BUFFY, AKT-1 and Purine genes of D. melanogaster were determined by RT-PCR. Besides, molecular docking and dynamic properties of Cucurbitacin E with human and insectoid enzymes were presented in silico.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The IC50 value of Cucurbitacin E in the HeLa ovarian and Caco 2 colon cancer cell lines was determined to be 42 ug/ml and 85 ug/ml, respectively. The LC50 and LC99 doses for fruit flies were determined to be 47,693 µg/ml and 133,251 µg/ml, respectively. Gene expression analysis revealed that Cucurbitacin E showed the greatest effect on Purine and AKT-1 genes in D. melanogaster. We analyzed all genes by Western blot, but we did not detect significant changes in genes other than H-purine. In silico studies revealed that the Purine protein of D. melanogaster had the highest bonding energy with Cucurbitacin E as a ligand. Similarly, Cucurbitacin E showed great affinity towards H-purine (-10.2 kcal/mol). Molecular dynamics simulation studies were also performed to determine the stability of the dynamic process.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">As a result of our in vivo, in vitro and bioinformatic analyzes, it has been seen that Cucurbitacine E is effective against the cancer types and model insect studied.</AbstractText><CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tunçbilek</LastName><ForeName>Aydın Ş</ForeName><Initials>AŞ</Initials><AffiliationInfo><Affiliation>Department of Biology, Faculty of Science, Erciyes University, Kayseri, TURKEY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azarkan</LastName><ForeName>Serap Yalçın</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Medical Pharmacology, Faculty of Medicine, Kırşehir Ahi Evran University, Kırşehir, TURKEY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ercan</LastName><ForeName>Fahriye Sümer</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Department of Plant Protection, Faculty of Agriculture, Kırşehir Ahi Evran University, Kırşehir, TURKEY.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Comput Aided Drug Des</MedlineTA><NlmUniqueID>101265750</NlmUniqueID><ISSNLinking>1573-4099</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cucurbitacin E</Keyword><Keyword MajorTopicYN="N">Drosophila melanogaster</Keyword><Keyword MajorTopicYN="N">Molecular docking</Keyword><Keyword MajorTopicYN="N">Molecular dynamic analyses</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">toxicity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>09</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321227</ArticleId><ArticleId IdType="pii">CAD-EPUB-127288</ArticleId><ArticleId IdType="doi">10.2174/1573409919666221031112223</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36321226</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-6697</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Oct</Month><Day>31</Day></PubDate></JournalIssue><Title>Current computer-aided drug design</Title><ISOAbbreviation>Curr Comput Aided Drug Des</ISOAbbreviation></Journal><ArticleTitle>Identification of multi-kinase allosteric inhibitors of oncogenic targets EGFR1, PI3 &amp; BRAF Kinase.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.2174/1573409919666221031110341</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To identify promising allosteric inhibitors with the potential to inhibit EGFR1, PI3K, and BRAF kinase as a single agent or in a combination of existing drugs, thus acting as a therapeutic option when traditional drugs fail to give a beneficial response in disease pathology.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Upregulation of EGFR1 activates several downstream signaling pathways, resulting in pathophysiological alterations that contribute to cancer. The RAS/RAF/MEK/ERK (MAPK) and PI3K/Akt/mTOR (PI3K/Akt/mTOR) pathways are major downstream signalling partners induced by EGFR1 activation. Despite their vast importance, allosteric FDA-approved drugs targeting EGFR1 and these pathways are not available.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To identify novel multi-kinase small molecules with the potential to inhibit major sites of amplification of cancer signalling pathways i.e., EGFR1, PI3K/Akt/mTOR, and RAS/RAF/MEK/ERK (MAPK) signalling pathways targeting allosteric sites.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">In silico methods were used to identify the potential inhibitors using EGFR1, PI3 kinase, and BRAF kinase crystal structures complexed with allosteric inhibitors. The potential novel molecules were confirmed for their drug-likeness. Their stability of binding was also confirmed using molecular dynamics simulation studies. To eliminate false negatives, this study used a pharmacophore and structure-based targeting method.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The current study was effective in identifying druglike small molecules: ZINC38783966, ZINC01456629, ZINC01456628, and 124173751, 137352549, 137353176, 137352399, 132020316 from ZINC and PubChem database respectively with a potential to bind EGFR1 (6DUK), PI3Kinase (4A55) and BRAF (6P3D) at allosteric sites. A 50 ns molecular dynamics investigation also revealed that these potential novel multitarget kinase allosteric inhibitors exhibited stable binding.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">EGFR1, PI3K/Akt/mTOR, and RAS/RAF/MEK/ERK (MAPK) signalling pathways alternation is observed in cancers in high frequency and are also used by viral and environmental toxicants for pathologic purposes. These multi-kinase allosteric inhibitors will stimulate novel ideas for allosteric drug discovery and deepen our understanding of targeting these pathways either singly or in a combination of orthosteric inhibitors.</AbstractText><CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kakarala</LastName><ForeName>Kavita Kumari</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Bhagawan Mahavir Medical Research Centre. 10-1-1, Mahavir Marg, AC Guards, Lakdikapul, Hyderabad, Telangana 500004, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jamil</LastName><ForeName>Kaiser</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Bhagawan Mahavir Medical Research Centre. 10-1-1, Mahavir Marg, AC Guards, Lakdikapul, Hyderabad, Telangana 500004, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Comput Aided Drug Des</MedlineTA><NlmUniqueID>101265750</NlmUniqueID><ISSNLinking>1573-4099</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Kinase</Keyword><Keyword MajorTopicYN="N">binding affinity</Keyword><Keyword MajorTopicYN="N">docking</Keyword><Keyword MajorTopicYN="N">druglike</Keyword><Keyword MajorTopicYN="N">free energy</Keyword><Keyword MajorTopicYN="N">multi-kinase</Keyword><Keyword MajorTopicYN="N">scoring</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321226</ArticleId><ArticleId IdType="pii">CAD-EPUB-127286</ArticleId><ArticleId IdType="doi">10.2174/1573409919666221031110341</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36321210</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1463-1318</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland</Title><ISOAbbreviation>Colorectal Dis</ISOAbbreviation></Journal><ArticleTitle>Application of sandwich method in radical rectal cancer resection- a video vignette.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/codi.16396</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>C Z</ForeName><Initials>CZ</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-5219-8210</Identifier><AffiliationInfo><Affiliation>Department of General Surgery, Affiliated Cancer Hospital of ZhengZhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>X J</ForeName><Initials>XJ</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-7353-9283</Identifier><AffiliationInfo><Affiliation>Department of General Surgery, Affiliated Cancer Hospital of ZhengZhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Z Y</ForeName><Initials>ZY</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Affiliated Cancer Hospital of ZhengZhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Y Z</ForeName><Initials>YZ</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Affiliated Cancer Hospital of ZhengZhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Colorectal Dis</MedlineTA><NlmUniqueID>100883611</NlmUniqueID><ISSNLinking>1462-8910</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>06</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>04</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>07</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321210</ArticleId><ArticleId IdType="doi">10.1111/codi.16396</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36321209</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-277X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of human nutrition and dietetics : the official journal of the British Dietetic Association</Title><ISOAbbreviation>J Hum Nutr Diet</ISOAbbreviation></Journal><ArticleTitle>Sources of Nutrition Advice and Desired Nutrition Guidance in Oncology Care: Patient's Perspectives.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/jhn.13111</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">To describe the proportion of cancer patients and survivors who receive nutrition advice, the sources of that advice, and to explore the nutrition advice this cohort would like to have received.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A descriptive cross-sectional survey was completed by 211 cancer patients and survivors recruited through two hospitals in the North-West of Ireland. The survey consisted of open-ended and closed questions that aimed to explore the provision of and sources of nutrition advice and desired guidance in this cohort. Descriptive analysis was conducted using SPPS, while open-ended questions underwent thematic analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Respondents were mainly female (n=133, 63%), aged 50-69 years old (n=118, 56%), attending the outpatient department (n=128, 60.7%) and less than five years since diagnosis (n=150, 71.7%). Breast (n=69, 32.7%) was the most common cancer type. Respondents experienced, on average, 5 (±3.1) nutrition impact symptoms. The most common were changes in taste/smell (n=122, 57.8%). While 53.6% (n=113) reported being given advice, only 34.1% (n=72) received this advice from a dietitian. The main sources of nutritional advice were friends and family. Respondents expressed their desire for nutrition advice from a dietitian and that this should be individualised, clear and practical. There was also a desire to avoid misinformation and uncertainty.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Results can be used to tailor nutrition support for this group. There is a need to ensure that patients and survivors consistently receive evidence-based advice tailored to their needs, cancer stage and treatment stage. This article is protected by copyright. All rights reserved.</AbstractText><CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Keaver</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-1369-5035</Identifier><AffiliationInfo><Affiliation>Department of Health and Nutritional Science, Atlantic Technological University, ATU Sligo, Ash Lane, Sligo, F91 YW50, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health and Biomedical Research Centre (HEAL), Atlantic Technological University, ATU Sligo, Ash Lane, Sligo, F91 YW50, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richmond</LastName><ForeName>Janice</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Oncology, Letterkenny University Hospital, Donegal, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rafferty</LastName><ForeName>Fiona</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>HSE CHO1 Carrickmacross Primary Care Centre, Oriel Road, Carrickmacross, Co Monaghan, Ireland, A81 C462.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Douglas</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Nutrition Innovation Centre for Food and Health (NICHE), School of Biomedical Science, Ulster University, Coleraine.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Hum Nutr Diet</MedlineTA><NlmUniqueID>8904840</NlmUniqueID><ISSNLinking>0952-3871</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer Disease</Keyword><Keyword MajorTopicYN="N">Clinical Nutrition</Keyword><Keyword MajorTopicYN="N">Clinical practice</Keyword><Keyword MajorTopicYN="N">Nutrition education</Keyword><Keyword MajorTopicYN="N">therapeutic areas</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321209</ArticleId><ArticleId IdType="doi">10.1111/jhn.13111</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36321193</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0142</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Cancer</Title><ISOAbbreviation>Cancer</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of triennial screening with clinical breast examination: 14-years follow-up outcomes of randomized clinical trial in Trivandrum, India.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.34526</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study presents the preliminary results of a randomized controlled trial (RCT) initiated in January 2006 in India to evaluate the effectiveness of clinical breast examination (CBE) in reducing breast cancer mortality as compared to a no-screening control group reported significant downstaging in the intervention group. The present manuscript reports long-term follow-up outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Women 30-69 years old from 133 intervention clusters and 141 control clusters were invited to participate. Women in the intervention arm underwent three rounds of CBE every 3 years. CBE-positive women were reexamined by a physician, and triple-assessment was performed on those confirmed to have abnormalities. All participants were followed through home visits and linkage with population-based cancer registry.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 55,843 eligible women in the intervention arm, 95.7% had CBE at least once and 11.5% were CBE-positive. Breast cancers were diagnosed in 335 participants in the intervention group and 273 in the control group (N = 59,447). Age-standardized incidence rate of early cancer was 30.4 of 100,000 in the intervention and 21.9 of 100,000 in the control group, with a rate ratio (RR) of 1.4 (95% confidence interval [CI], 1.1-1.8). The age-standardized breast cancer mortality rates were 11.3 and 11.1 per 100,000 in intervention and control arms, respectively (RR, 1.1; 95% CI, 0.8-1.5) after 15 years. Five-year breast cancer survival rates were 77.0% in the intervention and 71.2% in the control groups (overall p value = .043).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Triennial CBE screening failed to demonstrate any mortality benefit despite achieving a shift toward earlier stage at detection and improved survival in the intervention arm. CBE is a valuable tool for diagnosis of breast cancer in symptomatic women especially in areas where mammography and/or breast cancer screening programs are not widely available.</AbstractText><CopyrightInformation>© 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ramadas</LastName><ForeName>Kunnambath</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Karkinos Healthcare, Kerala Operations, Ernakulam, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basu</LastName><ForeName>Partha</ForeName><Initials>P</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-0124-4050</Identifier><AffiliationInfo><Affiliation>Early Detection, Prevention &amp; Infections Branch, International Agency for Research on Cancer, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathew</LastName><ForeName>Beela S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Regional Cancer Centre, Trivandrum, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muwonge</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Early Detection, Prevention &amp; Infections Branch, International Agency for Research on Cancer, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venugopal</LastName><ForeName>Muraleedharan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Regional Cancer Centre, Trivandrum, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prakasan</LastName><ForeName>Aparna M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Regional Cancer Centre, Trivandrum, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malu</LastName><ForeName>Rafi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Regional Cancer Centre, Trivandrum, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucas</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Early Detection, Prevention &amp; Infections Branch, International Agency for Research on Cancer, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Augustine</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Regional Cancer Centre, Trivandrum, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mony</LastName><ForeName>Rari P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Regional Cancer Centre, Trivandrum, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thara</LastName><ForeName>Somanathan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Regional Cancer Centre, Trivandrum, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sankaranarayanan</LastName><ForeName>Rengaswamy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Karkinos Healthcare, Kerala Operations, Ernakulam, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Early Detection, Prevention &amp; Infections Branch, International Agency for Research on Cancer, Lyon, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>International Agency for Research on Cancer (WHO)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer</MedlineTA><NlmUniqueID>0374236</NlmUniqueID><ISSNLinking>0008-543X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">breast cancer</Keyword><Keyword MajorTopicYN="N">breast cancer mortality</Keyword><Keyword MajorTopicYN="N">clinical breast examination</Keyword><Keyword MajorTopicYN="N">randomized clinical trial</Keyword><Keyword MajorTopicYN="N">screening</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>09</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321193</ArticleId><ArticleId IdType="doi">10.1002/cncr.34526</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer; 2020. Accessed March 28, 2022. https://gco.iarc.fr/today</Citation></Reference><Reference><Citation>Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. https://doi.org/10.3322/caac.21660</Citation></Reference><Reference><Citation>Lima SM, Kehm RD, Terry MB. Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns. EClinicalMedicine. 2021;38:100985. https://doi.org/10.1016/j.eclinm.2021.100985</Citation></Reference><Reference><Citation>Lopes LV, Miguel F, Freitas H, et al. Stage at presentation of breast cancer in Luanda, Angola - a retrospective study. BMC Health Serv Res. 2015;15(1):471. https://doi.org/10.1186/s12913-015-1092-9</Citation></Reference><Reference><Citation>Jedy-Agba E, McCormack V, Adebamowo C, Dos-Santos-Silva I. Stage at diagnosis of breast cancer in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health. 2016;4(12):e923-e935. https://doi.org/10.1016/s2214-109x(16)30259-5</Citation></Reference><Reference><Citation>Sankaranarayanan R, Swaminathan R, Brenner H, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol. 2010;11(2):165-173. https://doi.org/10.1016/s1470-2045(09)70335-3</Citation></Reference><Reference><Citation>Lauby-Secretan B, Scoccianti C, Loomis D, et al. Breast-cancer screening--viewpoint of the IARC Working Group. N Engl J Med. 2015;372(24):2353-2358. https://doi.org/10.1056/nejmsr1504363</Citation></Reference><Reference><Citation>Sankaranarayanan R, Alwan N, Denny L. How can we improve survival from breast cancer in developing countries? Breast Cancer Manage. 2013;2(3):179-183. https://doi.org/10.2217/bmt.13.11</Citation></Reference><Reference><Citation>Chiarelli AM, Majpruz V, Brown P, Thériault M, Shumak R, Mai V. The contribution of clinical breast examination to the accuracy of breast screening. J Natl Cancer Inst. 2009;101(18):1236-1243. https://doi.org/10.1093/jnci/djp241</Citation></Reference><Reference><Citation>Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. CMAJ. 1992;147(10):1459-1476.</Citation></Reference><Reference><Citation>Shapiro S. Periodic screening for breast cancer: the HIP Randomized Controlled Trial. Health Insurance Plan. J Natl Cancer Inst Monogr. 1997;1997(22):27-30. https://doi.org/10.1093/jncimono/1997.22.27</Citation></Reference><Reference><Citation>Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348(feb11 9):g366. https://doi.org/10.1136/bmj.g366</Citation></Reference><Reference><Citation>Breast cancer risk assessment and screening average risk women. Practice bulletin no: 179, ACOG Committee on practice bulletins; 2017. Accessed March 27, 2022. https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2017/07/breast-cancer-risk-assessment-and-screening-in-average-risk-women</Citation></Reference><Reference><Citation>Ngan TT, Nguyen NTQ, Van Minh H, Donnelly M, O'Neill C. Effectiveness of clinical breast examination as a 'stand-alone' screening modality: an overview of systematic reviews. BMC Cancer. 2020;20(1):1070. https://doi.org/10.1186/s12885-020-07521-w</Citation></Reference><Reference><Citation>Sankaranarayanan R, Ramadas K, Thara S, et al. Clinical breast examination: preliminary results from a cluster randomized controlled trial in India. J Natl Cancer Inst. 2011;103(19):1476-1480. https://doi.org/10.1093/jnci/djr304</Citation></Reference><Reference><Citation>Dobson AJ, Kuulasmaa K, Eberle E, Scherer J. Confidence intervals for weighted sums of Poisson parameters. Stat Med. 1991;10(3):457-462. https://doi.org/10.1002/sim.4780100317</Citation></Reference><Reference><Citation>Armaroli P, Riggi E, Basu P, et al. Performance indicators in breast cancer screening in the European Union: a comparison across countries of screen positivity and detection rates. Int J Cancer. 2020;147(7):1855-1863. https://doi.org/10.1002/ijc.32968</Citation></Reference><Reference><Citation>Mittra I, Mishra GA, Dikshit RP, et al. Effect of screening by clinical breast examination on breast cancer incidence and mortality after 20 years: prospective, cluster randomised controlled trial in Mumbai. BMJ. 2021;372:n256. https://doi.org/10.1136/bmj.n256</Citation></Reference><Reference><Citation>Suryanarayana M, Agrawal A, Prabhu KS. Inequality adjusted Human Development Index for India’s States. United Nations Development Programme; 2011.</Citation></Reference><Reference><Citation>National Institution for Transforming India. Government of India. http://social.niti.gov.in/hlt-rankingmet</Citation></Reference><Reference><Citation>Pramesh CS, Badwe RA, Borthakur BB, et al. Delivery of affordable and equitable cancer care in India. Lancet Oncol. 2014;15(6):e223-e233. https://doi.org/10.1016/s1470-2045(14)70117-2</Citation></Reference><Reference><Citation>Provencher L, Hogue JC, Desbiens C, et al. Is clinical breast examination important for breast cancer detection? Curr Oncol. 2016;23(4):332-339. https://doi.org/10.3747/co.23.2881</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36321189</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-0261</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Molecular oncology</Title><ISOAbbreviation>Mol Oncol</ISOAbbreviation></Journal><ArticleTitle>Post-prostatic-massage urine exosomes of men with chronic prostatitis/chronic pelvic pain syndrome carry prostate-cancer-typical microRNAs and activate proto-oncogenes.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/1878-0261.13329</ELocationID><Abstract><AbstractText>Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) has a high prevalence of up to 15% and accounts for 90-95% of prostatitis diagnoses, and yet its etiopathogenesis and link to prostate cancer (PCa) are still unclear. Here, we investigated microRNAs in exosomes isolated from blood and post-prostatic-massage urine of CP/CPPS type IIIb patients and healthy men. THP-1 monocytes (human leukemia monocytic cell line) were treated with exosomes and subjected to mRNA arrays "Cancer Inflammation and Immunity Crosstalk" and "Transcription Factors". Using The Cancer Genome Atlas (TCGA), the expression of CP/CPPS-associated microRNAs was analyzed in PCa and normal prostate tissue. In silico functional studies were carried out to explore the disease ontology of CP/CPPS. In CP/CPPS, urine exosomes exhibited significant upregulation of eight PCa-specific microRNAs (e.g., hsa-miR-501, hsa-miR-20a, hsa-miR-106), whose target genes were significantly enriched for GO terms, hallmark gene sets and pathways specific for carcinogenesis. In THP-1 monocytes, CP/CPPS-derived urine exosomes induced an upregulation of PCa-associated proinflammatory genes (e.g., CCR2 and TLR2) and proto-oncogene transcription factors (e.g., MYB and JUNB). In contrast, CP/CPPS-derived blood exosomes exhibited molecular properties similar to those of healthy men. Thus, CP/CPPS exhibits molecular changes that constitute a risk for PCa and should be considered in development of PCa biomarkers and cancer screening programmes.</AbstractText><CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Schneider</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-2292-5819</Identifier><AffiliationInfo><Affiliation>Clinic of Urology, Pediatric Urology and Andrology, Justus-Liebig-University Giessen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Working group "Epigenetics of the Urogenital System", Clinic of Urology, Pediatric Urology and Andrology, Justus-Liebig-University Giessen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Dansranjav</LastName><ForeName>Temuujin</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Clinic of Urology, Pediatric Urology and Andrology, Justus-Liebig-University Giessen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University of Giessen, Bad Nauheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Hang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinic of Urology, Pediatric Urology and Andrology, Justus-Liebig-University Giessen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Working group "Epigenetics of the Urogenital System", Clinic of Urology, Pediatric Urology and Andrology, Justus-Liebig-University Giessen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pilatz</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinic of Urology, Pediatric Urology and Andrology, Justus-Liebig-University Giessen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuppe</LastName><ForeName>Hans-Christian</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Clinic of Urology, Pediatric Urology and Andrology, Justus-Liebig-University Giessen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagenlehner</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Clinic of Urology, Pediatric Urology and Andrology, Justus-Liebig-University Giessen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schagdarsurengin</LastName><ForeName>Undraga</ForeName><Initials>U</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-0127-4938</Identifier><AffiliationInfo><Affiliation>Clinic of Urology, Pediatric Urology and Andrology, Justus-Liebig-University Giessen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Working group "Epigenetics of the Urogenital System", Clinic of Urology, Pediatric Urology and Andrology, Justus-Liebig-University Giessen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Oncol</MedlineTA><NlmUniqueID>101308230</NlmUniqueID><ISSNLinking>1574-7891</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CP/CPPS</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">early cancer risk assessment</Keyword><Keyword MajorTopicYN="N">exosomes</Keyword><Keyword MajorTopicYN="N">liquid biopsies</Keyword><Keyword MajorTopicYN="N">microRNA</Keyword><Keyword MajorTopicYN="N">prostate cancer</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321189</ArticleId><ArticleId IdType="doi">10.1002/1878-0261.13329</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">36321176</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1001-9294</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih</Title><ISOAbbreviation>Chin Med Sci J</ISOAbbreviation></Journal><ArticleTitle>Prostate Cancer Risk Prediction and Online Calculation Based on Machine Learning Algorithm.</ArticleTitle><Pagination><MedlinePgn>210-217</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24920/004086</ELocationID><Abstract><AbstractText>Objective To build a prostate cancer (PCa) risk prediction model based on common clinical indicators to provide a theoretical basis for the diagnosis and treatment of PCa and to evaluate the value of artificial intelligence (AI) technology under healthcare data platforms. Methods After preprocessing of the data from Population Health Data Archive, smuothly clipped absolute deviation (SCAD) was used to select features. Random forest (RF), support vector machine (SVM), back propagation neural network (BP), and convolutional neural network (CNN) were used to predict the risk of PCa, among which BP and CNN were used on the enhanced data by SMOTE. The performances of models were compared using area under the curve (AUC) of the receiving operating characteristic curve. After the optimal model was selected, we used the Shiny to develop an online calculator for PCa risk prediction based on predictive indicators. Results Inorganic phosphorus, triglycerides, and calcium were closely related to PCa in addition to the volume of fragmented tissue and free prostate-specific antigen (PSA). Among the four models, RF had the best performance in predicting PCa (accuracy: 96.80%; AUC: 0.975, 95% <i>CI</i>: 0.964-0.986). Followed by BP (accuracy: 85.36%; AUC: 0.892, 95% <i>CI</i>: 0.849-0.934) and SVM (accuracy: 82.67%; AUC: 0.824, 95% <i>CI</i>: 0.805-0.844). CNN performed worse (accuracy: 72.37%; AUC: 0.724, 95% <i>CI</i>: 0.670-0.779). An online platform for PCa risk prediction was developed based on the RF model and the predictive indicators. Conclusions This study revealed the application value of traditional machine learning and deep learning models in disease risk prediction under healthcare data platform, proposed new ideas for PCa risk prediction in patients suspected for PCa and had undergone core needle biopsy. Besides, the online calculation may enhance the practicability of AI prediction technology and facilitate medical diagnosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chun</LastName><ForeName>Wang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Health Statistics, School of Public Health, Tianjin Medical University, Tianjin 300070, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin-Xue</LastName><ForeName>Chang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Health Statistics, School of Public Health, Tianjin Medical University, Tianjin 300070, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao-Meng</LastName><ForeName>Wang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Health Statistics, School of Public Health, Tianjin Medical University, Tianjin 300070, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ke-Yun</LastName><ForeName>Wang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Health Statistics, School of Public Health, Tianjin Medical University, Tianjin 300070, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Wang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Medical Imaging, Peking University First Hospital, Beijing 100034, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuang</LastName><ForeName>Cui</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Health Statistics, School of Public Health, Tianjin Medical University, Tianjin 300070, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang-Ping</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Health Statistics, School of Public Health, Tianjin Medical University, Tianjin 300070, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Chin Med Sci J</MedlineTA><NlmUniqueID>9112559</NlmUniqueID><ISSNLinking>1001-9294</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.21.77</RegistryNumber><NameOfSubstance UI="D017430">Prostate-Specific Antigen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001185" MajorTopicYN="Y">Artificial Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017430" MajorTopicYN="N">Prostate-Specific Antigen</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="Y">Prostatic Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">back-propagation neural network</Keyword><Keyword MajorTopicYN="N">convolutional neural network</Keyword><Keyword MajorTopicYN="N">prostate cancer</Keyword><Keyword MajorTopicYN="N">random forest</Keyword><Keyword MajorTopicYN="N">support vector machine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321176</ArticleId><ArticleId IdType="pii">4086</ArticleId><ArticleId IdType="doi">10.24920/004086</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36321161</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1359-0286</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Current opinion in solid state &amp; materials science</Title><ISOAbbreviation>Curr Opin Solid State Mater Sci</ISOAbbreviation></Journal><ArticleTitle>Systems approaches to uncovering the contribution of environment-mediated drug resistance.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">101005</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cossms.2022.101005</ELocationID><Abstract><AbstractText>Cancer drug response is heavily influenced by the extracellular matrix (ECM) environment. Despite a clear appreciation that the ECM influences cancer drug response and progression, a unified view of how, where, and when environment-mediated drug resistance contributes to cancer progression has not coalesced. Here, we survey some specific ways in which the ECM contributes to cancer resistance with a focus on how materials development can coincide with systems biology approaches to better understand and perturb this contribution. We argue that part of the reason that environment-mediated resistance remains a perplexing problem is our lack of a wholistic view of the entire range of environments and their impacts on cell behavior. We cover a series of recent experimental and computational tools that will aid exploration of ECM reactions space, and how they might be synergistically integrated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Creixell</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, University of California Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyuna</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Molecular and Cellular Biology Graduate Program, University of Massachusetts Amherst.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammadi</LastName><ForeName>Farnaz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, University of California Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peyton</LastName><ForeName>Shelly R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Molecular and Cellular Biology Graduate Program, University of Massachusetts Amherst.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemical Engineering, University of Massachusetts Amherst.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Aaron S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, University of California Los Angeles.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Opin Solid State Mater Sci</MedlineTA><NlmUniqueID>101568837</NlmUniqueID><ISSNLinking>1359-0286</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ECM</Keyword><Keyword MajorTopicYN="N">cell signaling</Keyword><Keyword MajorTopicYN="N">drug resistance</Keyword><Keyword MajorTopicYN="N">tensor decomposition</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321161</ArticleId><ArticleId IdType="doi">10.1016/j.cossms.2022.101005</ArticleId><ArticleId IdType="pmc">PMC9620953</ArticleId></ArticleIdList><?nihms ?></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36321156</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2516-0230</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>20</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Nanoscale advances</Title><ISOAbbreviation>Nanoscale Adv</ISOAbbreviation></Journal><ArticleTitle>Zirconia-based nanomaterials: recent developments in synthesis and applications.</ArticleTitle><Pagination><MedlinePgn>4210-4236</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d2na00367h</ELocationID><Abstract><AbstractText>In the last decade, the whole scientific community has witnessed great advances and progress in the various fields of nanoscience. Among the different nanomaterials, zirconia nanomaterials have found numerous applications as nanocatalysts, nanosensors, adsorbents, <i>etc.</i> Additionally, their exceptional biomedical applications in dentistry and drug delivery, and interesting biological properties, <i>viz.</i> anti-microbial, antioxidant, and anti-cancer activity, have further motivated the researchers to explore their physico-chemical properties using different synthetic pathways. With such an interest in zirconia-based nanomaterials, the present review focuses systematically on different synthesis approaches and their impact on the structure, size, shape, and morphology of these nanomaterials. Broadly, there are two approaches, <i>viz.</i>, chemical synthesis which includes hydrothermal, solvothermal, sol-gel, microwave, solution combustion, and co-precipitation methods, and a greener approach which employs bacteria, fungus, and plant parts for the preparation of zirconia nanoparticles. In this review article, the aforementioned methods have been critically analyzed for obtaining specific phases and shapes. The review also incorporates a detailed survey of the applications of zirconia-based nanomaterials. Furthermore, the influence of specific phases, morphology, and the comparison with their counterpart composites for different applications have also been included. Finally, the concluding remarks, prospects and possible scope are given in the last section.</AbstractText><CopyrightInformation>This journal is © The Royal Society of Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumari</LastName><ForeName>Nisha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University Institute of Science, Chandigarh University Mohali Punjab-140 413 India vishal.mutreja@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sareen</LastName><ForeName>Shweta</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Centre of Advanced Studies in Chemistry, Panjab University Chandigarh-160 014 India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verma</LastName><ForeName>Meenakshi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University Institute of Science, Chandigarh University Mohali Punjab-140 413 India vishal.mutreja@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of UCRD, Chandigarh University Gharuan Mohali Punjab-140 413 India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Shelja</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University Institute of Science, Chandigarh University Mohali Punjab-140 413 India vishal.mutreja@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Ajay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University Institute of Science, Chandigarh University Mohali Punjab-140 413 India vishal.mutreja@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of UCRD, Chandigarh University Gharuan Mohali Punjab-140 413 India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sohal</LastName><ForeName>Harvinder Singh</ForeName><Initials>HS</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-7190-8508</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, University Institute of Science, Chandigarh University Mohali Punjab-140 413 India vishal.mutreja@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>S K</ForeName><Initials>SK</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-3560-8214</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Centre of Advanced Studies in Chemistry, Panjab University Chandigarh-160 014 India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jeongwon</ForeName><Initials>J</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-4988-302X</Identifier><AffiliationInfo><Affiliation>Department of Electrical and Biomedical Engineering, University of Nevada Reno NV 89557 USA jepark@unr.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mutreja</LastName><ForeName>Vishal</ForeName><Initials>V</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-5311-1108</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, University Institute of Science, Chandigarh University Mohali Punjab-140 413 India vishal.mutreja@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nanoscale Adv</MedlineTA><NlmUniqueID>101738708</NlmUniqueID><ISSNLinking>2516-0230</ISSNLinking></MedlineJournalInfo><CoiStatement>There are no conflicts to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321156</ArticleId><ArticleId IdType="doi">10.1039/d2na00367h</ArticleId><ArticleId IdType="pii">d2na00367h</ArticleId><ArticleId IdType="pmc">PMC9552756</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36321141</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2516-0230</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>20</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Nanoscale advances</Title><ISOAbbreviation>Nanoscale Adv</ISOAbbreviation></Journal><ArticleTitle>MnO<sub>2</sub> doped graphene nanosheets for carotid body tumor combination therapy.</ArticleTitle><Pagination><MedlinePgn>4304-4313</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d2na00086e</ELocationID><Abstract><AbstractText>Combination therapy is a cornerstone of tumor therapy, which can make up for the shortcomings of a single treatment and improve the cure rate of cancer. Near infrared induced therapy is widely applied owing to good accessibility, safety profile, and a wide range of effectiveness. Here, we use reduced nanographene oxide (rNGO) sheets with MnO<sub>2</sub> nanoparticles as a photothermal agent to trigger further photodynamic therapy and chemotherapy. Doxorubicin (DOX, chemotherapeutic agent) and methyl blue (MB, photosensitizer) are loaded onto graphene oxide through a strong physical bond and rapidly released under high temperature. Besides, MnO<sub>2</sub> nanoparticles can catalyze hydrogen peroxide inside of tumor and produce oxygen as a raw material for photodynamic therapy. <i>In vitro</i> experiments illustrated an effective ablation of PC-12 cells by rGO@MnO<sub>2</sub>/MB/Dox incubation combined with 808 nm near-infrared (NIR) laser radiation. For <i>in vivo</i> experiments in a model of carotid body tumor, rGO@MnO<sub>2</sub>/MB/Dox was locally injected, followed by 808 nm NIR laser irradiation. We found that the number of tumor cells was significantly reduced, the tumor volume was reduced, and there were no side effects. This may provide a new idea for the combination treatment of carotid body tumor.</AbstractText><CopyrightInformation>This journal is © The Royal Society of Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Huaxiang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine Shanghai 200011 China jinbaoqin@163.com luxinwu@shsmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Weimin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine Shanghai 200011 China jinbaoqin@163.com luxinwu@shsmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine Shanghai 200011 China jinbaoqin@163.com luxinwu@shsmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine Shanghai 200011 China jinbaoqin@163.com luxinwu@shsmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Jinbao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine Shanghai 200011 China jinbaoqin@163.com luxinwu@shsmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Yuting</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Chemical and Biological Engineering, Guangdong-Hong Kong-Macao Joint Laboratory for Intelligent Micro-Nano Optoelectronic Technology, William Mong Institute of Nano Science and Technology, Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction, The Hong Kong University of Science and Technology Clear Water Bay Kowloon Hong Kong 999077 P. R. China ycaiat@connect.ust.hk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Xinwu</ForeName><Initials>X</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-6503-5210</Identifier><AffiliationInfo><Affiliation>Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine Shanghai 200011 China jinbaoqin@163.com luxinwu@shsmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nanoscale Adv</MedlineTA><NlmUniqueID>101738708</NlmUniqueID><ISSNLinking>2516-0230</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>02</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321141</ArticleId><ArticleId IdType="doi">10.1039/d2na00086e</ArticleId><ArticleId IdType="pii">d2na00086e</ArticleId><ArticleId IdType="pmc">PMC9552922</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36321136</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2372-7705</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><PubDate><Year>2022</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Molecular therapy oncolytics</Title><ISOAbbreviation>Mol Ther Oncolytics</ISOAbbreviation></Journal><ArticleTitle>Enhanced genomic stability of new miRNA-regulated oncolytic coxsackievirus B3.</ArticleTitle><Pagination><MedlinePgn>89-99</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.omto.2022.10.003</ELocationID><Abstract><AbstractText>Genetic modification of coxsackievirus B3 (CVB3) by inserting target sequences (TS) of tumor-suppressive and/or organ-selective microRNAs (miRs) into viral genome can efficiently eliminate viral pathogenesis without significant impacts on its oncolytic activity. Nonetheless, reversion mutants (loss of miR-TS inserts) were identified as early as day 35 post-injection in ∼40% immunodeficient mice. To improve the stability, here we re-engineered CVB3 by (1) replacing the same length of viral genome at the non-coding region with TS of cardiac-selective miR-1/miR-133 and pancreas-enriched miR-216/miR-375 or (2) inserting the above miR-TS into the coding region (i.e., P1 region) of viral genome. Serial passaging of these newly established miR-CVB3s in cultured cells for 20 rounds demonstrated significantly improved stability compared with the first-generation miR-CVB3 with 5'UTR insertion of miR-TS. The safety and stability of these new miR-CVB3s was verified in immunocompetent mice. Moreover, we showed that these new viruses retained the ability to suppress lung tumor growth in a xenograft mouse model. Finally, we observed that miR-CVB3 with insertion in P1 region was more stable than miR-CVB3 with preserved length of the 5'UTR, whereas the latter displayed significantly higher oncolytic activity. Overall, we presented here valid strategies to enhance the genomic stability of miR-CVB3 for virotherapy.</AbstractText><CopyrightInformation>© 2022 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Huitao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC V6Z 1Y6, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental Medicine, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahreyni</LastName><ForeName>Amirhossein</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC V6Z 1Y6, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory of Medicine, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohamud</LastName><ForeName>Yasir</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC V6Z 1Y6, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory of Medicine, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Yuan Chao</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC V6Z 1Y6, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory of Medicine, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>William W G</ForeName><Initials>WWG</Initials><AffiliationInfo><Affiliation>Virogin Biotech Ltd, Vancouver, BC V6S 2L9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Honglin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC V6Z 1Y6, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory of Medicine, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Ther Oncolytics</MedlineTA><NlmUniqueID>101666776</NlmUniqueID><ISSNLinking>2372-7705</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">coxsackievirus B3</Keyword><Keyword MajorTopicYN="N">cytotoxicity</Keyword><Keyword MajorTopicYN="N">genomic stability</Keyword><Keyword MajorTopicYN="N">lung cancer</Keyword><Keyword MajorTopicYN="N">miRNA</Keyword><Keyword MajorTopicYN="N">oncolytic activity</Keyword><Keyword MajorTopicYN="N">oncolytic virus</Keyword></KeywordList><CoiStatement>H. Luo is collaborating with Virogin Biotech Ltd for the development of oncolytic CVB3 under the MITACS Accelerate program agreement between the university and the company. W.W.G.J is the Chief Scientific Officer at Virogin Biotech Ltd. H. Liu is partially sponsored by Virogin Biotech Ltd.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321136</ArticleId><ArticleId IdType="doi">10.1016/j.omto.2022.10.003</ArticleId><ArticleId IdType="pii">S2372-7705(22)00125-5</ArticleId><ArticleId IdType="pmc">PMC9593271</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36321135</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2372-7705</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><PubDate><Year>2022</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Molecular therapy oncolytics</Title><ISOAbbreviation>Mol Ther Oncolytics</ISOAbbreviation></Journal><ArticleTitle>HKI-272 contributes to gemcitabine-mediated anti-proliferative and anti-metastatic effects through EGFR suppression in gallbladder cancer.</ArticleTitle><Pagination><MedlinePgn>126-140</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.omto.2022.10.004</ELocationID><Abstract><AbstractText>Gallbladder cancer (GBC) is a rare malignancy of the biliary system and characterized by early metastasis and poor prognosis. To date, no efficient treatment is available for GBC patients. Based on the data from cBioPortal, TIMER, and GDSC, we performed an unbiased screening with 25 candidate compounds that predominantly target ErbB family and identified HKI-272, a highly selective EGFR/ErbB2 inhibitor, displayed decreased IC<sub>50</sub> values in three GBC cell lines. HKI-272 not only promoted gemcitabine-mediated anti-proliferative and pro-apoptotic effects and induced cell cycle arrest in GBC, but also enhanced gemcitabine-induced suppressive effects of GBC cell migration and invasion by inhibiting pathways downstream of EGFR. Furthermore, HKI-272, together with gemcitabine, effectively suppressed tumor growth and metastases in mouse models. Immunostaining and HE staining data from both primary tumor and lung metastasis indicated that the anti-proliferative and anti-metastatic effects were mediated through EGFR suppression. Moreover, the expression of EGFR, measured by both immunostaining and HE staining, was correlated with a poor prognosis in GBC. In addition, EGFR in tumor tissues are independent indicators for overall survival in GBC patients. Taken together, our findings suggest that HKI-272 could be a potential therapeutic agent and EGFR might serve as a potential biomarker for patients with GBC.</AbstractText><CopyrightInformation>© 2022 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xuli</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The Second Affiliated Hospital of University of South China, Hengyang, Hunan 421001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Pancreatic Surgery, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu 211100, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Ther Oncolytics</MedlineTA><NlmUniqueID>101666776</NlmUniqueID><ISSNLinking>2372-7705</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EGFR</Keyword><Keyword MajorTopicYN="N">HKI-272</Keyword><Keyword MajorTopicYN="N">gallbladder cancer</Keyword><Keyword MajorTopicYN="N">gemcitabine</Keyword><Keyword MajorTopicYN="N">small molecule inhibitor</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>04</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321135</ArticleId><ArticleId IdType="doi">10.1016/j.omto.2022.10.004</ArticleId><ArticleId IdType="pii">S2372-7705(22)00126-7</ArticleId><ArticleId IdType="pmc">PMC9596964</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36321134</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2372-7705</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><PubDate><Year>2022</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Molecular therapy oncolytics</Title><ISOAbbreviation>Mol Ther Oncolytics</ISOAbbreviation></Journal><ArticleTitle>Adding recombinant AAVs to the cancer therapeutics mix.</ArticleTitle><Pagination><MedlinePgn>73-88</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.omto.2022.09.009</ELocationID><Abstract><AbstractText>Gene therapy is a powerful biological tool that is reshaping therapeutic landscapes for several diseases. Researchers are using both non-viral and viral-based gene therapy methods with success in the lab and the clinic. In the cancer biology field, gene therapies are expanding treatment options and the possibility of favorable outcomes for patients. While cellular immunotherapies and oncolytic virotherapies have paved the way in cancer treatments based on genetic engineering, recombinant adeno-associated virus (rAAV), a viral-based module, is also emerging as a potential cancer therapeutic through its malleability, specificity, and broad application to common as well as rare tumor types, tumor microenvironments, and metastatic disease. A wide range of AAV serotypes, promoters, and transgenes have been successful at reducing tumor growth and burden in preclinical studies, suggesting more groundbreaking advances using rAAVs in cancer are on the horizon.</AbstractText><CopyrightInformation>© 2022 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mulcrone</LastName><ForeName>Patrick L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Herman B Wells Center for Pediatric Research, Indiana University, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Indiana University, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herzog</LastName><ForeName>Roland W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Herman B Wells Center for Pediatric Research, Indiana University, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Weidong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Herman B Wells Center for Pediatric Research, Indiana University, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Ther Oncolytics</MedlineTA><NlmUniqueID>101666776</NlmUniqueID><ISSNLinking>2372-7705</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AAV design</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">gene therapy</Keyword><Keyword MajorTopicYN="N">rAAV</Keyword><Keyword MajorTopicYN="N">tissue tropism</Keyword><Keyword MajorTopicYN="N">tumor microenvironment</Keyword></KeywordList><CoiStatement>R.W.H. is editor-in-chief of Molecular Therapy and has served on scientific advisory boards for Regeneron Pharmaceuticals and BioMarin Pharmaceuticals. W.X. holds equity in the following: Ivygen Corportion and Nikegen LLC.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321134</ArticleId><ArticleId IdType="doi">10.1016/j.omto.2022.09.009</ArticleId><ArticleId IdType="pii">S2372-7705(22)00121-8</ArticleId><ArticleId IdType="pmc">PMC9588955</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36321133</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2372-7705</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><PubDate><Year>2022</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Molecular therapy oncolytics</Title><ISOAbbreviation>Mol Ther Oncolytics</ISOAbbreviation></Journal><ArticleTitle>DNA-damaging cancer cells to improve virotherapy.</ArticleTitle><Pagination><MedlinePgn>124-125</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.omto.2022.10.002</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garcia-Moure</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Health Research Institute of Navarra (IdiSNA), Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Solid Tumor Program, Center for the Applied Medical Research, Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tallon-Cobos</LastName><ForeName>Antonio Carlos</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Health Research Institute of Navarra (IdiSNA), Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Solid Tumor Program, Center for the Applied Medical Research, Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso</LastName><ForeName>Marta M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Health Research Institute of Navarra (IdiSNA), Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Solid Tumor Program, Center for the Applied Medical Research, Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016433">News</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Ther Oncolytics</MedlineTA><NlmUniqueID>101666776</NlmUniqueID><ISSNLinking>2372-7705</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DDR</Keyword><Keyword MajorTopicYN="N">oncolytic adenoviruses</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321133</ArticleId><ArticleId IdType="doi">10.1016/j.omto.2022.10.002</ArticleId><ArticleId IdType="pii">S2372-7705(22)00124-3</ArticleId><ArticleId IdType="pmc">PMC9593301</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36321132</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2372-7705</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><PubDate><Year>2022</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Molecular therapy oncolytics</Title><ISOAbbreviation>Mol Ther Oncolytics</ISOAbbreviation></Journal><ArticleTitle>Non-coding RNAs and glioma: Focus on cancer stem cells.</ArticleTitle><Pagination><MedlinePgn>100-123</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.omto.2022.09.005</ELocationID><Abstract><AbstractText>Glioblastoma and gliomas can have a wide range of histopathologic subtypes. These heterogeneous histologic phenotypes originate from tumor cells with the distinct functions of tumorigenesis and self-renewal, called glioma stem cells (GSCs). GSCs are characterized based on multi-layered epigenetic mechanisms, which control the expression of many genes. This epigenetic regulatory mechanism is often based on functional non-coding RNAs (ncRNAs). ncRNAs have become increasingly important in the pathogenesis of human cancer and work as oncogenes or tumor suppressors to regulate carcinogenesis and progression. These RNAs by being involved in chromatin remodeling and modification, transcriptional regulation, and alternative splicing of pre-mRNA, as well as mRNA stability and protein translation, play a key role in tumor development and progression. Numerous studies have been performed to try to understand the dysregulation pattern of these ncRNAs in tumors and cancer stem cells (CSCs), which show robust differentiation and self-regeneration capacity. This review provides recent findings on the role of ncRNAs in glioma development and progression, particularly their effects on CSCs, thus accelerating the clinical implementation of ncRNAs as promising tumor biomarkers and therapeutic targets.</AbstractText><CopyrightInformation>© 2022 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rajabi</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kayedi</LastName><ForeName>Mehrdad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiology, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahimi</LastName><ForeName>Shiva</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Medicine,Fasa University of Medical Sciences, Fasa, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dashti</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirazimi</LastName><ForeName>Seyed Mohammad Ali</ForeName><Initials>SMA</Initials><AffiliationInfo><Affiliation>School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Homayoonfal</LastName><ForeName>Mina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahdian</LastName><ForeName>Seyed Mohammad Amin</ForeName><Initials>SMA</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamblin</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein 2028, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamtaji</LastName><ForeName>Omid Reza</ForeName><Initials>OR</Initials><AffiliationInfo><Affiliation>Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afrasiabi</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jafari</LastName><ForeName>Ameneh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Advanced Therapy Medicinal Product (ATMP) Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirzaei</LastName><ForeName>Hamed</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Ther Oncolytics</MedlineTA><NlmUniqueID>101666776</NlmUniqueID><ISSNLinking>2372-7705</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer stem cells</Keyword><Keyword MajorTopicYN="N">Glioma</Keyword><Keyword MajorTopicYN="N">MT: Non-coding RNAs</Keyword></KeywordList><CoiStatement>M.R.H. declares the following potential conflicts of interest. Scientific Advisory Boards: Transdermal Cap Inc., Cleveland, OH; Hologenix Inc. Santa Monica, CA; Vielight, Toronto, Canada; JOOVV Inc., Minneapolis-St. Paul MN. Consulting; USHIO Corp., Japan; Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321132</ArticleId><ArticleId IdType="doi">10.1016/j.omto.2022.09.005</ArticleId><ArticleId IdType="pii">S2372-7705(22)00117-6</ArticleId><ArticleId IdType="pmc">PMC9593299</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36321101</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2046-2069</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>46</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>RSC advances</Title><ISOAbbreviation>RSC Adv</ISOAbbreviation></Journal><ArticleTitle>Anti-SARS-CoV-2 and cytotoxic activity of two marine alkaloids from green alga <i>Caulerpa cylindracea</i> Sonder in the Dardanelles.</ArticleTitle><Pagination><MedlinePgn>29983-29990</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d2ra03358e</ELocationID><Abstract><AbstractText><i>Caulerpa cylindracea</i> Sonder is a green alga belonging to the Caulerpaceae family. This is the first chemical investigation of <i>C. cylindracea</i> in the Dardanelles which resulted in the isolation of four compounds, caulerpin (1), monomethyl caulerpinate (2), beta-sitosterol (3), and palmitic acid (4). Their structures were elucidated by spectroscopic analyses including 1D- and 2D NMR and mass. The isolated compounds 1 and 2 were tested against the SARS-CoV-2 viral targets spike protein and main protease (3CL) enzyme, and both compounds significantly inhibit the interaction of spike protein and ACE2, while the main protease activity was not significantly reduced. Docking studies suggested that compounds 1 and 2 may bind to the ACE2 binding pocket on spike, and compound 2 may also bind to an allosteric site on spike. As such, these compounds may inhibit the spike-ACE2 complex formation competitively and/or allosterically and have the potential to be used against SARS-CoV-2 virus infection. In addition, compounds 1 and 2 showed at least two-fold higher cytotoxicity against breast cancer cell lines MCF7 and MDA-MB-231 compared to the CCD fibroblast control cell line.</AbstractText><CopyrightInformation>This journal is © The Royal Society of Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Erol</LastName><ForeName>Ebru</ForeName><Initials>E</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-6342-4298</Identifier><AffiliationInfo><Affiliation>Dept. of Analytical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University Istanbul Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orhan</LastName><ForeName>Muge Didem</ForeName><Initials>MD</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-9014-3838</Identifier><AffiliationInfo><Affiliation>Bahcesehir University, Health Sciences Institute, Neuroscience Laboratory Istanbul Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avsar</LastName><ForeName>Timucin</ForeName><Initials>T</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-8841-4811</Identifier><AffiliationInfo><Affiliation>Bahcesehir University, Health Sciences Institute, Neuroscience Laboratory Istanbul Turkey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bahcesehir University, School of Medicine, Department of Medical Biology Istanbul Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akdemir</LastName><ForeName>Atilla</ForeName><Initials>A</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-8416-0471</Identifier><AffiliationInfo><Affiliation>Computer-Aided Drug Discovery Lab., Dept. of Pharmacology, Faculty of Pharmacy, Bezmialem Vakif University Istanbul Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okudan</LastName><ForeName>Emine Sukran</ForeName><Initials>ES</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-5309-7238</Identifier><AffiliationInfo><Affiliation>Faculty of Aquatic Sciences and Fisheries, Akdeniz University Antalya Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alim Toraman</LastName><ForeName>Gulbahar Ozge</ForeName><Initials>GO</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-7816-7551</Identifier><AffiliationInfo><Affiliation>Dept. of Pharmacognosy, Faculty of Pharmacy, Bezmialem Vakif University Istanbul Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Topcu</LastName><ForeName>Gulacti</ForeName><Initials>G</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-7946-6545</Identifier><AffiliationInfo><Affiliation>Dept. of Pharmacognosy, Faculty of Pharmacy, Bezmialem Vakif University Istanbul Turkey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Drug Application &amp; Research Center, Bezmialem Vakif University Istanbul Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RSC Adv</MedlineTA><NlmUniqueID>101581657</NlmUniqueID><ISSNLinking>2046-2069</ISSNLinking></MedlineJournalInfo><CoiStatement>There are no conflicts to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321101</ArticleId><ArticleId IdType="doi">10.1039/d2ra03358e</ArticleId><ArticleId IdType="pii">d2ra03358e</ArticleId><ArticleId IdType="pmc">PMC9580487</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36321100</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2046-2069</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>46</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>RSC advances</Title><ISOAbbreviation>RSC Adv</ISOAbbreviation></Journal><ArticleTitle>3,4,3'-Tri-<i>O</i>-methylellagic acid as an anticancer agent: <i>in vitro</i> and <i>in silico</i> studies.</ArticleTitle><Pagination><MedlinePgn>29884-29891</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d2ra05246f</ELocationID><Abstract><AbstractText>We report a natural product compound isolated from <i>Syzygium polycephalum</i> known as 3,4,3'-tri-<i>O</i>-methylellagic acid (T-EA) as a candidate drug for cancer treatment. The characterization of the isolated T-EA compound was carried out using various spectroscopic methods. The <i>in vitro</i> evaluation showcased the inhibition activity of T-EA towards the T47D and HeLa cell lines with EC<sub>50</sub> values of 55.35 ± 6.28 μg mL<sup>-1</sup> and 12.57 ± 2.22 μg mL<sup>-1</sup>, respectively. Meanwhile, the <i>in silico</i> evaluation aimed to understand the interaction of T-EA with enzymes responsible for cancer regulation at the molecular level by targeting the hindrance of cyclin-dependent kinase 9 (CDK9) and sirtuin 1 (SIRT1) enzymes. T-EA showed a binding free energy towards the SIRT1 protein of Δ<i>G</i> <sub>bind (MM-GBSA)</sub>: -30.98 ± 0.25 kcal mol<sup>-1</sup> and Δ<i>G</i> <sub>bind (MM-PBSA)</sub>: -24.07 ± 0.30 kcal mol<sup>-1</sup>, while that of CDK9 was Δ<i>G</i> <sub>bind (MM-GBSA)</sub>: -29.50 ± 0.22 kcal mol<sup>-1</sup> and Δ<i>G</i> <sub>bind (MM-PBSA)</sub>: -25.87 ± 0.40 kcal mol<sup>-1</sup>. The obtained results from this research could be considered as important information on 3,4,3'-tri-<i>O</i>-methylellagic acid as a drug to treat cervical and breast cancers.</AbstractText><CopyrightInformation>This journal is © The Royal Society of Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wardana</LastName><ForeName>Andika Pramudya</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>PhD Student of Mathematics and Natural Sciences, Faculty of Science and Technology, Universitas Airlangga Surabaya 60115 Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Science and Technology, Universitas Airlangga Surabaya 60115 Indonesia nanik-s-a@fst.unair.ac.id +62-31-5936502 +62-31-5936501.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdjan</LastName><ForeName>Muhammad Ikhlas</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Science and Technology, Universitas Airlangga Surabaya 60115 Indonesia nanik-s-a@fst.unair.ac.id +62-31-5936502 +62-31-5936501.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aminah</LastName><ForeName>Nanik Siti</ForeName><Initials>NS</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-2767-6006</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Science and Technology, Universitas Airlangga Surabaya 60115 Indonesia nanik-s-a@fst.unair.ac.id +62-31-5936502 +62-31-5936501.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biotechnology of Tropical Medicinal Plants Research Group, Universitas Airlangga Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fahmi</LastName><ForeName>Mochamad Zakki</ForeName><Initials>MZ</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-5430-9992</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Science and Technology, Universitas Airlangga Surabaya 60115 Indonesia nanik-s-a@fst.unair.ac.id +62-31-5936502 +62-31-5936501.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siswanto</LastName><ForeName>Imam</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Science and Technology, Universitas Airlangga Surabaya 60115 Indonesia nanik-s-a@fst.unair.ac.id +62-31-5936502 +62-31-5936501.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bioinformatic Laboratory, UCoE Research Center for Bio-Molecule Engineering, Universitas Airlangga Surabaya Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kristanti</LastName><ForeName>Alfinda Novi</ForeName><Initials>AN</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-3023-7098</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Science and Technology, Universitas Airlangga Surabaya 60115 Indonesia nanik-s-a@fst.unair.ac.id +62-31-5936502 +62-31-5936501.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biotechnology of Tropical Medicinal Plants Research Group, Universitas Airlangga Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saputra</LastName><ForeName>Mirza Ardella</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Nanotechnology Engineering, Faculty of Advanced Technology and Multidiscipline, Universitas Airlangga Surabaya 60115 Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takaya</LastName><ForeName>Yoshiaki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Faculty of Pharmacy, Meijo University 150 Yagotoyama, Tempaku Nagoya 468-8503 Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RSC Adv</MedlineTA><NlmUniqueID>101581657</NlmUniqueID><ISSNLinking>2046-2069</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>08</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321100</ArticleId><ArticleId IdType="doi">10.1039/d2ra05246f</ArticleId><ArticleId IdType="pii">d2ra05246f</ArticleId><ArticleId IdType="pmc">PMC9580503</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36321091</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2046-2069</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>46</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>RSC advances</Title><ISOAbbreviation>RSC Adv</ISOAbbreviation></Journal><ArticleTitle>Fabrication and characterization of novel macroporous hydrogels based on the polymerizable surfactant AAc-Span80 and their enhanced drug-delivery capacity.</ArticleTitle><Pagination><MedlinePgn>29677-29687</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d2ra02443h</ELocationID><Abstract><AbstractText>In this study, macroporous pH-sensitive poly[<i>N</i>-isopropylacrylamide-<i>co</i>-acrylic acid-sorbitan monooleate] hydrogels, termed as PNIPAM-<i>co</i>-AAc-Span80 hydrogels, with an enhanced hydrophobic property and a rich pore structure were prepared by free-radical polymerization in an ethanol/water mixture. The polymerizable surfactant AAc-Span80 was obtained by the esterification of acrylic acid (AAc) and sorbitan monooleate (Span80), which was used to copolymerize with <i>N</i>-isopropylacrylamide (NIPAM). The chemical structure, thermal stability, morphology, and amphipathy of the PNIPAM-<i>co</i>-AAc-Span80 hydrogels were characterized. The results showed that the polymerizable surfactant AAc-Span80 macromolecule introduced into the hydrogels could not only increase the hydrophobic property but also ameliorate the porous network morphology, which was conducive to high adsorption capacity for adriamycin hydrochloride (DOX). The adsorption results showed that the equilibrium adsorption capacity of DOX reached 467.5 mg g<sup>-1</sup> within 48 h at pH 7.4, and the hydrophobic interactions and intermolecular hydrogen bonds were the main force in the adsorption process of DOX. The release results demonstrated that the macroporous pH-sensitive hydrogels loaded with DOX could release 98.7% of DOX at pH 5.0, which would be highly beneficial for the release of anti-cancer drugs in the environment of cancer cells. All the results demonstrate that the PNIPAM-<i>co</i>-AAc-Span80 hydrogels have great potential for the delivery of anti-cancer drugs.</AbstractText><CopyrightInformation>This journal is © The Royal Society of Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tu</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>School of Chemical Engineering, Zhengzhou University Zhengzhou 450001 Henan China zhuweixia@zzu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Junyan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Chemical Engineering, Zhengzhou University Zhengzhou 450001 Henan China zhuweixia@zzu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Weixia</ForeName><Initials>W</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-7354-9975</Identifier><AffiliationInfo><Affiliation>School of Chemical Engineering, Zhengzhou University Zhengzhou 450001 Henan China zhuweixia@zzu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RSC Adv</MedlineTA><NlmUniqueID>101581657</NlmUniqueID><ISSNLinking>2046-2069</ISSNLinking></MedlineJournalInfo><CoiStatement>Authors declare that there is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>04</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321091</ArticleId><ArticleId IdType="doi">10.1039/d2ra02443h</ArticleId><ArticleId IdType="pii">d2ra02443h</ArticleId><ArticleId IdType="pmc">PMC9577311</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36321062</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>A Review of the Abscopal Effect in the Era of Immunotherapy.</ArticleTitle><Pagination><MedlinePgn>e29620</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.29620</ELocationID><Abstract><AbstractText>The abscopal effect is a systemic immune response mediated by the effects of radiation on the immune system. This effect has been observed in a number of cancer types in addition to lung cancer, including but not limited to renal cell carcinoma, hepatocellular carcinoma, lymphoma, and melanoma. The combination of radiation therapy and immune checkpoint inhibition (ICI) acts at several stages of the antitumor response, suggesting a mechanism of synergy between the two modalities. This review focuses on recent advances in the understanding of the effect of radiation and immunotherapy in the context of the abscopal effect.</AbstractText><CopyrightInformation>Copyright © 2022, Nabrinsky et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nabrinsky</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hematology and Oncology, Advocate Lutheran General Hospital, Park Ridge, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macklis</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hematology and Oncology, Advocate Lutheran General Hospital, Park Ridge, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bitran</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hematology and Oncology, Advocate Lutheran General Hospital, Park Ridge, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">abscopal</Keyword><Keyword MajorTopicYN="N">effect</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">malignancy</Keyword><Keyword MajorTopicYN="N">radiation</Keyword><Keyword MajorTopicYN="N">radiotherapy</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321062</ArticleId><ArticleId IdType="doi">10.7759/cureus.29620</ArticleId><ArticleId IdType="pmc">PMC9604762</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36321023</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Tender Cutaneous Neoplasms: Case Reports of Patients With a Symptomatic Dermatofibroma and a New Acrostic for Painful Tumors of the Skin.</ArticleTitle><Pagination><MedlinePgn>e29713</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.29713</ELocationID><Abstract><AbstractText>The most common tender cutaneous neoplasm is a dermatofibroma. The characteristics of three women (35 to 42 years old) with painful dermatofibromas are described. One woman was receiving immunosuppressive therapy for the past decade following a liver transplant; the other women were healthy. The dermatofibroma was located on the buttock, shoulder, and arm, respectively; tumor-related pain had been present for several months to at least a year. The dermal nodules ranged in diameter from 5 millimeters to 12 millimeters and were either flesh-colored to slightly red or brown or tan; one tumor was surrounded by a hyperpigmented patch. Microscopic examination showed the following dermatofibroma variants: classic (fibrocollagenous) in two women and histiocytic in one woman. All the women experienced resolution, without recurrence, of pain following the punch biopsy that only removed the majority (but not all) of the dermatofibroma. Tender cutaneous neoplasms include not only dermatofibromas and other fibrous lesions, but also adipose, bone, calcium, cartilage, eccrine, infiltrative, lymphoproliferative, muscle, neural, and vascular tumors. Acronyms and acrostics are mnemonic devices that have been used by clinicians to aid in recalling the diagnoses associated with painful skin tumors. When there were only 11 or less number of pain-related cutaneous conditions, shorter acronyms associated with either a woman's name, a country or an egg were used. A unique acrostic inspired by Charlotte's Web, a children's book by E. B. White, was created when the differential diagnosis of tender cutaneous neoplasms expanded to 25 tumors. The sequential discovery of additional tender skin lesions resulted in two subsequent minor revisions to the original, hog-related, mnemonic. Herein, a new acrostic -- that is not only able to incorporate the inspiration from Charlotte's Web, but also includes cutaneous lymphoma and a final category of "everything else" in order to maintain the future integrity of mnemonic -- for the painful tumors of the skin is proposed: HOG FLED PEN AND GETS CALM LIFE BACK (hidradenoma, osteoma cutis, glomus tumor, fibromyxoma [superficial acral], leiomyosarcoma [cutaneous], eccrine angiomatous hamartoma, Dercum's disease, piezogenic pedal papule, eccrine spiradenoma, neurilemmoma, angiolipoma, neuroma, dermatofibroma, granular cell tumor, endometriosis [cutaneous], thrombus [cutaneous organizing], scar, calcinosis cutis, angioendotheliomatosis [reactive], leiomyoma, metastases [cutaneous], lymphoma [cutaneous], intravenous lobular capillary hemangioma, foreign body [and foreign body reaction], everything else, blue rubber bled nevus, angioma [tufted], chondrodermatitis nodularis helicis, and keloid).</AbstractText><CopyrightInformation>Copyright © 2022, Cohen et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Philip R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Dermatology, University of California, Davis Medical Center, Sacramento, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acronym</Keyword><Keyword MajorTopicYN="N">cutaneous</Keyword><Keyword MajorTopicYN="N">dermal</Keyword><Keyword MajorTopicYN="N">dermatofibroma</Keyword><Keyword MajorTopicYN="N">mnemonic</Keyword><Keyword MajorTopicYN="N">neoplasm</Keyword><Keyword MajorTopicYN="N">painful</Keyword><Keyword MajorTopicYN="N">skin</Keyword><Keyword MajorTopicYN="N">tender</Keyword><Keyword MajorTopicYN="N">tumor</Keyword></KeywordList><CoiStatement>The authors have declared financial relationships, which are detailed in the next section.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321023</ArticleId><ArticleId IdType="doi">10.7759/cureus.29713</ArticleId><ArticleId IdType="pmc">PMC9616610</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36321009</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>The Case of the Young Male with a Longstanding History of Dyspeptic Symptoms: Peritoneal Tuberculosis.</ArticleTitle><Pagination><MedlinePgn>e29612</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.29612</ELocationID><Abstract><AbstractText>Portal vein thrombosis associated with peritoneal tuberculosis is an uncommon manifestation of extrapulmonary tuberculosis. We report one such case of a 33-year-old male with a one-year history of dyspepsia, having been on proton pump inhibitors all this time with temporary relief. In view of ongoing symptoms, an endoscopy was done, which at first showed duodenal ulcer. On repeat endoscopy after an interval, there was evidence of mucosa-associated lymphoid tissue (MALT) lymphoma, which prompted a host of investigations in the patient. A positron emission tomography (PET) scan revealed extensive omento-peritoneal involvement along with a hypodense lesion in the liver with interval development of portal vein thrombosis on a CT scan of the abdomen. The biopsy of the hepatic lesion showed granulomatous inflammation. Faced with a diagnostic dilemma, finally, a laparoscopic biopsy was done, which confirmed the diagnosis of peritoneal TB with portal vein thrombosis. This case highlights the importance of keeping a high index of suspicion to include tuberculosis as a differential when presented with a case such as this and to conduct appropriate investigations to establish the correct diagnosis.</AbstractText><CopyrightInformation>Copyright © 2022, Iftikhar et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iftikhar</LastName><ForeName>Ayesha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Shaukat Khanum Memorial Cancer Hospital &amp; Research Centre, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nisar</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Shaukat Khanum Memorial Cancer Hospital &amp; Research Centre, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheikh</LastName><ForeName>Hassan S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital &amp; Research Centre, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sultan</LastName><ForeName>Faisal</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Shaukat Khanum Memorial Cancer Hospital &amp; Research Centre, Lahore, PAK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">abdominal tb</Keyword><Keyword MajorTopicYN="N">dyspepsia</Keyword><Keyword MajorTopicYN="N">peritoneal tb</Keyword><Keyword MajorTopicYN="N">peritoneal tuberculosis</Keyword><Keyword MajorTopicYN="N">portal vein thrombosis</Keyword><Keyword MajorTopicYN="N">tuberculosis</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321009</ArticleId><ArticleId IdType="doi">10.7759/cureus.29612</ArticleId><ArticleId IdType="pmc">PMC9601928</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36321000</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>A Rare Case of Neuroendocrine Tumor in a Patient With Neurofibromatosis Type 1: Is There Any Association?</ArticleTitle><Pagination><MedlinePgn>e29621</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.29621</ELocationID><Abstract><AbstractText>Neurofibromatosis type 1 (NF1) is an autosomal dominant condition characterized by café-au-lait spots, cutaneous neurofibromas, axillary and inguinal freckling, and iris Lisch nodules; however, the presentations vary greatly, even within families. NF1 is also a recognized risk factor for the development of malignancy particularly malignant peripheral nerve sheath tumors (MPNST), optic gliomas, other gliomas, and leukemia. Nevertheless, the occurrence of lung cancer in a patient with neurofibromatosis type 1 is a rare phenomenon. Here we present a case of neuroendocrine tumor in a patient with neurofibromatosis type 1, highlighting the association between the two diseases. This case report also aimed to raise awareness of possible malignancies in patients with neurofibromatosis type 1.</AbstractText><CopyrightInformation>Copyright © 2022, Baddi et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baddi</LastName><ForeName>Fatima Zahra</ForeName><Initials>FZ</Initials><AffiliationInfo><Affiliation>Department of Respiratory Diseases, Mohammed VI University Hospital, Oujda, MAR.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pulmonology, Faculty of Medicine and Pharmacy, Mohammed I University, Oujda, MAR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahsayen</LastName><ForeName>Fatima Zohra</ForeName><Initials>FZ</Initials><AffiliationInfo><Affiliation>Department of Radiology, Mohammed VI University Hospital, Oujda, MAR.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Faculty of Medicine and Pharmacy, Mohammed I University, Oujda, MAR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramdani</LastName><ForeName>Hiba</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Departement of Medicine, Mohammed VI University Hospital, Oujda, MAR.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine and Pharmacy, Mohammed I University, Oujda, MAR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhazari</LastName><ForeName>Meriem</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Respiratory Diseases, Mohammed VI University Hospital, Oujda, MAR.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pulmonology, Faculty of Medicine and Pharmacy, Mohammed I University, Oujda, MAR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skiker</LastName><ForeName>Imane</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Radiology, Mohammed VI University Hospital, Oujda, MAR.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Faculty of Medicine and Pharmacy, Mohammed I University, Oujda, MAR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thouil</LastName><ForeName>Afaf</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Respiratory Diseases, Mohammed VI University Hospital, Oujda, MAR.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pulmonology, Faculty of Medicine and Pharmacy, Mohammed I University, Oujda, MAR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kouismi</LastName><ForeName>Hatim</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Respiratory Diseases, Mohammed VI University Hospital, Oujda, MAR.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pulmonology, Faculty of Medicine and Pharmacy, Mohammed I University, Oujda, MAR.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">lung cancer</Keyword><Keyword MajorTopicYN="N">malignancies</Keyword><Keyword MajorTopicYN="N">neuroendocrine tumor</Keyword><Keyword MajorTopicYN="N">neurofibromatosis type 1 (nf1)</Keyword><Keyword MajorTopicYN="N">risk factor</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321000</ArticleId><ArticleId IdType="doi">10.7759/cureus.29621</ArticleId><ArticleId IdType="pmc">PMC9604765</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320996</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Pancreatic Neuroendocrine Tumor (PNET) Presenting as a Pseudocyst: A Case Report.</ArticleTitle><Pagination><MedlinePgn>e29617</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.29617</ELocationID><Abstract><AbstractText>Pancreatic neuroendocrine tumors (PNETs) account for a very small proportion of all pancreatic tumors. The presence or absence of a specific clinical manifestation associated with hormone oversecretion determines whether a PNET is functional or nonfunctional. Imaging expressions differ significantly, from the common to the extremely rare. Diffuse, uniform pancreatic enlargement, without abnormalities in contour or a central mass, is the most common radiological finding. We report the case of a 43-year-old male who presented with abdominal pain and early satiety over the course of two months and was found to have a non-functioning pancreatic neuroendocrine tumor, with the pseudocyst being the initial diagnostic finding. In comparison to patients with exocrine pancreatic cancer, those with PNET have a much better prognosis and longer expected survival time. This case report highlights the importance of the diagnostic evaluation of PNET and timely intervention to prolong the survival of the patient.</AbstractText><CopyrightInformation>Copyright © 2022, Sedhai et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sedhai</LastName><ForeName>Swastika</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medicine, Kathmandu University, Kathmandu, NPL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammed</LastName><ForeName>Fathia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Internal Medicine, University of Gezira, Madani, SDN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahtiya</LastName><ForeName>Saveeta</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Internal Medicine, People's University of Medical &amp; Health Sciences, Nawabshah, Karachi, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanaullah</LastName><ForeName>Sadaf</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Internal Medicine, University of Tripoli Faculty of Medicine, Tripoli, LBY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pritwani</LastName><ForeName>Payal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Internal Medicine, Ghulam Muhammad Mahar Medical College, Sukkur, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saleem</LastName><ForeName>Faraz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Internal Medicine, Akhtar Saeed Medical and Dental College, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abere</LastName><ForeName>Ayodeji</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Internal Medicine, Karazin National University, Kharkov, UKR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghaffari</LastName><ForeName>Muhammad Abu Zar</ForeName><Initials>MAZ</Initials><AffiliationInfo><Affiliation>Internal Medicine, Akhtar Saeed Medical and Dental College, Lahore, PAK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">neuroendocrine</Keyword><Keyword MajorTopicYN="N">pancreas tumor</Keyword><Keyword MajorTopicYN="N">pancreatic neuroendocrine tumor</Keyword><Keyword MajorTopicYN="N">pnet</Keyword><Keyword MajorTopicYN="N">primitive neuroectodermal tumor (pnet)</Keyword><Keyword MajorTopicYN="N">pseudocyst</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320996</ArticleId><ArticleId IdType="doi">10.7759/cureus.29617</ArticleId><ArticleId IdType="pmc">PMC9603887</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320989</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Young-Onset Colon Cancer: A Case Report.</ArticleTitle><Pagination><MedlinePgn>e29667</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.29667</ELocationID><Abstract><AbstractText>Colorectal cancer (CRC) which is diagnosed in patients under the age of 50 years is defined as young-onset CRC. There has been a substantial increase in the incidence and mortality of young-onset CRC in the past four decades and the patients have delayed diagnoses leading to the advanced stages of CRC at the time of diagnosis. Here we present a case of a 34-year-old male patient with colon cancer and a literature review on young-onset colon cancer to highlight the age-related disparities in CRC incidence and try to explore the possible causative factors for the rise in incidence and mortality in young patients due to CRC.</AbstractText><CopyrightInformation>Copyright © 2022, Hashmi et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hashmi</LastName><ForeName>Syed Salman Hamid</ForeName><Initials>SSH</Initials><AffiliationInfo><Affiliation>Internal Medicine, NYU (New York University) Langone, Woodhull Medical Center, New York City, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shady</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Gastroenterology, New York Medical College, Metropolitan Hospital Center, New York City, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atallah-Vinograd</LastName><ForeName>Jean</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Gastroenterology, New York Medical College, Metropolitan Hospital Center, New York City, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Donelle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Advanced Endoscopy/Gastroenterology, New York Medical College, Metropolitan Hospital Center, New York City, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maranino</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Gastroenterology, New York Medical College, Metropolitan Hospital Center, New York City, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harley</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Gastroenterology, New York Medical College, Metropolitan Hospital Center, New York City, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">african american colon cancer</Keyword><Keyword MajorTopicYN="N">hispanic health</Keyword><Keyword MajorTopicYN="N">screening colonoscopy</Keyword><Keyword MajorTopicYN="N">young colon cancer</Keyword><Keyword MajorTopicYN="N">young colon cancer awareness</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320989</ArticleId><ArticleId IdType="doi">10.7759/cureus.29667</ArticleId><ArticleId IdType="pmc">PMC9613351</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320987</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Clinical Characteristics and Mortality-Associated Factors in COVID-19 Critical Patients in a Portuguese ICU.</ArticleTitle><Pagination><MedlinePgn>e29610</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.29610</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Severe COVID-19 is associated with serious complications and poor outcomes. Older age and underlying comorbidities are known risk factors for severe COVID-19, but a better understanding of baseline characteristics and outcomes of patients with severe COVID-19 is urgently needed.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study was a retrospective case series of 227 consecutive patients with laboratory-confirmed COVID-19 admitted to the intensive care unit (ICU) at our institution between March 2020 and December 2021. Demographic and clinical data were collected.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median age of patients was 65 years, and 180 (79.3%) were male. Cardiovascular comorbidities were frequent and included hypertension (n=148; 65.2%), dyslipidemia (n=116; 51.1%), obesity (n=114; 50.2%), and diabetes mellitus (n=80; 35.2%). About 20% of the patients had the chronic respiratory disease, with sleep apnea being the most common. Immunosuppression was identified in 13% of the patients, with autoimmunity, post-transplantation, and neoplasms being the most represented causes. Most patients were admitted to the ICU at six to 15 days after symptom onset, corresponding to stages IIb (pulmonary involvement/hypoxia) and III (hyperinflammatory). All patients received systemic steroids, with an average treatment duration of 22 days. Several ventilatory support strategies were used; 80 patients were supported entirely noninvasively with high flow nasal oxygenation and noninvasive ventilation, while 164 patients were invasively ventilated. Most intubations (65%) occurred in the first 24 hours after admission, and the mean duration of mechanical ventilation was 14 days. The reintubation rate was 10%, occurring on average two to three days after planned extubation. Thirty-two tracheostomies were performed. Bacterial co-infection was treated in 75% of patients, and <i>Aspergillus</i> co-infection complicating COVID-19 pneumonia was diagnosed in eight patients. Median ICU and hospital stays were 15 and 25 days, respectively, and the 28-day mortality rate was 38%. Patients over 75 years experienced a higher mortality rate (56%). Increased age and multimorbidity, particularly comprising cardiovascular disease and associated risk factors, were significantly more common in patients who died within 28 days after ICU admission.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A large proportion of critically ill COVID-19 patients required prolonged mechanical ventilation. ICU/hospital stay and mortality were particularly elevated in older patients and patients with cardiovascular risk factors. Considerable discrepancy existed between the proportion of patients with microbiological documentation of bacterial infections and those receiving antimicrobials. Improved methods for adequate microbiological diagnosis are needed and stewardship programs should be reinforced.</AbstractText><CopyrightInformation>Copyright © 2022, Costa et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Critical Care, Serviço de Medicina Intensiva, Hospital de Braga, Braga, PRT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>José</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Internal Medicine, Hospital of Braga, Braga, PRT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Critical Care, Hospital de Braga, Braga, PRT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Ana Isabel</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Internal Medicine, Hospital of Braga, Braga, PRT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leal</LastName><ForeName>Dina</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Intensive Care Medicine, Hospital of Braga, Braga, PRT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lencastre</LastName><ForeName>Luís</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Critical Care, Hospital of Braga, Braga, PRT.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">comorbidity</Keyword><Keyword MajorTopicYN="N">covid-19</Keyword><Keyword MajorTopicYN="N">critical illness</Keyword><Keyword MajorTopicYN="N">sars-cov-2</Keyword><Keyword MajorTopicYN="N">ventilation</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320987</ArticleId><ArticleId IdType="doi">10.7759/cureus.29610</ArticleId><ArticleId IdType="pmc">PMC9601929</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320968</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Correlation of Tumor Budding With Known Clinicopathological, Histomorphological and Hormonal Receptor Status in Patients With Invasive Breast Carcinoma.</ArticleTitle><Pagination><MedlinePgn>e29637</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.29637</ELocationID><Abstract><AbstractText><i>Introduction</i>: Tumor blossoming may be a predictive indicator for a variety of cancers. At the invasive origin of the tumor, cells get detached from the original tumor mass. <i>Aims &amp; objectives</i>: Studying breast cancer tumor budding, as well as its link to other prognostic indicators, such as clinicopathological features and hormone receptor status, will be the focus of this study. <i>Materials &amp; methods</i>: Over six years, 110 cases of invasive breast cancer were examined. Ten high-power fields were used to analyze H&amp;E-stained slices for tumor sprouting. It was determined that the tumor buds were divided into low and high grades. Tumor budding and other prognostic factors were compared using the chi-square test. It was considered significant if the p-value was less than or equal to 0.05. <i>Results</i>: There were 110 cases of invasive ductal carcinoma, which accounts for more than half of the total cases (88.18%). A total of 144 tumors were present, of which 74 displayed strong budding and 36 displayed poor budding. A correlation between tumor budding and tumor size, lymph node metastasis, and tumor stage is statistically significant (P = 0.0099). <i>Conclusion</i>: Tumor budding in breast cancer is an easily visible in microscopy, novel prognostic indicator. A new prognostic element may be added to the reporting process.</AbstractText><CopyrightInformation>Copyright © 2022, Rathod et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rathod</LastName><ForeName>Gunvanti B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Pathology, AIl India Institute of Medical Sciences (AIIMS), Hyderabad, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Killol N</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>Pathology, Nootan Medical College &amp; Research Centre, Visnagar, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shrivastava</LastName><ForeName>Atul</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pathology, Gujarat Medical &amp; Education Research Society (GMERS) Medical College and Civil Hospital, Gandhinagar, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maru</LastName><ForeName>Alpeshkumar M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Pathology, Dr. N. D. Desai Faculty of Medical Science &amp; Research Centre, Nadiad, IND.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">breast carcinoma</Keyword><Keyword MajorTopicYN="N">histomorphology</Keyword><Keyword MajorTopicYN="N">immunohistochemistry</Keyword><Keyword MajorTopicYN="N">infiltrating ductal carcinoma</Keyword><Keyword MajorTopicYN="N">tumor buds</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>08</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320968</ArticleId><ArticleId IdType="doi">10.7759/cureus.29637</ArticleId><ArticleId IdType="pmc">PMC9606632</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320966</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>A Multidisciplinary Approach and Current Perspective of Nonalcoholic Fatty Liver Disease: A Systematic Review.</ArticleTitle><Pagination><MedlinePgn>e29657</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.29657</ELocationID><Abstract><AbstractText>In recent times, nonalcoholic fatty liver disease (NAFLD) has been considered one of the major causes of liver disease across the world. NAFLD is defined as the deposition of triglycerides in the liver and is associated with obesity and metabolic syndrome. Hyperinsulinemia, insulin resistance (IR), fatty liver, hepatocyte injury, unbalanced proinflammatory cytokines, mitochondrial dysfunction, oxidative stress, liver inflammation, and fibrosis are the main pathogenesis in NAFLD. Recent studies suggest that the action of intestinal microbiota through chronic inflammation, increased intestinal permeability, and energy uptake plays a vital role in NAFLD. Moreover, polycystic ovarian syndrome also causes NAFLD development through IR. Age, gender, race, ethnicity, sleep, diet, sedentary lifestyle, and genetic and epigenetic pathways are some contributing factors of NAFLD that can exacerbate the risk of liver cirrhosis and hepatocellular carcinoma (HCC) and eventually lead to death. NAFLD has various presentations, including fatigue, unexplained weight loss, bloating, upper abdominal pain, decreased appetite, headache, anxiety, poor sleep, increased thirst, palpitation, and a feeling of warmth. Some studies have shown that NAFLD with severe coronavirus disease 2019 (COVID-19) has poor outcomes. The gold standard for NAFLD diagnosis is liver biopsy. Other diagnostic tools are imaging tests, serum biomarkers, microbiota markers, and tests for extrahepatic complications. There are no specific treatments for NAFLD. Therefore, the main concern for NAFLD is treating the comorbid conditions such as anti-diabetic agents for type 2 diabetes mellitus, statins to reduce HCC progression, antioxidants to prevent hepatocellular damage, and bariatric surgery for patients with a BMI of &gt;40 kg/m<sup>2</sup> and &gt;35 kg/m<sup>2</sup> with comorbidities. Lifestyle and dietary changes are considered preventive strategies against NAFLD advancement. Inadequate treatment of NAFLD further leads to cardiac consequences, sleep apnea, chronic kidney disease, and inflammatory bowel disease. In this systematic review, we have briefly discussed the risk factors, pathogenesis, clinical features, and numerous consequences of NAFLD. We have also reviewed various guidelines for NAFLD diagnosis along with existing therapeutic strategies for the management and prevention of the disease.</AbstractText><CopyrightInformation>Copyright © 2022, Zaman et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zaman</LastName><ForeName>Chowdhury F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Medicine and Surgery, Jahurul Islam Medical College and Hospital, Kishoreganj, BGD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sultana</LastName><ForeName>Jakia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medicine, Comilla Medical College, Cumilla, BGD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dey</LastName><ForeName>Proma</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Internal Medicine, Chittagong Medical College, Chattogram, BGD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dutta</LastName><ForeName>Jui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medicine, Comilla Medical College, Cumilla, BGD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mustarin</LastName><ForeName>Sadia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medicine, Mymensingh Medical College, Mymensingh, BGD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamanna</LastName><ForeName>Nuzhat</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Medicine, Rangpur Medical College and Hospital, Rangpur, BGD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roy</LastName><ForeName>Aditi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medicine, Sher-e-Bangla Medical College, Barisal, BGD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhowmick</LastName><ForeName>Nisha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Medicine, Shaheed Ziaur Rahman Medical College, Bogra, BGD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanam</LastName><ForeName>Mousumi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Internal Medicine, Dhaka Medical College, Dhaka, BGD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sultana</LastName><ForeName>Sadia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medicine, Anwer Khan Modern Medical College, Dhaka, BGD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Selia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Internal Medicine, Dhaka Medical College, Dhaka, BGD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanam</LastName><ForeName>Farjana</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Medicine, Central Medical College, Cumilla, BGD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakibuzzaman</LastName><ForeName>Md</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurology, The University of Toledo, Toledo, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine, University of Mississippi Medical Center, Jackson, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine, Sir Salimullah Medical College, Dhaka, BGD.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Experimental Pathology (Cancer Biology), Mayo Clinic, Rochester, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dutta</LastName><ForeName>Priyata</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Internal Medicine, Trinity Health, St. Joseph Mercy Ann Arbor, Ann Arbor, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">covid-19</Keyword><Keyword MajorTopicYN="N">gut microbiota</Keyword><Keyword MajorTopicYN="N">hepatocellular carcinoma (hcc)</Keyword><Keyword MajorTopicYN="N">metabolic syndrome</Keyword><Keyword MajorTopicYN="N">nafld</Keyword><Keyword MajorTopicYN="N">nonalcoholic fatty liver disease</Keyword><Keyword MajorTopicYN="N">nonalcoholic fatty liver disease (nafld)</Keyword><Keyword MajorTopicYN="N">obesity</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320966</ArticleId><ArticleId IdType="doi">10.7759/cureus.29657</ArticleId><ArticleId IdType="pmc">PMC9612896</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320942</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Electronic Cigarettes for Smoking Cessation: The Gap Between Behavior in Smokers and Medical Education.</ArticleTitle><Pagination><MedlinePgn>e29603</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.29603</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">E-cigarettes have engendered a great deal of controversy within the public health and medical communities.  Methods: Two cross-sectional surveys were administered. First, patients at an annual lung cancer screening appointment who self-identified as former smokers were asked about strategies for achieving and maintaining smoking cessation with open-ended questions. Second, medical students at a single university reported their opinion and knowledge of combustible cigarettes and e-cigarettes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the n=102 in the patient survey indicating that they used e-cigarettes or over-the-counter (OTC) nicotine replacement products for smoking cessation, 34.3% (35/102) vaped e-cigarettes, making it the second most common next to patches (47.1% {48/102}). By comparison, n=48 reported using medication. Medical student participants (n=168) were mixed regarding whether a patient should switch from traditional to electronic cigarettes (56.0% yes; 44.0% no) and reported receiving education about traditional cigarettes (92.3%) at a much higher rate than for e-cigarettes (46.4%), p&lt;.001.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Many former heavy smokers undergoing a lung cancer screen used e-cigarettes to achieve smoking cessation. However, nearly half of medical students surveyed do not think patients should switch from traditional to e-cigarettes.</AbstractText><CopyrightInformation>Copyright © 2022, Bernstein et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Michael H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Imaging, Rhode Island Hospital, Brown University, Providence, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Diagnostic Imaging, Brown Radiology Human Factors Lab, Providence, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oueidat</LastName><ForeName>Karim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Imaging, Rhode Island Hospital, Brown University, Providence, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wasserman</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Medical School, Brown University, Providence, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Saurabh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Imaging, Rhode Island Hospital, Brown University, Providence, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baird</LastName><ForeName>Grayson L</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Imaging, Rhode Island Hospital, Brown University, Providence, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Diagnostic Imaging, Brown Radiology Human Factors Lab, Providence, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sokolovsky</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Public Health, Brown University, Providence, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maxwell</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Imaging, Rhode Island Hospital, Brown University, Providence, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Diagnostic Imaging, Brown Radiology Human Factors Lab, Providence, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Healey</LastName><ForeName>Terrance</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Imaging, Rhode Island Hospital, Brown University, Providence, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">electronic cigarettes' e-cigarettes' vaping' e-smoking</Keyword><Keyword MajorTopicYN="N">lung cancer screen</Keyword><Keyword MajorTopicYN="N">smoking</Keyword><Keyword MajorTopicYN="N">tobacco</Keyword><Keyword MajorTopicYN="N">tobacco cessation</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320942</ArticleId><ArticleId IdType="doi">10.7759/cureus.29603</ArticleId><ArticleId IdType="pmc">PMC9600939</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320934</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2692-4609</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>DEN open</Title><ISOAbbreviation>DEN Open</ISOAbbreviation></Journal><ArticleTitle>Performance of a novel computer-aided diagnosis system in the characterization of colorectal polyps, and its role in meeting Preservation and Incorporation of Valuable Endoscopic Innovations standards set by the American Society of Gastrointestinal Endoscopy.</ArticleTitle><Pagination><MedlinePgn>e178</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/deo2.178</ELocationID><Abstract><AbstractText Label="Background and aims" NlmCategory="UNASSIGNED">There has been an increasing role of artificial intelligence (AI) in the characterization of colorectal polyps. Recently, a novel AI algorithm for the characterization of polyps was developed by NEC Corporation (Japan). The aim of our study is to perform an external validation of this algorithm.</AbstractText><AbstractText Label="Methods" NlmCategory="UNASSIGNED">The study was a video-based evaluation of the computer-aided diagnosis (CADx) system. Patients undergoing colonoscopy were recruited to record videos of colonic polyps. The frozen polyp images extracted from these videos were used for real-time histological prediction by the endoscopists and by the CADx system, and the results were compared.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">A total of 115 polyp images were extracted from 66 patients. Sensitivity, negative predictive value and accuracy for diminutive polyps on white light imaging (WLI) and image-enhanced endoscopy (IEE) when assessed by CADx was 90.9% [95% confidence interval (CI) 77.3-100] and 95.8% [95% CI 87.5-100], 80% [95% CI 44.4-97.5] and 90.9% [95% CI 58.7-99.8], 84.8% [95% CI 72.7-97] and 84.6% [95%CI 71.8-94.9], respectively, compared to 48.1% [95%CI 37.7-59.1] and 72% [95% CI 62.5-81], 37.5% [95% CI 28.8-46.8] and 55% [95% CI 44.7-65.0], 53.7% [95% CI 44.2-63.2] and 66.7% [95% CI 59.7-73.3] when assessed by endoscopists. Concordance between histology and CADx-based post-polypectomy surveillance intervals was 93.02% on WLI and 96% on IEE.</AbstractText><AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">AI-based optical diagnosis is promising and has the potential to be better than the performance of general endoscopists. We believe that AI can help make real-time optical diagnoses of polyps meeting the Preservation and Incorporation of Valuable endoscopic Innovations standards set by the American Society of Gastrointestinal Endoscopy.</AbstractText><CopyrightInformation>© 2022 The Authors. DEN Open published by John Wiley &amp; Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hossain</LastName><ForeName>Ejaz</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Portsmouth Hospitals NHS Trust Portsmouth UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdelrahim</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Portsmouth Hospitals NHS Trust Portsmouth UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanasescu</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Portsmouth Hospitals NHS Trust Portsmouth UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Masayoshi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Cancer Center Hospital Endoscopy Division Tokyo Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Cancer Center Research Institute Division of Molecular Modification and Cancer Biology Tokyo Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kondo</LastName><ForeName>Hiroko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>National Cancer Center Research Institute Division of Molecular Modification and Cancer Biology Tokyo Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>RIKEN Center for Advanced Intelligence Project Tokyo Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Shijemi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Cancer Center Research Institute Division of Molecular Modification and Cancer Biology Tokyo Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>RIKEN Center for Advanced Intelligence Project Tokyo Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamamoto</LastName><ForeName>Ryuji</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>National Cancer Center Research Institute Division of Molecular Modification and Cancer Biology Tokyo Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>RIKEN Center for Advanced Intelligence Project Tokyo Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marugame</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>NEC Corporation Medical AI Research Department Tokyo Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Yutaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Portsmouth Hospitals NHS Trust Portsmouth UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhandari</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Portsmouth Hospitals NHS Trust Portsmouth UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Portsmouth, University House Portsmouth UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>DEN Open</MedlineTA><NlmUniqueID>9918317682706676</NlmUniqueID><ISSNLinking>2692-4609</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">artificial intelligence</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">characterization</Keyword><Keyword MajorTopicYN="N">colorectal</Keyword><Keyword MajorTopicYN="N">polyps</Keyword></KeywordList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>07</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>09</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320934</ArticleId><ArticleId IdType="doi">10.1002/deo2.178</ArticleId><ArticleId IdType="pii">DEO2178</ArticleId><ArticleId IdType="pmc">PMC9614381</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320916</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2041-6520</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>40</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>19</Day></PubDate></JournalIssue><Title>Chemical science</Title><ISOAbbreviation>Chem Sci</ISOAbbreviation></Journal><ArticleTitle>Palladium-peptide oxidative addition complexes for bioconjugation.</ArticleTitle><Pagination><MedlinePgn>11891-11895</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d2sc04074c</ELocationID><Abstract><AbstractText>The synthesis of palladium oxidative addition complexes derived from unprotected peptides is described. Incorporation of 4-halophenylalanine into a peptide during solid phase peptide synthesis allows for subsequent oxidative addition at this position upon treatment with a palladium precursor and suitable ligand. The resulting palladium-peptide complexes are solid, storable, water-soluble, and easily purified <i>via</i> high-performance liquid chromatography. These complexes react with thiols in aqueous buffer, offering an efficient method for bioconjugation. Using this strategy, peptides can be functionalized with small molecules to prepare modified aryl thioether side-chains at low micromolar concentrations. Additionally, peptide-peptide and peptide-protein ligations are demonstrated under dilute aqueous conditions.</AbstractText><CopyrightInformation>This journal is © The Royal Society of Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rojas</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-1975-7113</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA blp@mit.edu sbuchwal@mit.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, Kennesaw State University 1000 Chastain Road NW Kennesaw GA 30144 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolfe</LastName><ForeName>Justin M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA blp@mit.edu sbuchwal@mit.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhanjee</LastName><ForeName>Heemal H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA blp@mit.edu sbuchwal@mit.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buslov</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA blp@mit.edu sbuchwal@mit.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Truex</LastName><ForeName>Nicholas L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA blp@mit.edu sbuchwal@mit.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Richard Y</ForeName><Initials>RY</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Chemical Biology, Harvard University 12 Oxford Street Cambridge MA 02138 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massefski</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA blp@mit.edu sbuchwal@mit.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pentelute</LastName><ForeName>Bradley L</ForeName><Initials>BL</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-7242-801X</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA blp@mit.edu sbuchwal@mit.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology 500 Main Street Cambridge MA 02142 USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Environmental Health Sciences, Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard 415 Main Street Cambridge MA 02142 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buchwald</LastName><ForeName>Stephen L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-3875-4775</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA blp@mit.edu sbuchwal@mit.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Chem Sci</MedlineTA><NlmUniqueID>101545951</NlmUniqueID><ISSNLinking>2041-6520</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare the following competing financial interest(s): B. L. P. is a co-founder and/or member of the scientific advisory board of several companies focusing on the development of protein and peptide therapeutics. MIT has obtained or has filed patents on some of the ligands that are described in the paper from which S. L. B. and former co-workers receive royalty payments.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>07</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320916</ArticleId><ArticleId IdType="doi">10.1039/d2sc04074c</ArticleId><ArticleId IdType="pii">d2sc04074c</ArticleId><ArticleId IdType="pmc">PMC9580489</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320913</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2041-6520</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>40</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>19</Day></PubDate></JournalIssue><Title>Chemical science</Title><ISOAbbreviation>Chem Sci</ISOAbbreviation></Journal><ArticleTitle>Photochemistry of pyruvic acid is governed by photo-induced intermolecular electron transfer through hydrogen bonds.</ArticleTitle><Pagination><MedlinePgn>11849-11855</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d2sc03038a</ELocationID><Abstract><AbstractText>Despite more than 85 years of research, the mechanism behind the photodecarboxylation of pyruvic acid remains elusive. Most studies focused on the gas and liquid phase of diluted solutions of pyruvic acid to understand the impact of sun light on the degradation of this molecule in the atmosphere. By analyzing concentrated supercooled solutions at 77 K, we demonstrate that instead of decarboxylating, the pyruvic acid molecule plays the role of electron donor and transfers an electron to an acceptor molecule that subsequently degrades to form CO<sub>2</sub>. We show that this electron transfer occurs <i>via</i> hydrogen bonding and that in aqueous solutions of pyruvic acid, the hydrated form is the electron acceptor. These findings demonstrate that photo-induced electron transfer <i>via</i> hydrogen bonding can occur between two simple carboxylic acids and that this mechanism governs the photochemistry of pyruvic acid, providing unexplored alternative pathways for the decarboxylation of photo-inactive molecules.</AbstractText><CopyrightInformation>This journal is © The Royal Society of Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Cancer Research UK Cambridge Institute, University of Cambridge Robinson Way Cambridge CB2 0RE UK arnaud.comment@ge.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaunt</LastName><ForeName>Adam P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Cancer Research UK Cambridge Institute, University of Cambridge Robinson Way Cambridge CB2 0RE UK arnaud.comment@ge.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Comment</LastName><ForeName>Arnaud</ForeName><Initials>A</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-8484-3448</Identifier><AffiliationInfo><Affiliation>Cancer Research UK Cambridge Institute, University of Cambridge Robinson Way Cambridge CB2 0RE UK arnaud.comment@ge.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>General Electric Healthcare Pollards Wood, Nightingales Lane, Chalfont St Giles HP8 4SP UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Chem Sci</MedlineTA><NlmUniqueID>101545951</NlmUniqueID><ISSNLinking>2041-6520</ISSNLinking></MedlineJournalInfo><CoiStatement>A. C. was employed by General Electric Medical Systems Inc. at the time of manuscript preparation.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320913</ArticleId><ArticleId IdType="doi">10.1039/d2sc03038a</ArticleId><ArticleId IdType="pii">d2sc03038a</ArticleId><ArticleId IdType="pmc">PMC9580485</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320893</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2633-0679</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>RSC chemical biology</Title><ISOAbbreviation>RSC Chem Biol</ISOAbbreviation></Journal><ArticleTitle>QSAR models reveal new EPAC-selective allosteric modulators.</ArticleTitle><Pagination><MedlinePgn>1230-1239</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d2cb00106c</ELocationID><Abstract><AbstractText>Exchange proteins directly activated by cAMP (EPAC) are guanine nucleotide exchange factors for the small GTPases, Rap1 and Rap2. They regulate several physiological functions and mitigation of their activity has been suggested as a possible treatment for multiple diseases such as cardiomyopathy, diabetes, chronic pain, and cancer. Several EPAC-specific modulators have been developed, however studies that quantify their structure-activity relationships are still lacking. Here we propose a quantitative structure-activity relationship (QSAR) model for a series of EPAC-specific compounds. The model demonstrated high reproducibility and predictivity and the predictive ability of the model was tested against a series of compounds that were unknown to the model. The compound with the highest predicted affinity was validated experimentally through fluorescence-based competition assays and NMR experiments revealed its mode of binding and mechanism of action as a partial agonist. The proposed QSAR model can, therefore, serve as an effective screening tool to identify promising EPAC-selective drug leads with enhanced potency.</AbstractText><CopyrightInformation>This journal is © The Royal Society of Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mohamed</LastName><ForeName>Hebatallah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Chemical Biology, McMaster University, Hamilton Ontario L8S 4L8 Canada melacin@mcmaster.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Hongzhao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Chemical Biology, McMaster University, Hamilton Ontario L8S 4L8 Canada melacin@mcmaster.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akimoto</LastName><ForeName>Madoka</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-0510-5613</Identifier><AffiliationInfo><Affiliation>Department of Chemistry and Chemical Biology, McMaster University, Hamilton Ontario L8S 4L8 Canada melacin@mcmaster.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darveau</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Chemical Biology, McMaster University, Hamilton Ontario L8S 4L8 Canada melacin@mcmaster.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacKinnon</LastName><ForeName>Marc R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton Ontario L8S 4L8 Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magolan</LastName><ForeName>Jakob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton Ontario L8S 4L8 Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melacini</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-1164-2853</Identifier><AffiliationInfo><Affiliation>Department of Chemistry and Chemical Biology, McMaster University, Hamilton Ontario L8S 4L8 Canada melacin@mcmaster.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton Ontario L8S 4L8 Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RSC Chem Biol</MedlineTA><NlmUniqueID>101768727</NlmUniqueID><ISSNLinking>2633-0679</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare no competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>04</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320893</ArticleId><ArticleId IdType="doi">10.1039/d2cb00106c</ArticleId><ArticleId IdType="pii">d2cb00106c</ArticleId><ArticleId IdType="pmc">PMC9533425</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320886</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2633-0679</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>RSC chemical biology</Title><ISOAbbreviation>RSC Chem Biol</ISOAbbreviation></Journal><ArticleTitle>A multicomponent reaction platform towards multimodal near-infrared BODIPY dyes for STED and fluorescence lifetime imaging.</ArticleTitle><Pagination><MedlinePgn>1251-1259</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d2cb00168c</ELocationID><Abstract><AbstractText>We report a platform combining multicomponent reaction synthesis and automated cell-based screening to develop biocompatible NIR-BODIPY fluorophores. From a library of over 60 fluorophores, we optimised compound NIRBD-62c as a multimodal probe with suitable properties for STED super-resolution and fluorescence lifetime imaging. Furthermore, we employed NIRBD-62c for imaging trafficking inside cells and to examine how pharmacological inhibitors can alter the vesicular traffic between intracellular compartments and the plasma membrane.</AbstractText><CopyrightInformation>This journal is © The Royal Society of Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-9816-8482</Identifier><AffiliationInfo><Affiliation>Centre for Inflammation Research, The University of Edinburgh Edinburgh UK marc.vendrell@ed.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dpt Organic Chemistry, Faculty of Chemistry, University of Murcia Spain ajfvargas@ugr.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kielland</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Centre for Inflammation Research, The University of Edinburgh Edinburgh UK marc.vendrell@ed.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Medicinal Chemistry, Faculty of Pharmacy and Institute of Biomedicine (IBUB), University of Barcelona Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makda</LastName><ForeName>Ashraff</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Genetics and Cancer, The University of Edinburgh Edinburgh UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carragher</LastName><ForeName>Neil O</ForeName><Initials>NO</Initials><AffiliationInfo><Affiliation>Institute of Genetics and Cancer, The University of Edinburgh Edinburgh UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>González-García</LastName><ForeName>M Carmen</ForeName><Initials>MC</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-6128-0884</Identifier><AffiliationInfo><Affiliation>Nanoscopy-UGR Laboratory, Facultad de Farmacia, Universidad de Granada Granada Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espinar-Barranco</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Nanoscopy-UGR Laboratory, Facultad de Farmacia, Universidad de Granada Granada Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>González-Vera</LastName><ForeName>Juan A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-8199-1330</Identifier><AffiliationInfo><Affiliation>Nanoscopy-UGR Laboratory, Facultad de Farmacia, Universidad de Granada Granada Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orte</LastName><ForeName>Angel</ForeName><Initials>A</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-1905-4183</Identifier><AffiliationInfo><Affiliation>Nanoscopy-UGR Laboratory, Facultad de Farmacia, Universidad de Granada Granada Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavilla</LastName><ForeName>Rodolfo</ForeName><Initials>R</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-5006-9917</Identifier><AffiliationInfo><Affiliation>Laboratory of Medicinal Chemistry, Faculty of Pharmacy and Institute of Biomedicine (IBUB), University of Barcelona Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vendrell</LastName><ForeName>Marc</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-5392-9740</Identifier><AffiliationInfo><Affiliation>Centre for Inflammation Research, The University of Edinburgh Edinburgh UK marc.vendrell@ed.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RSC Chem Biol</MedlineTA><NlmUniqueID>101768727</NlmUniqueID><ISSNLinking>2633-0679</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors have no conflicts to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>07</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320886</ArticleId><ArticleId IdType="doi">10.1039/d2cb00168c</ArticleId><ArticleId IdType="pii">d2cb00168c</ArticleId><ArticleId IdType="pmc">PMC9533399</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320882</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2306-9759</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Stem cell investigation</Title><ISOAbbreviation>Stem Cell Investig</ISOAbbreviation></Journal><ArticleTitle>Eph receptor B2 (EPHB2) regulates cancer stem cell-like properties in hepatocellular carcinoma.</ArticleTitle><Pagination><MedlinePgn>5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/sci-2022-031</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Jhin Jieh</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Cancer Science Institute of Singapore, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Edward Kai-Hua</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Cancer Science Institute of Singapore, National University of Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The N.1 Institute for Health, National University of Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toh</LastName><ForeName>Tan Boon</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>The N.1 Institute for Health, National University of Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Stem Cell Investig</MedlineTA><NlmUniqueID>101672113</NlmUniqueID><ISSNLinking>2306-9759</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Cancer Res. 2021 Jun 15;81(12):3229-3240</RefSource><PMID Version="1">33903122</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://sci.amegroups.com/article/view/10.21037/sci-2022-031/coif). The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>09</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320882</ArticleId><ArticleId IdType="doi">10.21037/sci-2022-031</ArticleId><ArticleId IdType="pii">sci-09-2022-031</ArticleId><ArticleId IdType="pmc">PMC9618362</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320862</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2399-3669</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Communications chemistry</Title><ISOAbbreviation>Commun Chem</ISOAbbreviation></Journal><ArticleTitle>An open-source molecular builder and free energy preparation workflow.</ArticleTitle><Pagination><MedlinePgn>136</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s42004-022-00754-9</ELocationID><Abstract><AbstractText>Automated free energy calculations for the prediction of binding free energies of congeneric series of ligands to a protein target are growing in popularity, but building reliable initial binding poses for the ligands is challenging. Here, we introduce the open-source FEgrow workflow for building user-defined congeneric series of ligands in protein binding pockets for input to free energy calculations. For a given ligand core and receptor structure, FEgrow enumerates and optimises the bioactive conformations of the grown functional group(s), making use of hybrid machine learning/molecular mechanics potential energy functions where possible. Low energy structures are optionally scored using the gnina convolutional neural network scoring function, and output for more rigorous protein-ligand binding free energy predictions. We illustrate use of the workflow by building and scoring binding poses for ten congeneric series of ligands bound to targets from a standard, high quality dataset of protein-ligand complexes. Furthermore, we build a set of 13 inhibitors of the SARS-CoV-2 main protease from the literature, and use free energy calculations to retrospectively compute their relative binding free energies. FEgrow is freely available at https://github.com/cole-group/FEgrow, along with a tutorial.</AbstractText><CopyrightInformation>© The Author(s) 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Bieniek</LastName><ForeName>Mateusz K</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0002-3065-5417</Identifier><AffiliationInfo><Affiliation>School of Natural and Environmental Sciences, Newcastle University, Newcastle upon Tyne, NE1 7RU UK.</Affiliation><Identifier Source="GRID">grid.1006.7</Identifier><Identifier Source="ISNI">0000 0001 0462 7212</Identifier></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cree</LastName><ForeName>Ben</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>School of Natural and Environmental Sciences, Newcastle University, Newcastle upon Tyne, NE1 7RU UK.</Affiliation><Identifier Source="GRID">grid.1006.7</Identifier><Identifier Source="ISNI">0000 0001 0462 7212</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pirie</LastName><ForeName>Rachael</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-2449-3458</Identifier><AffiliationInfo><Affiliation>School of Natural and Environmental Sciences, Newcastle University, Newcastle upon Tyne, NE1 7RU UK.</Affiliation><Identifier Source="GRID">grid.1006.7</Identifier><Identifier Source="ISNI">0000 0001 0462 7212</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horton</LastName><ForeName>Joshua T</ForeName><Initials>JT</Initials><Identifier Source="ORCID">0000-0001-8694-7200</Identifier><AffiliationInfo><Affiliation>School of Natural and Environmental Sciences, Newcastle University, Newcastle upon Tyne, NE1 7RU UK.</Affiliation><Identifier Source="GRID">grid.1006.7</Identifier><Identifier Source="ISNI">0000 0001 0462 7212</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatum</LastName><ForeName>Natalie J</ForeName><Initials>NJ</Initials><Identifier Source="ORCID">0000-0003-3878-9265</Identifier><AffiliationInfo><Affiliation>Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH UK.</Affiliation><Identifier Source="GRID">grid.1006.7</Identifier><Identifier Source="ISNI">0000 0001 0462 7212</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0003-2933-0719</Identifier><AffiliationInfo><Affiliation>School of Natural and Environmental Sciences, Newcastle University, Newcastle upon Tyne, NE1 7RU UK.</Affiliation><Identifier Source="GRID">grid.1006.7</Identifier><Identifier Source="ISNI">0000 0001 0462 7212</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Commun Chem</MedlineTA><NlmUniqueID>101725670</NlmUniqueID><ISSNLinking>2399-3669</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Computational chemistry</Keyword><Keyword MajorTopicYN="N">Structure-based drug design</Keyword></KeywordList><CoiStatement>Competing interestsThe authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320862</ArticleId><ArticleId IdType="doi">10.1038/s42004-022-00754-9</ArticleId><ArticleId IdType="pii">754</ArticleId><ArticleId IdType="pmc">PMC9607723</ArticleId></ArticleIdList><?pmcsd ?></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320859</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2046-2069</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>41</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>RSC advances</Title><ISOAbbreviation>RSC Adv</ISOAbbreviation></Journal><ArticleTitle>Functional block copolymer micelles based on poly (jasmine lactone) for improving the loading efficiency of weakly basic drugs.</ArticleTitle><Pagination><MedlinePgn>26763-26775</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d2ra03962a</ELocationID><Abstract><AbstractText>Functionalization of polymers is an attractive approach to introduce specific molecular forces that can enhance drug-polymer interaction to achieve higher drug loading when used as drug delivery systems. The novel amphiphilic block copolymer of methoxy poly(ethylene glycol) and poly(jasmine lactone) <i>i.e.</i>, mPEG-<i>b</i>-PJL, derived from renewable jasmine lactone provides free allyl groups on the backbone thus, allowing flexible and facile post-synthesis functionalization. In this study, mPEG-<i>b</i>-PJL and its carboxyl functionalized polymer mPEG-<i>b</i>-PJL-COOH were utilised to explore the effect of ionic interactions on the drug-polymer behaviour. Various drugs with different p<i>K</i> <sub>a</sub> values were employed to prepare drug-loaded polymeric micelles (PMs) of mPEG-<i>b</i>-PJL, mPEG-<i>b</i>-PJL-COOH and Soluplus® (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer) <i>via</i> a nanoprecipitation method. Electrostatic interactions between the COOH pendant on mPEG-<i>b</i>-PJL-COOH and the basic drugs were shown to influence the entrapment efficiency. Additionally, molecular dynamics (MD) simulations were employed to understand the polymer-drug interactions at the molecular level and how polymer functionalization influenced these interactions. The release kinetics of the anti-cancer drug sunitinib from mPEG-<i>b</i>-PJL and mPEG-<i>b</i>-PJL-COOH was assessed, and it demonstrated a sustainable drug release pattern, which depended on both pH and temperature. Furthermore, the cytotoxicity of sunitinib-loaded micelles on cancer cells was evaluated. The drug-loaded micelles exhibited dose-dependent toxicity. Also, haemolysis capacity of these polymers was investigated. In summary, polymer functionalization seems a promising approach to overcome challenges that hinder the application of polymer-based drug delivery systems such as low drug loading degree.</AbstractText><CopyrightInformation>This journal is © The Royal Society of Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Aliaa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, BioCity (3rd floor) Tykistökatu 6A 20520 Turku Finland jessica.rosenholm@abo.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhadane</LastName><ForeName>Rajendra</ForeName><Initials>R</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-7330-4801</Identifier><AffiliationInfo><Affiliation>Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, BioCity (3rd floor) Tykistökatu 6A 20520 Turku Finland jessica.rosenholm@abo.fi.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Structural Bioinformatics Laboratory, Faculty of Science and Engineering, Biochemistry, Åbo Akademi University 20520 Turku Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asl</LastName><ForeName>Afshin Ansari</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, BioCity (3rd floor) Tykistökatu 6A 20520 Turku Finland jessica.rosenholm@abo.fi.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Molecular Science and Engineering, Åbo Akademi University, Aurum Henrikinkatu 2 20500 Turku Finland kuldeep.bansal@abo.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilén</LastName><ForeName>Carl-Eric</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Science and Engineering, Åbo Akademi University, Aurum Henrikinkatu 2 20500 Turku Finland kuldeep.bansal@abo.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salo-Ahen</LastName><ForeName>Outi</ForeName><Initials>O</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-0725-126X</Identifier><AffiliationInfo><Affiliation>Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, BioCity (3rd floor) Tykistökatu 6A 20520 Turku Finland jessica.rosenholm@abo.fi.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Structural Bioinformatics Laboratory, Faculty of Science and Engineering, Biochemistry, Åbo Akademi University 20520 Turku Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenholm</LastName><ForeName>Jessica M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-6085-1112</Identifier><AffiliationInfo><Affiliation>Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, BioCity (3rd floor) Tykistökatu 6A 20520 Turku Finland jessica.rosenholm@abo.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bansal</LastName><ForeName>Kuldeep K</ForeName><Initials>KK</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-8782-6689</Identifier><AffiliationInfo><Affiliation>Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, BioCity (3rd floor) Tykistökatu 6A 20520 Turku Finland jessica.rosenholm@abo.fi.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Molecular Science and Engineering, Åbo Akademi University, Aurum Henrikinkatu 2 20500 Turku Finland kuldeep.bansal@abo.fi.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RSC Adv</MedlineTA><NlmUniqueID>101581657</NlmUniqueID><ISSNLinking>2046-2069</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320859</ArticleId><ArticleId IdType="doi">10.1039/d2ra03962a</ArticleId><ArticleId IdType="pii">d2ra03962a</ArticleId><ArticleId IdType="pmc">PMC9490767</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320846</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2046-2069</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>41</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>RSC advances</Title><ISOAbbreviation>RSC Adv</ISOAbbreviation></Journal><ArticleTitle>Scalable synthesis and structural characterization of reversible KLK6 inhibitors.</ArticleTitle><Pagination><MedlinePgn>26989-26993</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d2ra04670a</ELocationID><Abstract><AbstractText>Scalable asymmetric syntheses of two kallikrein-related protease 6 (KLK6) inhibitors are reported. The inhibitors are assembled by linking enantiomerically enriched fragments <i>via</i> amide bond formation, followed by conversion of a cyano group to an amidine. One fragment, an amine, was prepared using the Ellman auxiliary, and a lack of clarity in the literature regarding the stereochemical outcome of this reaction was solved <i>via</i> X-ray crystallographic analysis of two derivatives. Complexes of the inhibitors bound to human KLK6 were solved by X-ray crystallography, revealing the binding poses.</AbstractText><CopyrightInformation>This journal is © The Royal Society of Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baumann</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cancer Drug Development Group, German Cancer Research Center (DKFZ) Im Neuenheimer Feld 280 69120 Heidelberg Germany aubry.miller@dkfz.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isak</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cancer Drug Development Group, German Cancer Research Center (DKFZ) Im Neuenheimer Feld 280 69120 Heidelberg Germany aubry.miller@dkfz.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lohbeck</LastName><ForeName>Jasmin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cancer Drug Development Group, German Cancer Research Center (DKFZ) Im Neuenheimer Feld 280 69120 Heidelberg Germany aubry.miller@dkfz.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagtap</LastName><ForeName>Pravin Kumar Ankush</ForeName><Initials>PKA</Initials><AffiliationInfo><Affiliation>Structural and Computational Biology Unit, European Molecular Biology Laboratory (EMBL) 69117 Heidelberg Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hennig</LastName><ForeName>Janosch</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Structural and Computational Biology Unit, European Molecular Biology Laboratory (EMBL) 69117 Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chair of Biochemistry IV, Biophysical Chemistry, University of Bayreuth 95447 Bayreuth Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Aubry K</ForeName><Initials>AK</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-1761-4143</Identifier><AffiliationInfo><Affiliation>Cancer Drug Development Group, German Cancer Research Center (DKFZ) Im Neuenheimer Feld 280 69120 Heidelberg Germany aubry.miller@dkfz.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Cancer Consortium (DKTK) Im Neuenheimer Feld 280 69120 Heidelberg Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RSC Adv</MedlineTA><NlmUniqueID>101581657</NlmUniqueID><ISSNLinking>2046-2069</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>RSC Adv. 2022 Oct 10;12(44):28677</RefSource><PMID Version="1">36321863</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>There are no conflicts to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>07</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320846</ArticleId><ArticleId IdType="doi">10.1039/d2ra04670a</ArticleId><ArticleId IdType="pii">d2ra04670a</ArticleId><ArticleId IdType="pmc">PMC9490775</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320813</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2052-6113</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Veterinary record open</Title><ISOAbbreviation>Vet Rec Open</ISOAbbreviation></Journal><ArticleTitle>Validation of the Burden Transfer Inventory-abbreviated and examination across veterinary medicine positions and settings in the United States.</ArticleTitle><Pagination><MedlinePgn>e46</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/vro2.46</ELocationID><Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">Burden transfer, when veterinary client caregiver burden underlies stressful encounters with providers, elevates risk for occupational distress in veterinary medicine. To date, burden transfer has been primarily examined in veterinarians working in general practice, using methods that are time consuming. The current work validates an abbreviated Burden Transfer Inventory (BTI-A) and explores burden transfer across positions of employment and veterinary settings.</AbstractText><AbstractText Label="Methods" NlmCategory="UNASSIGNED">Participants completed online measures of burden transfer, stress and burnout. A BTI-A with items representing each BTI domain was created with an initial validation sample (<i>n</i> = 1151 veterinarians). Confirmatory psychometric analyses were conducted in a cross-validation sample (<i>n</i> = 440 veterinarians and support staff), followed by exploration of the BTI and BTI-A across veterinary settings and position of employment.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">The BTI-A correlated with the full-length BTI (<i>r</i> = 0.89-0.96) shows good internal consistency (<i>α</i> = 0.72-0.88) and 1-month test-retest reliability (<i>r</i> = 0.69-0.74). The BTI-A correlated significantly (<i>p</i> &lt; 0.001) with stress and burnout. Exploratory comparisons suggested group differences including greater reactivity in general compared to specialty referral/emergency practice (<i>p</i> = 0.02).</AbstractText><AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">The BTI-A can be used in place of the original measure when brevity is important. Use of the BTI-A may help guide allied mental health professionals in providing support for wellbeing in veterinary healthcare team members.</AbstractText><CopyrightInformation>© 2022 The Authors. Veterinary Record Open published by John Wiley &amp; Sons Ltd on behalf of British Veterinary Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spitznagel</LastName><ForeName>Mary B</ForeName><Initials>MB</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-4314-1252</Identifier><AffiliationInfo><Affiliation>Department of Psychological Sciences Kent State University Kent Ohio USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>John T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Psychological Sciences Kent State University Kent Ohio USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>Mark D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Stow Kent Animal Hospital Kent Ohio USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fulkerson</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-4201-821X</Identifier><AffiliationInfo><Affiliation>Department of Veterinary Clinical Sciences College of Veterinary Medicine and Center for Cancer Research Purdue University West Lafayette Indiana USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Vet Rec Open</MedlineTA><NlmUniqueID>101653671</NlmUniqueID><ISSNLinking>2052-6113</ISSNLinking></MedlineJournalInfo><CoiStatement>Mary Spitznagel routinely presents scientific work related to burden transfer and has received honoraria for doing so. The other authors have not declared any conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>07</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>08</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320813</ArticleId><ArticleId IdType="doi">10.1002/vro2.46</ArticleId><ArticleId IdType="pii">VRO246</ArticleId><ArticleId IdType="pmc">PMC9614379</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320810</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1611-2156</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>EXCLI journal</Title><ISOAbbreviation>EXCLI J</ISOAbbreviation></Journal><ArticleTitle>Association between expression of ZBP1, AIM2, and MDA5 genes and severity of COVID-19.</ArticleTitle><Pagination><MedlinePgn>1171-1183</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.17179/excli2022-5141</ELocationID><Abstract><AbstractText>Antiviral and inflammatory responses following the detection of the virus genome by nucleic acid sensors play a vital role in the pathogenesis and outcome of diseases. In this study, we investigated the ZBP1, AIM2, and MDA5 expression levels in COVID-19 patients with different intensities of the disease. 75 quantitative Real-Time PCR (qRT-PCR)-confirmed COVID-19 patients were included consecutively and divided into 3 groups of mild, severe, and critical based on the severity of the disease. Also, 25 healthy volunteer subjects were included. PBMCs were collected from the whole blood, and RNA was extracted using commercial kit. The expression of ZBP1, AIM2, and MDA5 genes was investigated using qRT-PCR technique. The mean age of the patients and healthy volunteers was 52.73±13.78 and 49.120±12.490, respectively. In each group, 13 out of 25 participants were male. The expression levels of ZBP1 (P=0.001), AIM2 (P=0.001), and MDA5 (P= 0.003) transcript were significantly higher in COVID-19 patients than the control group. The results also revealed that the expression levels of ZBP1, AIM2, and MDA5 were significantly higher in the critical and severe COVID-19 patients compared to those with mild disease (P&lt;0.05). Moreover, regarding the gender, the expression levels of AIM2 and MDA5 were significantly elevated in male severe (P=0.04 and P=0.003, respectively) and critical (P=0.005 and P=0.0004, respectively) patients than the female ones. The results indicated that ZBP1, AIM2, and MDA5 genes might have an important role in the severity of COVID-19 disease. Moreover, the severity of COVID-19 disease in male and female patients might be related to AIM2, and MDA5 expression levels. More studies are recommended to be conducted to clarify this issue.</AbstractText><CopyrightInformation>Copyright © 2022 Arefinia et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arefinia</LastName><ForeName>Nasir</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramezani</LastName><ForeName>Amin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farokhnia</LastName><ForeName>Mehrdad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, School of Medicine, Research Center for Hydatid Disease in Iran, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arab Zadeh</LastName><ForeName>Ali Mohammad</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, School of Medicine, Research Center for Hydatid Disease in Iran, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaghobi</LastName><ForeName>Ramin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Transplant Research Center, Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarvari</LastName><ForeName>Jamal</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>EXCLI J</MedlineTA><NlmUniqueID>101299402</NlmUniqueID><ISSNLinking>1611-2156</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AIM2</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">MDA5</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">ZBP1</Keyword><Keyword MajorTopicYN="N">severity of COVID-19</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320810</ArticleId><ArticleId IdType="doi">10.17179/excli2022-5141</ArticleId><ArticleId IdType="pii">2022-5141</ArticleId><ArticleId IdType="pmc">PMC9618740</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36320803</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2198-1833</ISSN><JournalIssue CitedMedium="Print"><PubDate><Year>2022</Year><Month>Oct</Month><Day>28</Day></PubDate></JournalIssue><Title>Zeitschrift fur Gesundheitswissenschaften = Journal of public health</Title><ISOAbbreviation>Z Gesundh Wiss</ISOAbbreviation></Journal><ArticleTitle>Essential barriers and considerations for the implementation of electronic patient-reported outcome (ePRO) measures in oncological practice: contextualizing the results of a feasibility study with existing literature.</ArticleTitle><Pagination><MedlinePgn>1-18</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10389-022-01767-3</ELocationID><Abstract><AbstractText Label="Aim" NlmCategory="UNASSIGNED">Monitoring electronic patient-reported outcomes (ePRO) can provide various benefits to cancer patients, such as enhanced quality of life, reduction of hospital admissions, and even prolonged survival. Furthermore, ePRO might offer significant benefits to patients under antineoplastic treatment in the context of the current COVID-19 pandemic. However, evidence on feasibility of ePRO in routine cancer care and barriers met in a real-life setting remains limited.</AbstractText><AbstractText Label="Subject and methods" NlmCategory="UNASSIGNED">We conducted a feasibility study among patients diagnosed with multiple myeloma currently under antineoplastic treatment. Patients filled out weekly ePRO questionnaires and were followed up for 6 months. In case of adverse events, an alert was sent to the clinic. We assessed uptake and adherence, as well as subjective perceptions of patients and clinic staff. A semi-structured literature review was conducted to contextualize results.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">Eleven patients were recruited and followed up for 6 months. Overall adherence was found at a high level and remained stable throughout the study period. Feedback from patients was positive; however, clinic staff expressed disappointment and frustration, criticising an increase of workload while not perceiving any benefit to the oncological treatment. Both findings were backed by evidence we found in literature.</AbstractText><AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">Implementation of ePRO monitoring to routine cancer treatment seems to be feasible regarding patients' acceptance and compliance. However, integration of the tool into clinical workflow without increasing workload and deterring clinicians proves to be a major challenge.</AbstractText><AbstractText Label="Supplementary Information" NlmCategory="UNASSIGNED">The online version contains supplementary material available at 10.1007/s10389-022-01767-3.</AbstractText><CopyrightInformation>© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kiderlen</LastName><ForeName>Til Ramón</ForeName><Initials>TR</Initials><Identifier Source="ORCID">0000-0003-3158-9527</Identifier><AffiliationInfo><Affiliation>Department of Hematology, Oncology and Palliative Care, Vivantes Hospital Neukoelln, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Brandenburg an der Havel, Germany.</Affiliation><Identifier Source="GRID">grid.473452.3</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schnack</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology and Palliative Care, Vivantes Hospital Neukoelln, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Wit</LastName><ForeName>Maike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology and Palliative Care, Vivantes Hospital Neukoelln, Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Z Gesundh Wiss</MedlineTA><NlmUniqueID>9425271</NlmUniqueID><ISSNLinking>0943-1853</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Barriers</Keyword><Keyword MajorTopicYN="N">Oncology</Keyword><Keyword MajorTopicYN="N">Patient-reported outcome</Keyword><Keyword MajorTopicYN="N">ePRO</Keyword></KeywordList><CoiStatement>Competing interestsThe authors declare that they have no disclosures or competing interests (financial or non-financial) related to this study.Conflict of interestThe ePROM evaluated was provided by Noona® in the context of a test trial in the clinic. There was contract or agreement in regard to the study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320803</ArticleId><ArticleId IdType="doi">10.1007/s10389-022-01767-3</ArticleId><ArticleId IdType="pii">1767</ArticleId><ArticleId IdType="pmc">PMC9613453</ArticleId></ArticleIdList><?pmcsd ?></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320771</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2046-2069</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>45</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>RSC advances</Title><ISOAbbreviation>RSC Adv</ISOAbbreviation></Journal><ArticleTitle>Enhancing the compatibility of BioCaRGOS silica sol-gel technology with ctDNA extraction and droplet digital PCR (ddPCR) analysis.</ArticleTitle><Pagination><MedlinePgn>29399-29404</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d2ra05862f</ELocationID><Abstract><AbstractText>Previously, our group had demonstrated long term stabilization of protein biomarkers using BioCaRGOS, a silica sol-gel technology. Herein, we describe workflow modifications to allow for extraction of cell free DNA (cfDNA) from primary samples containing working concentrations of BioCaRGOS, as well as the compatibility of BioCaRGOS with droplet digital PCR (ddPCR) analysis for pancreatic cancer biomarkers <i>i.e.</i>, KRAS circulating tumor DNA (ctDNA). Preliminary attempts to extract ctDNA from BioCaRGOS containing samples demonstrated interference in the extraction of primary samples and the interference with ddPCR analysis when BioCaRGOS was directly introduced to stabilize sample extracts. In our modified technique, we have minimized the interference caused by methanol with ddPCR by complete removal of methanol from the activated BioCaRGOS formulation prior to addition to the biospecimen or ctDNA extract. Interference of the silica matrix present in BioCaRGOS with ctDNA extraction was eliminated through the introduction of invert filtration of the sample prior to extraction. These modifications to the workflow of BioCaRGOS containing samples allow for use of BioCaRGOS for stabilization of trace quantities of nucleic acid biomarkers such as plasma ctDNA, while retaining the capability to extract the biomarker and quantify based on ddPCR.</AbstractText><CopyrightInformation>This journal is © The Royal Society of Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Potnis</LastName><ForeName>Chinmay S</ForeName><Initials>CS</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-6953-9106</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, University of Louisville Louisville 40292 Kentucky USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chauhan</LastName><ForeName>Rajat</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering, University of Louisville Louisville 40292 Kentucky USA gautam.gupta@louisville.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalbfleisch</LastName><ForeName>Theodore S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering, University of Louisville Louisville 40292 Kentucky USA gautam.gupta@louisville.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Louisville Louisville 40292 Kentucky USA mark.linder@louisville.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eichhold</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering, University of Louisville Louisville 40292 Kentucky USA gautam.gupta@louisville.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bansal</LastName><ForeName>Meenakshi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Thomas More University Crestview Hills KY 41017 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grapperhaus</LastName><ForeName>Craig A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Louisville Louisville 40292 Kentucky USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keynton</LastName><ForeName>Robert S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>William States Lee College of Engineering, University of North Carolina at Charlotte 28223 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linder</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Louisville Louisville 40292 Kentucky USA mark.linder@louisville.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Gautam</ForeName><Initials>G</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-7607-4055</Identifier><AffiliationInfo><Affiliation>Department of Chemical Engineering, University of Louisville Louisville 40292 Kentucky USA gautam.gupta@louisville.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RSC Adv</MedlineTA><NlmUniqueID>101581657</NlmUniqueID><ISSNLinking>2046-2069</ISSNLinking></MedlineJournalInfo><CoiStatement>There are no conflicts to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>09</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320771</ArticleId><ArticleId IdType="doi">10.1039/d2ra05862f</ArticleId><ArticleId IdType="pii">d2ra05862f</ArticleId><ArticleId IdType="pmc">PMC9557972</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320760</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2046-2069</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>45</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>RSC advances</Title><ISOAbbreviation>RSC Adv</ISOAbbreviation></Journal><ArticleTitle>Prediction of the electronic structure of single-walled GeS nanotubes.</ArticleTitle><Pagination><MedlinePgn>29291-29299</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d2ra04969d</ELocationID><Abstract><AbstractText>The structure and electronic properties of puckered GeS nanotubes have been investigated using first-principles density functional theory calculation. Our results show that both the armchair and zigzag GeS nanotubes are semiconductor materials with an adjustable band gap. The band gap increases gradually with increasing the tube diameter, and slowly converges to the monolayer limit. On the application of strain, the GeS nanotubes provide interesting strain-induced band gap variation. When the compressive strain reached 20%, zigzag GeS nanotubes are completely transformed into armchair GeS nanotubes. In addition, the elastic properties of the relatively stable armchair GeS nanotubes have been studied, the Young's modulus of the armchair (11, 11), (13, 13) and (15, 15) nanotubes were calculated to be 227.488 GPa, 211.888 GPa and 213.920 GPa, respectively. Our work confirms that compared with carbon nanotubes, two-dimensional materials with a puckered structure are easier to realize phase transition by stress.</AbstractText><CopyrightInformation>This journal is © The Royal Society of Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Deyang</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Materials Science and Chemical Engineering, Harbin University of Science and Technology Harbin 150080 China guiling-002@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Physics, Harbin Institute of Technology Harbin 150001 China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Physics, Harbin Medical University Cancer Hospital Harbin 150081 China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ku</LastName><ForeName>Ruiqi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Physics, Harbin Institute of Technology Harbin 150001 China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Technology Innovation Center of Materials and Devices at Extreme Environment Harbin 150001 China tccliweiqi@hit.edu.cn yangjianqun@hit.edu.cn lxj0218@hit.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yangyang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-7992-836X</Identifier><AffiliationInfo><Affiliation>School of Materials Science and Chemical Engineering, Harbin University of Science and Technology Harbin 150080 China guiling-002@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Green Chemical Technology of College of Heilongjiang Province, Harbin University of Science and Technology Harbin 150080 China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Yadong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-0997-4392</Identifier><AffiliationInfo><Affiliation>School of Physics, Harbin Institute of Technology Harbin 150001 China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Technology Innovation Center of Materials and Devices at Extreme Environment Harbin 150001 China tccliweiqi@hit.edu.cn yangjianqun@hit.edu.cn lxj0218@hit.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Cuancuan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Physics, Harbin Institute of Technology Harbin 150001 China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhongli</ForeName><Initials>Z</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-3234-310X</Identifier><AffiliationInfo><Affiliation>Technology Innovation Center of Materials and Devices at Extreme Environment Harbin 150001 China tccliweiqi@hit.edu.cn yangjianqun@hit.edu.cn lxj0218@hit.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Guiling</ForeName><Initials>G</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-3413-5926</Identifier><AffiliationInfo><Affiliation>School of Materials Science and Chemical Engineering, Harbin University of Science and Technology Harbin 150080 China guiling-002@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Green Chemical Technology of College of Heilongjiang Province, Harbin University of Science and Technology Harbin 150080 China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Weiqi</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Physics, Harbin Institute of Technology Harbin 150001 China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Lab of Micro-Optics and Photonic Technology of Heilongjiang Province Harbin 150001 China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Technology Innovation Center of Materials and Devices at Extreme Environment Harbin 150001 China tccliweiqi@hit.edu.cn yangjianqun@hit.edu.cn lxj0218@hit.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jianqun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Technology Innovation Center of Materials and Devices at Extreme Environment Harbin 150001 China tccliweiqi@hit.edu.cn yangjianqun@hit.edu.cn lxj0218@hit.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xingji</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Technology Innovation Center of Materials and Devices at Extreme Environment Harbin 150001 China tccliweiqi@hit.edu.cn yangjianqun@hit.edu.cn lxj0218@hit.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RSC Adv</MedlineTA><NlmUniqueID>101581657</NlmUniqueID><ISSNLinking>2046-2069</ISSNLinking></MedlineJournalInfo><CoiStatement>There are no conflicts to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>08</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320760</ArticleId><ArticleId IdType="doi">10.1039/d2ra04969d</ArticleId><ArticleId IdType="pii">d2ra04969d</ArticleId><ArticleId IdType="pmc">PMC9558261</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320727</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2046-2069</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>45</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>RSC advances</Title><ISOAbbreviation>RSC Adv</ISOAbbreviation></Journal><ArticleTitle>Naphthylisoindolinone alkaloids: the first ring-contracted naphthylisoquinolines, from the tropical liana <i>Ancistrocladus abbreviatus</i>, with cytotoxic activity.</ArticleTitle><Pagination><MedlinePgn>28916-28928</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d2ra05758a</ELocationID><Abstract><AbstractText>The West African liana <i>Ancistrocladus abbreviatus</i> is a rich source of structurally most diverse naphthylisoquinoline alkaloids. From its roots, a series of four novel representatives, named ancistrobrevolines A-D (14-17) have now been isolated, displaying an unprecedented heterocyclic ring system, where the usual isoquinoline entity is replaced by a ring-contracted isoindolinone part. Their constitutions were elucidated by 1D and 2D NMR and HR-ESI-MS. The absolute configurations at the chiral axis and at the stereogenic center were assigned by using experimental and computational electronic circular dichroism (ECD) investigations and a ruthenium-mediated oxidative degradation, respectively. For the biosynthetic origin of the isoindolinones from 'normal' naphthyltetrahydroisoquinolines, a hypothetic pathway is presented. It involves oxidative decarboxylation steps leading to a ring contraction by a benzilic acid rearrangement. Ancistrobrevolines A (14) and B (15) were found to display moderate cytotoxic effects (up to 72%) against MCF-7 breast and A549 lung cancer cells and to reduce the formation of spheroids (mammospheres) in the breast cancer cell line.</AbstractText><CopyrightInformation>This journal is © The Royal Society of Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fayez</LastName><ForeName>Shaimaa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Organic Chemistry, University of Würzburg Am Hubland D-97074 Würzburg Germany bringman@chemie.uni-wuerzburg.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Organization of African Unity Street 1 11566 Cairo Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruhn</LastName><ForeName>Torsten</ForeName><Initials>T</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-9604-1004</Identifier><AffiliationInfo><Affiliation>Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Organization of African Unity Street 1 11566 Cairo Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feineis</LastName><ForeName>Doris</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Organic Chemistry, University of Würzburg Am Hubland D-97074 Würzburg Germany bringman@chemie.uni-wuerzburg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assi</LastName><ForeName>Laurent Aké</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Federal Institute for Risk Assessment Max-Dohrn-Str. 8-10 D-10589 Berlin Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kushwaha</LastName><ForeName>Prem Prakash</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Centre National de Floristique, Université d'Abidjan Conservatoire et Jardin Botanique Abidjan 08 Ivory Coast.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Signaling &amp; Drug Discovery Laboratory, Department of Biochemistry, Central University of Punjab Bathinda-151401 Punjab India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Shashank</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre National de Floristique, Université d'Abidjan Conservatoire et Jardin Botanique Abidjan 08 Ivory Coast.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bringmann</LastName><ForeName>Gerhard</ForeName><Initials>G</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-3583-5935</Identifier><AffiliationInfo><Affiliation>Institute of Organic Chemistry, University of Würzburg Am Hubland D-97074 Würzburg Germany bringman@chemie.uni-wuerzburg.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RSC Adv</MedlineTA><NlmUniqueID>101581657</NlmUniqueID><ISSNLinking>2046-2069</ISSNLinking></MedlineJournalInfo><CoiStatement>There are no conflicts to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>09</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320727</ArticleId><ArticleId IdType="doi">10.1039/d2ra05758a</ArticleId><ArticleId IdType="pii">d2ra05758a</ArticleId><ArticleId IdType="pmc">PMC9555057</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320712</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2041-6520</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>36</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Chemical science</Title><ISOAbbreviation>Chem Sci</ISOAbbreviation></Journal><ArticleTitle>Rational development of molecularly imprinted nanoparticles for blocking PD-1/PD-L1 axis.</ArticleTitle><Pagination><MedlinePgn>10897-10903</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d2sc03412c</ELocationID><Abstract><AbstractText>Blocking the PD-1/PD-L1 immune checkpoint has emerged as a promising strategy in cancer immunotherapy, in which monoclonal antibodies are predominately used as inhibitors. Despite their remarkable success, monoclonal antibody-based therapeutics suffer from drawbacks due to the use of antibodies, such as high cost, low stability and high frequency of immune-related adverse effects. Therefore, novel anti-PD-1/PD-L1 therapeutics that can address these issues are of significant importance. Herein, we report a molecularly imprinted polymer (MIP) based PD-1 nano inhibitor for blocking the PD-1/PD-L1 axis. The anti-PD-1 nanoMIP was rationally designed and engineered by epitope imprinting using the N-terminal epitope of PD-1 as the binding site. The anti-PD-1 nanoMIP showed good specificity and high affinity towards PD-1, yielding a disassociation constant at the 10<sup>-8</sup> M level, much better than that between PD-1 and PD-L1. <i>Via</i> steric hindrance, this inhibitor could effectively block PD-1/PD-L1 interaction. Besides, it could effectively reactivate T cells and reverse the chemoresistance of tumor cells. Therefore, this present study not only provides a novel and promising immune checkpoint blockade inhibitor but also boosts further development of MIPs for cancer immunotherapy.</AbstractText><CopyrightInformation>This journal is © The Royal Society of Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Zikuan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University 163 Xianlin Avenue Nanjing 210023 China zhenliu@nju.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Shuxin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University 163 Xianlin Avenue Nanjing 210023 China zhenliu@nju.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Zhanchen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University 163 Xianlin Avenue Nanjing 210023 China zhenliu@nju.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-8440-2554</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University 163 Xianlin Avenue Nanjing 210023 China zhenliu@nju.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Chem Sci</MedlineTA><NlmUniqueID>101545951</NlmUniqueID><ISSNLinking>2041-6520</ISSNLinking></MedlineJournalInfo><CoiStatement>There are no conflicts to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320712</ArticleId><ArticleId IdType="doi">10.1039/d2sc03412c</ArticleId><ArticleId IdType="pii">d2sc03412c</ArticleId><ArticleId IdType="pmc">PMC9491213</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320699</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2041-6520</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>36</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Chemical science</Title><ISOAbbreviation>Chem Sci</ISOAbbreviation></Journal><ArticleTitle>BQ-AurIPr: a redox-active anticancer Au(i) complex that induces immunogenic cell death.</ArticleTitle><Pagination><MedlinePgn>10779-10785</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d2sc03756d</ELocationID><Abstract><AbstractText>Immunogenic Cell Death (ICD) is a unique cell death mechanism that kills cancer cells while rejuvenating the anticancer immunosurveillance, thereby benefiting the clinical outcomes of various immuno-chemotherapeutic regimens. Herein, we report development of a library of benzo[<i>a</i>]quinolizinium-based Au(i) complexes through an intramolecular amino-auration reaction of pyridino-alkynes. We tested 40 candidates and successfully identified BQ-AurIPr as a novel redox-active Au(i) complex with potent anticancer properties. BQ-AurIPr efficiently triggered generation of DAMPs - the hallmarks of ICD - and was superior in terms of efficiency compared to FDA-approved drugs known to induce ICD. BQ-AurIPr significantly increased immunogenicity of cancer cells enhancing their phagocytosis when co-cultured with immune cells. Our investigation reveals that BQ-AurIPr induces oxidative stress inside mitochondria leading to mitophagy, as the mechanism for immunogenic cell death in A549 cells.</AbstractText><CopyrightInformation>This journal is © The Royal Society of Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mule</LastName><ForeName>Ravindra D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Division of Organic Chemistry, CSIR-National Chemical Laboratory Dr Homi Bhabha Road Pune - 411008 India b.senthilkumar@ncl.res.in.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academy of Scientific and Innovative Research Ghaziabad - 201 002 India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Akhilesh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Immunology and Infectious Diseases, Department of Biological Sciences, IISER Bhopal Bhopal - 462 066 India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sancheti</LastName><ForeName>Shashank P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Indian Institute of Science Education and Research Bhopal Bhopal Bypass Road, Bhauri Bhopal - 462 066 India npatil@iiserb.ac.in.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Senthilkumar</LastName><ForeName>B</ForeName><Initials>B</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-1522-4221</Identifier><AffiliationInfo><Affiliation>Division of Organic Chemistry, CSIR-National Chemical Laboratory Dr Homi Bhabha Road Pune - 411008 India b.senthilkumar@ncl.res.in.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Himanshu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory of Immunology and Infectious Diseases, Department of Biological Sciences, IISER Bhopal Bhopal - 462 066 India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunology Frontier Research Center (IFReC), Osaka University Osaka - 565-0871 Japan hkumar@iiserb.ac.in.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patil</LastName><ForeName>Nitin T</ForeName><Initials>NT</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-8372-2759</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Indian Institute of Science Education and Research Bhopal Bhopal Bypass Road, Bhauri Bhopal - 462 066 India npatil@iiserb.ac.in.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Chem Sci</MedlineTA><NlmUniqueID>101545951</NlmUniqueID><ISSNLinking>2041-6520</ISSNLinking></MedlineJournalInfo><CoiStatement>There are no conflicts to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>07</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320699</ArticleId><ArticleId IdType="doi">10.1039/d2sc03756d</ArticleId><ArticleId IdType="pii">d2sc03756d</ArticleId><ArticleId IdType="pmc">PMC9491088</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320672</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1989-5488</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of clinical and experimental dentistry</Title><ISOAbbreviation>J Clin Exp Dent</ISOAbbreviation></Journal><ArticleTitle>Liquid biopsy in the assessment of microRNAs in oral squamous cell carcinoma: A systematic review.</ArticleTitle><Pagination><MedlinePgn>e875-e884</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4317/jced.59736</ELocationID><Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">The identification of non-invasive biomarkers from biological fluids collected by liquid biopsy provides new horizons for individualized therapeutic strategies and improves clinical decision-making in OSCC patients. Circulating microRNAs have emerged as biomarkers that may reflect not only the existence of cancer, but also the dynamic, malignant potential, and drug resistance of tumors. The aim of the systematic review is to evaluate and summarize the results of the published studies regarding the use of microRNAs as biomarkers for OSCC.</AbstractText><AbstractText Label="Material and Methods" NlmCategory="UNASSIGNED">A literature search was conducted on PubMed, Scopus, Web of Science, and Cochrane databases till November 2020. A total of 34 studies met the inclusion criteria and were therefore subjected to quality assessment. Each study was subjected to data extraction including; patient characteristics, type of fluid sample (whole blood, plasma, serum, or saliva), molecular analysis method, specific dysregulated microRNA, and microRNA expression pattern.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">The analysis showed that 57 microRNAs of liquid biopsy samples of four different fluids (whole blood, serum, plasma, and saliva) were analyzed. The prognostic and therapeutic significance of these microRNAs were suggested by several studies; where 41 microRNAs were upregulated while 16 were downregulated.</AbstractText><AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">Scientific evidence supports the interest in the use of microRNAs in the diagnosis and prognosis in OSCC patients; however, further studies in a larger cohort of patients are mandatory to introduce liquid biopsy in the routine clinical practice for the OSCC management. <b>Key words:</b>Biomarkers, liquid biopsy, microRNA, oral squamous cell carcinoma, systematic review.</AbstractText><CopyrightInformation>Copyright: © 2022 Medicina Oral S.L.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Palaia</LastName><ForeName>Gaspare</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Oral Sciences and Maxillofacial Surgery, Sapienza University of Rome.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pippi</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Oral Sciences and Maxillofacial Surgery, Sapienza University of Rome.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocchetti</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Oral Sciences and Maxillofacial Surgery, Sapienza University of Rome.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caputo</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Oral Sciences and Maxillofacial Surgery, Sapienza University of Rome.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macali</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Oral Sciences and Maxillofacial Surgery, Sapienza University of Rome.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohsen</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Oral Sciences and Maxillofacial Surgery, Sapienza University of Rome.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Vecchio</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Oral Sciences and Maxillofacial Surgery, Sapienza University of Rome.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tenore</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Oral Sciences and Maxillofacial Surgery, Sapienza University of Rome.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romeo</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Oral Sciences and Maxillofacial Surgery, Sapienza University of Rome.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>J Clin Exp Dent</MedlineTA><NlmUniqueID>101603132</NlmUniqueID><ISSNLinking>1989-5488</ISSNLinking></MedlineJournalInfo><CoiStatement>Conflicts of interest All the authors have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320672</ArticleId><ArticleId IdType="doi">10.4317/jced.59736</ArticleId><ArticleId IdType="pii">59736</ArticleId><ArticleId IdType="pmc">PMC9617270</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320671</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1989-5488</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of clinical and experimental dentistry</Title><ISOAbbreviation>J Clin Exp Dent</ISOAbbreviation></Journal><ArticleTitle>Lung cancer metastasis to oral soft tissues; Systematic review of 122 cases.</ArticleTitle><Pagination><MedlinePgn>e854-e874</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4317/jced.59773</ELocationID><Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">Lung cancer metastasis to oral region is very rare. Studies have been published analysing the cases of metastatic tumours to the oral cavity by many researchers. But very few research work has been conducted till date to analyse only the oral soft tissue metastasis from Lung cancer as the primary source. The goal of this study was to examine published cases of oral soft tissue metastasis from lung cancer as the only primary source from 1st August 1977 to 31st December 2021.</AbstractText><AbstractText Label="Material and Methods" NlmCategory="UNASSIGNED">An electronic search of the published English literature was performed in PubMed/ Medline, Scopus, Google Scholar, and Research gate databases, using keywords like 'Lung cancer', OR/ AND 'Lung carcinoma' OR/ AND 'Oral cavity', OR/AND 'Metastasis', OR/AND 'Primary', OR/AND 'Source', OR/AND 'Initial', OR/AND 'Tongue', OR/AND 'Palate', OR/ AND 'Tonsil', OR/AND 'Lip', OR/AND 'Buccal mucosa', OR/AND 'Floor of mouth', OR/AND 'Salivary glands', OR/ AND 'Parotid', OR/ AND 'Submandibular', OR/ AND 'Sublingual' OR/ AND 'Mandible', OR/AND 'Maxilla. We also searched all related journals manually. Reference list of all articles was also checked.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">Our research revealed total 122 patients. The most prevalent diagnosed metastatic lung cancer was adenocarcinoma. Gingiva, tongue and tonsils were the most common site of metastasis. 54% patients died of metastasis with a survival time of 1 week to 2.5 years.</AbstractText><AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">Oral soft tissue metastasis from lung cancer has a bad prognosis. More cases need to be published in order to raise awareness of these lesions and gain a better understanding of their characteristics. <b>Key words:</b>Lung cancer, metastasis, oral, primary, soft tissues.</AbstractText><CopyrightInformation>Copyright: © 2022 Medicina Oral S.L.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>MDS, Reader, Dept. of Oral Pathology and Microbiology &amp; Forensic odontology, Rayat and Bahra Dental college and hospital, Mohali, Punjab, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jawanda</LastName><ForeName>Manveen-Kaur</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>MDS, Professor &amp; Head, Dept. of Oral Pathology and Microbiology &amp; Forensic odontology. Laxmi bai institute of dental sciences and hospital, Patiala, Punjab, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kedia</LastName><ForeName>Neal-Bharat</ForeName><Initials>NB</Initials><AffiliationInfo><Affiliation>MDS, Professor &amp; PG Guide, Dept. of Orthodontics &amp; Dentofacial Orthopedics, Buddha Institute of Dental Sciences &amp; Hospital, Patna, Bihar, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deb</LastName><ForeName>Aayush-Ranjan</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>BDS, Intern, Sri Ramachandra Faculty of Dental Sciences, Porur, Chennai, Tamilnadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganganna</LastName><ForeName>Aruna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>MDS, Assistant Professor, Department of Periodontology, JSS Dental College and Hospital, Mysore, Karnataka, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saurabh</LastName><ForeName>Kumar</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>MDS, Medical Officer (Dental Surgeon), PHC, Bind, Bihar, IndiaMDS, Medical Officer (Dental Surgeon), PHC, Bind, Bihar, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yadav</LastName><ForeName>Sumit-Kumar</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>MDS, Professor, Department of Orthodontics &amp; Dentofacial Orthopedics, D J College of Dental Sciences &amp; Research, Modinagar, UP, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yadav</LastName><ForeName>Achla-Bharti</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>MDS, Professor, Department of Oral Pathology &amp; Microbiology, D J College of Dental Sciences and Research, Modinagar, UP, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>J Clin Exp Dent</MedlineTA><NlmUniqueID>101603132</NlmUniqueID><ISSNLinking>1989-5488</ISSNLinking></MedlineJournalInfo><CoiStatement>Conflicts of interest Nil.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320671</ArticleId><ArticleId IdType="doi">10.4317/jced.59773</ArticleId><ArticleId IdType="pii">59773</ArticleId><ArticleId IdType="pmc">PMC9617267</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320666</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2253-5969</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Journal of hepatocellular carcinoma</Title><ISOAbbreviation>J Hepatocell Carcinoma</ISOAbbreviation></Journal><ArticleTitle>Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy.</ArticleTitle><Pagination><MedlinePgn>1109-1125</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/JHC.S381764</ELocationID><Abstract><AbstractText>Hepatocellular carcinoma (HCC) remains a serious medical therapeutic challenge as conventional curative avenues such as surgery and chemotherapy only benefit for few patients with limited tumor burden. Immunotherapy achieves clinical progress in the treatment of this prevalent malignant disease by virtue of the development of tumor immunology; however, most patients have experienced minimal or no clinical benefit in terms of overall survival. The complexity and diversity of tumor microenvironment (TME) built by immune and stromal cell subsets has been considered to be responsible for the insufficiency of immunotherapy. The advance of bioanalytical technology boosts the exploration of the composition and differentiation of these infiltrated cells, which reflect the immune state of the TME and impact the efficacy of the antitumor immune response. Targeting these cells to remodel the TME is one of the important immunotherapeutic approaches to improve HCC treatment. In this review, we focused on the role of these non-cancerous cells in the tumor progression, and elaborated their function on cancer immunotherapy when manipulating them as potential targets.</AbstractText><CopyrightInformation>© 2022 Feng et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Feng</LastName><ForeName>Hai</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-9820-7111</Identifier><AffiliationInfo><Affiliation>Institute of Infectious Disease, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhuo</LastName><ForeName>Yunhui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Liver Disease, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xuemei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Liver Disease, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuyao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Infectious Disease, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0846-3299</Identifier><AffiliationInfo><Affiliation>Institute of Infectious Disease, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Xiangjuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Liver Disease, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Infectious Disease, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Chengbin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Informatics, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Yueqiu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Infectious Disease, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Liver Disease, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Zhuo</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-4100-8415</Identifier><AffiliationInfo><Affiliation>Department of Liver Disease, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>J Hepatocell Carcinoma</MedlineTA><NlmUniqueID>101674775</NlmUniqueID><ISSNLinking>2253-5969</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">hepatocellular carcinoma</Keyword><Keyword MajorTopicYN="N">immune cells</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">stromal cells</Keyword><Keyword MajorTopicYN="N">tumor microenvironment</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>07</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320666</ArticleId><ArticleId IdType="doi">10.2147/JHC.S381764</ArticleId><ArticleId IdType="pii">381764</ArticleId><ArticleId IdType="pmc">PMC9618253</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320658</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2398-8835</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Health science reports</Title><ISOAbbreviation>Health Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Depression, anxiety, and performance status among the women with metastatic breast cancer receiving palliative care in Bangladesh: A cross sectional study.</ArticleTitle><Pagination><MedlinePgn>e911</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hsr2.911</ELocationID><Abstract><AbstractText Label="Background and Aims" NlmCategory="UNASSIGNED">Advanced breast cancer patients suffer from various psychological issues including depression and anxiety. This study aims to explore these psychological issues and their relationship with the performance status.</AbstractText><AbstractText Label="Methods" NlmCategory="UNASSIGNED">This cross-sectional study was conducted among 95 patients with metastatic breast cancer attending the Department of Palliative Medicine, Bangabandhu Sheikh Mujib Medical University, Bangladesh from April 2021 to September 2021. Data was collected by face-to-face interview using a structured questionnaire along with Hospital Depression and Anxiety Scale. The performance status of the patients was determined by the Eastern Cooperative Oncology Group (ECOG) performance scale. The association between different variables were assessed by <i>χ</i> <sup>2</sup> test and Fisher Exact test.</AbstractText><AbstractText Label="Result" NlmCategory="UNASSIGNED">Mean age of the respondents was 48.9 ± 9.9 years. Most of them were married (94.7%), muslim (92.6%) and homemakers (82.1%). More than half (52.6%) of the patients were evaluated having ECOG performance status grade II. Four out of ten  (44.2%) patients had moderate to severely anxiety, and almost one-third (36.9%) patients were suffering from moderate to severe depression. The patients with high educational status were found to have less depression. In addition, patients faring better on ECOG performance scale (Grade 0 to I) had significantly (<i>p</i> &lt; 0.05) less depression and anxiety.</AbstractText><AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Depression and anxiety are one of the major psychological sufferings among the women with metastatic breast cancers. All women suffering from breast cancer should be routinely screened and assessed for phychological distress and ensure early intervention.</AbstractText><CopyrightInformation>© 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Islam</LastName><ForeName>Nashid</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-5059-2441</Identifier><AffiliationInfo><Affiliation>Department of Palliative Medicine Bangabandhu Sheikh Mujib Medical University (BSMMU) Dhaka Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biswas</LastName><ForeName>Jheelam</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4977-6136</Identifier><AffiliationInfo><Affiliation>Department of Palliative Medicine Bangabandhu Sheikh Mujib Medical University (BSMMU) Dhaka Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowshik</LastName><ForeName>Mostofa Monwar</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Medicine Dhaka Medical College Dhaka Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molla</LastName><ForeName>Md Maruf Ahmed</ForeName><Initials>MMA</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-5062-9144</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology SUNY Upstate Medical University New York United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saker</LastName><ForeName>Mridul</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-8581-5182</Identifier><AffiliationInfo><Affiliation>Department of Palliative Medicine Bangabandhu Sheikh Mujib Medical University (BSMMU) Dhaka Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Mostofa Kamal</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Palliative Medicine Bangabandhu Sheikh Mujib Medical University (BSMMU) Dhaka Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhuiyan</LastName><ForeName>Akm Motiur Rahman</ForeName><Initials>AMR</Initials><AffiliationInfo><Affiliation>Department of Palliative Medicine Bangabandhu Sheikh Mujib Medical University (BSMMU) Dhaka Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Nezamuddin</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-3553-0952</Identifier><AffiliationInfo><Affiliation>Department of Palliative Medicine Bangabandhu Sheikh Mujib Medical University (BSMMU) Dhaka Bangladesh.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Health Sci Rep</MedlineTA><NlmUniqueID>101728855</NlmUniqueID><ISSNLinking>2398-8835</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bangladesh</Keyword><Keyword MajorTopicYN="N">ECOG status</Keyword><Keyword MajorTopicYN="N">anxiety</Keyword><Keyword MajorTopicYN="N">breast cancer</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">palliative care</Keyword></KeywordList><CoiStatement>Dr. Md. Maruf Ahmed Molla is an Editorial Board member of Health Science Reports, and a coauthor of this article. To minimize bias, he was excluded from all editorial decision‐making related to the acceptance of this article for publication. The remaining authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>05</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>09</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320658</ArticleId><ArticleId IdType="doi">10.1002/hsr2.911</ArticleId><ArticleId IdType="pii">HSR2911</ArticleId><ArticleId IdType="pmc">PMC9617648</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320657</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2398-8835</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Health science reports</Title><ISOAbbreviation>Health Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Patients' experience and satisfaction using telemedicine for outpatient services in a Tertiary Cancer Center in Qatar during COVID-19: A cross-sectional study.</ArticleTitle><Pagination><MedlinePgn>e883</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hsr2.883</ELocationID><Abstract><AbstractText Label="Background and&#xA0;Aim" NlmCategory="UNASSIGNED">The coronavirus-19 is an ongoing global pandemic resulting in millions of deaths worldwide. For a patient population at higher risk of infection, telemedicine is a promising means of providing safe and alternative care routes while minimizing their risk of exposure. This study gives insight into patients' experiences and satisfaction with telemedicine during this pandemic.</AbstractText><AbstractText Label="Methods" NlmCategory="UNASSIGNED">We conducted a cross-sectional study on 297 patients (RR: 85%) at the National Center for Cancer Care and Research (NCCCR), Qatar. Data was collected through electronic medical records of the eligibe patient population, and phone calls were made whereby the physician read a standard introductory script followed by a survey questionnaire. We focused on patients' experience with telemedicine services amid the pandemic. This was done using a six-point Likert scoring system of seven questions that were scaled from 1 to 6.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">More than 80% of patients somewhat to strongly agreed that telemedicine met their healthcare needs, improved their confidence in their healthcare system, and were generally satisfied with the quality of care provided. Nearly all patients (90%) understood their physicians' recommendations over the phone. In addition, more than half of the patients (89%) felt they could freely communicate their concerns. Patients also showed an inclination towards face-to-face consultations at 68%; however, 90% were willing to participate in future teleconsultations.</AbstractText><AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Our study indicates an overall positive experience among patients towards the use of telemedicine. Telemedicine is a safe, futuristic approach toward patient care management and, thus, provides healthcare professionals a platform to implement further patient and physician education. Even though our data also showed that patients liked in-person visits to some degree, this needs to be looked into more in future studies.</AbstractText><CopyrightInformation>© 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elhakeem</LastName><ForeName>Israa</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Medical Education Hamad Medical Corporation Doha Qatar.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hematology/Oncology Department Hamad Medical Corporation Doha Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iqbal</LastName><ForeName>Phool</ForeName><Initials>P</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-3472-9281</Identifier><AffiliationInfo><Affiliation>Internal Medicine Department New York Medical College/Metropolitan Hospital Center New York USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nashwan</LastName><ForeName>Abdulqadir J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-4845-4119</Identifier><AffiliationInfo><Affiliation>Nursing Department Hamad Medical Corporation Doha Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abubakar</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Education Hamad Medical Corporation Doha Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jawad</LastName><ForeName>Arsalan T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Medical Education Hamad Medical Corporation Doha Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>AlHiyari</LastName><ForeName>Mousa A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Medical Education Hamad Medical Corporation Doha Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandra</LastName><ForeName>Prem</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Academic Health System Hamad Medical Corporation Doha Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osman</LastName><ForeName>Maab A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Medical Education Hamad Medical Corporation Doha Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohamad</LastName><ForeName>Sara S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Medical Education Hamad Medical Corporation Doha Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alkhatib</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Education Hamad Medical Corporation Doha Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yassin</LastName><ForeName>Mohamed A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-1144-8076</Identifier><AffiliationInfo><Affiliation>Medical Critical Care Department Hamad Medical Corporation Qatar.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Health Sci Rep</MedlineTA><NlmUniqueID>101728855</NlmUniqueID><ISSNLinking>2398-8835</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">teleconsultations</Keyword><Keyword MajorTopicYN="N">telehealth</Keyword><Keyword MajorTopicYN="N">telemedicine</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. Note: Abdulqadir J. Nashwan is an Editorial Board member of Health Science Reports and co‐authorco‐author of this article. He is excluded from editorial decision‐making related to the acceptance of this article for publication in the journal.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>09</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320657</ArticleId><ArticleId IdType="doi">10.1002/hsr2.883</ArticleId><ArticleId IdType="pii">HSR2883</ArticleId><ArticleId IdType="pmc">PMC9617592</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320655</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2398-8835</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Health science reports</Title><ISOAbbreviation>Health Sci Rep</ISOAbbreviation></Journal><ArticleTitle>A cross-sectional study of the impact of COVID-19 pandemic on the physical activity of Jordanian population.</ArticleTitle><Pagination><MedlinePgn>e896</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hsr2.896</ELocationID><Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">Since the declaration of the COVID-19 pandemic on 11th March 2020, the public health recommendations have applied lockdowns and restrictions to limit the spread of the disease. These measures determined outdoor activities and access to many forms of exercise.</AbstractText><AbstractText Label="Objective" NlmCategory="UNASSIGNED">The primary objective of this study was to examine the impact of the COVID-19 pandemic on the physical activity (PA) of the Jordanian population.</AbstractText><AbstractText Label="Methods" NlmCategory="UNASSIGNED">A cross-sectional online survey was designed using Google Forms services and distributed on social media platforms during the first two weeks of November 2020 to evaluate the exercise activity changes during the COVID-19 pandemic in the study population. In this research, we included those who perform any form of physical activity (n = 1103). The data collected were analyzed using the Statistical Package for the Social Sciences (SPSS) version 26 (IBM SPSS Corp, SPSS Statistics ver. 26, USA). The categorical variables were summarized as frequencies and proportions and were compared using the Chi-square. For all analyses, P-value less than 0.05 was considered statistically significant.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">A total of 1103 out of 2,511 (43.9%) respondents who participated in the survey were physically exercising during the COVID-19 pandemic. 41.8% were exercising at an irregular frequency, while 21.5% were exercising daily, 16.8% were exercising three to five times a week, and 19.9% were exercising once or twice a week. Moreover, 282 (25.6%) respondents started doing some form of exercise during the pandemic. Those significantly were less than 18-year-old, male gender, were single, were non-smokers, and had a diploma or bachelor's degree in a health-related major. These changes in the level of exercise have been attributed by 57.8% of respondents to the health aspects where they realized the importance of exercising in strengthening the immune system against diseases, including COVID-19.</AbstractText><AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">The current study showed that lockdown, due to the COVID-19 pandemic, had a positive impact on the healthy lifestyle of the Jordanian population which was attributed to their feeling of the importance of sports practice on the immune system and the availability of time for those activities. However, the younger and individuals were more aware of the importance of these practices which highlights the importance of considering other age groups in future studies of healthy behaviors.</AbstractText><CopyrightInformation>© 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Awadi</LastName><ForeName>Sajeda</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine Yarmouk University Irbid Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khamees</LastName><ForeName>Almu'atasim</ForeName><Initials>A</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-6282-8351</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine Yarmouk University Irbid Jordan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King Hussein Cancer Center Amman Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almdallal</LastName><ForeName>Walaa</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Faculty of Medicine Yarmouk University Irbid Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alzoubi</LastName><ForeName>Mai</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Medicine Yarmouk University Irbid Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talafha</LastName><ForeName>Lana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Faculty of Medicine Yarmouk University Irbid Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsheikh</LastName><ForeName>Ahmad M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Faculty of Medicine Yarmouk University Irbid Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faiyoumi</LastName><ForeName>Baha Aldin</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Hamad Medical Corporation Doha Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Zoubi</LastName><ForeName>Raed M</ForeName><Initials>RM</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-0548-429X</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Surgical Research Section Hamad Medical Corporation Doha Qatar.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, College of Health Sciences, QU-Health Qatar University Doha Qatar.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry Jordan University of Science and Technology Irbid Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Zoubi</LastName><ForeName>Mazhar S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-0248-4777</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine Yarmouk University Irbid Jordan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Health Sci Rep</MedlineTA><NlmUniqueID>101728855</NlmUniqueID><ISSNLinking>2398-8835</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">exercise</Keyword><Keyword MajorTopicYN="N">health</Keyword><Keyword MajorTopicYN="N">lifestyle</Keyword><Keyword MajorTopicYN="N">lockdown</Keyword><Keyword MajorTopicYN="N">physical activity</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>08</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>03</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320655</ArticleId><ArticleId IdType="doi">10.1002/hsr2.896</ArticleId><ArticleId IdType="pii">HSR2896</ArticleId><ArticleId IdType="pmc">PMC9616167</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320651</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2398-8835</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Health science reports</Title><ISOAbbreviation>Health Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Identifying unmet information needs of advanced cancer patients in Iran: An in-depth qualitative study.</ArticleTitle><Pagination><MedlinePgn>e914</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hsr2.914</ELocationID><Abstract><AbstractText Label="Background and Aims" NlmCategory="UNASSIGNED">One of the main vital needs for self-care in patients with advanced cancer is information need. Meeting this need has significant positive effects on improving their treatment and care. This study was conducted to identify the unmet information needs of patients with advanced cancer in Iran.</AbstractText><AbstractText Label="Methods" NlmCategory="UNASSIGNED">This exploratory study was performed from July to February 2021 in the Kerman University of Medical Sciences cancer treatment centers. Oncologists selected eligible patients by purposeful sampling method. Semistructured and in-depth interviews were conducted with selected patients to collect data. Interviews continued until data saturation. Each interview was audio-recorded and transcribed verbatim.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">In the interviews, 15 patients with advanced cancer ranging in age from 43 to 65 years participated. The most common type of cancer in women was breast (71.4%) and prostate (50%) in men. The two main categories of "types of unmet information needs" and "reasons for not meeting information needs" were extracted from the analysis of patient interviews, with six and four subcategories, respectively.</AbstractText><AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Cancer patients had a large number of unmet information needs. At the time of identifying the unmet information needs of cancer patients, the basic reasons for not meeting these needs should also be considered because cultural differences and social gaps in societies are inevitable.</AbstractText><CopyrightInformation>© 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amiri</LastName><ForeName>Parasto</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-5654-1987</Identifier><AffiliationInfo><Affiliation>Medical Informatics Research Center, Institute for Futures Studies in Health Kerman University of Medical Sciences Kerman Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammadi</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Health Information Technology, Paramedical School Kermanshah University of Medical Sciences Kermanshah Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahaadinbeigy</LastName><ForeName>Kambiz</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-5430-3758</Identifier><AffiliationInfo><Affiliation>Medical Informatics Research Center, Institute for Futures Studies in Health Kerman University of Medical Sciences Kerman Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalantari Khandani</LastName><ForeName>Behjat</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Oncology, Shahid Bahonar Hospital, School of Medicine Kerman University of Medical Sciences Kerman Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maazed</LastName><ForeName>Vahid</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Hematology and Oncology, Faculty of Medicine Kerman University of Medical Sciences Kerman Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Health Sci Rep</MedlineTA><NlmUniqueID>101728855</NlmUniqueID><ISSNLinking>2398-8835</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">qualitative study</Keyword><Keyword MajorTopicYN="N">self‐care</Keyword><Keyword MajorTopicYN="N">unmet information needs</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>08</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>09</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320651</ArticleId><ArticleId IdType="doi">10.1002/hsr2.914</ArticleId><ArticleId IdType="pii">HSR2914</ArticleId><ArticleId IdType="pmc">PMC9617646</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320648</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2398-8835</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Health science reports</Title><ISOAbbreviation>Health Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Satisfaction with care provided by home-based palliative care service to the cancer patients in Dhaka City of Bangladesh: A cross-sectional study.</ArticleTitle><Pagination><MedlinePgn>e908</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hsr2.908</ELocationID><Abstract><AbstractText Label="Background and Aims" NlmCategory="UNASSIGNED">Patient satisfaction is an important quality indicator of health care service. The concept of home-based palliative care has been recently introduced in Bangladesh, but the patients' satisfaction with this care remained unexplored. This study aimed to assess the satisfaction of the cancer patients receiving this care.</AbstractText><AbstractText Label="Methods" NlmCategory="UNASSIGNED">This cross-sectional study was conducted among 51 surviving cancer patients above 18 years of age registered under the home-based care service of the Department of Palliative Medicine, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. Data were collected by face-to-face interviews using a structured questionnaire based on the FAMCARE P16 questionnaire from February to March 2019. Descriptive analysis was done for the sociodemographic and satisfaction-related indicators. A correlation matrix was done to see the correlation among the satisfaction indicators.</AbstractText><AbstractText Label="Result" NlmCategory="UNASSIGNED">The majority of the patients (88.2%) were satisfied with the service provided by the home care team. Most (76.5%) of the patients were women, and the mean age was 56.25 ± 14.8 years. The median duration of getting home-based care was 4 months. Main satisfaction indicators were-assessment of physical symptoms (70.6%), providing information about pain management (70.6%), the inclusion of the family in decision making (76.5%), coordination of care between the members of the home care team (84.3%) and availability of doctors, nurses and palliative care assistants (74.5%). A high correlation was observed between satisfaction regarding the care of physical symptoms and provision of information (<i>R</i> = 0.814, <i>p</i> &lt; 0.001). Also, satisfaction regarding the provision of information and support provided to the family is highly correlated (<i>R</i> = 0.722, <i>p</i> &lt; 0.001).</AbstractText><AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Despite the limitations, the overall satisfaction level of the patients regarding home-based palliative care services in Bangladesh is very high. Home-based palliative can be a solution to provide palliative care to patients who are unable to access institution-based care and improve their quality of life.</AbstractText><CopyrightInformation>© 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Biswas</LastName><ForeName>Jheelam</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4977-6136</Identifier><AffiliationInfo><Affiliation>Department of Noncommunicable Diseases Bangladesh University of Health Sciences (BUHS) Dhaka Bangladesh.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Palliative Medicine Bangabandhu Sheikh Mujib Medical University (BSMMU) Dhaka Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faruque</LastName><ForeName>Mithila</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4731-2824</Identifier><AffiliationInfo><Affiliation>Department of Noncommunicable Diseases Bangladesh University of Health Sciences (BUHS) Dhaka Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banik</LastName><ForeName>Palash Chandra</ForeName><Initials>PC</Initials><Identifier Source="ORCID">0000-0003-2395-9049</Identifier><AffiliationInfo><Affiliation>Department of Noncommunicable Diseases Bangladesh University of Health Sciences (BUHS) Dhaka Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Nezamuddin</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-3553-0952</Identifier><AffiliationInfo><Affiliation>Department of Palliative Medicine Bangabandhu Sheikh Mujib Medical University (BSMMU) Dhaka Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mashreky</LastName><ForeName>Saidur Rahman</ForeName><Initials>SR</Initials><Identifier Source="ORCID">0000-0001-7892-798X</Identifier><AffiliationInfo><Affiliation>Department of Noncommunicable Diseases Bangladesh University of Health Sciences (BUHS) Dhaka Bangladesh.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Health Sci Rep</MedlineTA><NlmUniqueID>101728855</NlmUniqueID><ISSNLinking>2398-8835</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bangladesh</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">home‐based palliative care</Keyword><Keyword MajorTopicYN="N">palliative care</Keyword><Keyword MajorTopicYN="N">patient satisfaction</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>07</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>09</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320648</ArticleId><ArticleId IdType="doi">10.1002/hsr2.908</ArticleId><ArticleId IdType="pii">HSR2908</ArticleId><ArticleId IdType="pmc">PMC9617647</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320634</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2639-5274</ISSN><JournalIssue CitedMedium="Internet"><Volume>2022</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Research (Washington, D.C.)</Title><ISOAbbreviation>Research (Wash D C)</ISOAbbreviation></Journal><ArticleTitle>In-Depth Metaproteomics Analysis of Oral Microbiome for Lung Cancer.</ArticleTitle><Pagination><MedlinePgn>9781578</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.34133/2022/9781578</ELocationID><Abstract><AbstractText>The human oral microbiome correlates with numerous diseases, including lung cancer. Identifying the functional changes by metaproteomics helps understand the disease-related dysbiosis, yet characterizing low-abundant bacteria is challenging. Here, we developed a free-flow isoelectric focusing electrophoresis-mass spectrometry- (FFIEF-MS-) based metaproteomics strategy to reduce host interferences and enrich low-abundant bacteria for in-depth interpretation of the oral microbiome. With our method, the number of interfering peptides decreased by 52.87%, whereas the bacterial peptides and species increased by 94.97% and 44.90%, respectively, compared to the conventional metaproteomics approach. We identified 3647 bacterial proteins, which is the most comprehensive oral metaproteomics study to date. Lung cancer-associated bacteria were validated among an independent cohort. The imbalanced <i>Fusobacterium nucleatum</i> and <i>Prevotella histicola</i> and their dysregulated functions in inhibiting immune response and maintaining cell redox homeostasis were revealed. The FFIEF-MS may serve as a valuable strategy to study the mechanisms between human diseases and microbiomes with broader applications.</AbstractText><CopyrightInformation>Copyright © 2022 Xiaoteng Jiang et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Jiang</LastName><ForeName>Xiaoteng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic &amp; Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Huiyu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic &amp; Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zeyuan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic &amp; Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Shen</ForeName><Initials>S</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-9488-0376</Identifier><AffiliationInfo><Affiliation>School of Dentistry and Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Chengxi</ForeName><Initials>C</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-3873-5112</Identifier><AffiliationInfo><Affiliation>Department of Instrument Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Hua</ForeName><Initials>H</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-2831-0436</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic &amp; Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Research (Wash D C)</MedlineTA><NlmUniqueID>101747148</NlmUniqueID><ISSNLinking>2639-5274</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>07</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320634</ArticleId><ArticleId IdType="doi">10.34133/2022/9781578</ArticleId><ArticleId IdType="pmc">PMC9590273</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320626</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2472-1972</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>26</Day></PubDate></JournalIssue><Title>Journal of the Endocrine Society</Title><ISOAbbreviation>J Endocr Soc</ISOAbbreviation></Journal><ArticleTitle>Deletion of Constitutive Androstane Receptor Led to Intestinal Alterations and Increased Imidacloprid in Murine Liver.</ArticleTitle><Pagination><MedlinePgn>bvac145</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1210/jendso/bvac145</ELocationID><Abstract><AbstractText>Imidacloprid (IMI) is the most frequently detected neonicotinoid pesticide in the environment. Despite typically low toxicity in vertebrates, IMI exposure is associated with liver and gastrointestinal toxicity. The mechanism underlying IMI toxicity in mammals is unclear. Pesticide exposure frequently activates xenobiotic nuclear receptors, such as the constitutive androstane receptor (CAR), to induce detoxification phase I and phase II genes. This study examined the role of CAR in mediating IMI off-target toxicity. Female <i>Car<sup>-/-</sup></i> and wild-type (WT) mice were orally administered imidacloprid (50 mg/kg, twice daily) for 21 days, following which serum, liver, and intestinal tissues were collected. Liver tissue analysis indicated mild inflammation and induction of detoxification gene <i>Cyp2b10</i> in IMI-exposed WT mice. The absence of CAR increased hepatic IMI accumulation. Microbiome analysis of ileal samples revealed IMI altered microbial diversity in a genotype-specific manner, with increased α-diversity in <i>Car<sup>-/-</sup></i> mice while decreased α-diversity in WT mice. We observed <i>Car<sup>-/-</sup></i> mice exhibit intestinal alterations with decreased CYP-P450 expression, blunted villi height, and increased small intestine length and weight independent of IMI exposure. Our results suggest that IMI is not overtly toxic. However, the absence of xenobiotic nuclear receptor CAR allows increased accumulation of IMI in the liver and disrupts the villi structure and <i>Cyp</i> gene expression in the intestine.</AbstractText><CopyrightInformation>© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sen</LastName><ForeName>Anushna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Toxicology Training Program, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goforth</LastName><ForeName>Madison</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Toxicology Training Program, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Animal and Comparative Biomedical Sciences, University of Arizona, Tucson, AZ 85721, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Kerry K</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>School of Animal and Comparative Biomedical Sciences, University of Arizona, Tucson, AZ 85721, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anakk</LastName><ForeName>Sayeepriyadarshini</ForeName><Initials>S</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-2819-695X</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Toxicology Training Program, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center at Illinois, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Endocr Soc</MedlineTA><NlmUniqueID>101697997</NlmUniqueID><ISSNLinking>2472-1972</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">gastrointestinal tract</Keyword><Keyword MajorTopicYN="N">imidacloprid</Keyword><Keyword MajorTopicYN="N">microbiome</Keyword><Keyword MajorTopicYN="N">neonicotinoids</Keyword><Keyword MajorTopicYN="N">nuclear receptor</Keyword><Keyword MajorTopicYN="N">toxicity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>04</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320626</ArticleId><ArticleId IdType="doi">10.1210/jendso/bvac145</ArticleId><ArticleId IdType="pii">bvac145</ArticleId><ArticleId IdType="pmc">PMC9597654</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36320614</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1728-6263</ISSN><JournalIssue CitedMedium="Print"><PubDate><Year>2022</Year><Month>Oct</Month><Day>27</Day></PubDate></JournalIssue><Title>Journal fur gastroenterologische und hepatologische Erkrankungen</Title><ISOAbbreviation>J Gastroenterol Hepatol Erkrank</ISOAbbreviation></Journal><ArticleTitle>[Quality Assurance of Screening Colonoscopy in Austria and Europe].</ArticleTitle><Pagination><MedlinePgn>1-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s41971-022-00137-w</ELocationID><Abstract><AbstractText>Screening colonoscopy, an efficient tool for reducing the incidence and mortality of colorectal cancer, is only effective if it is performed under high quality standards. The European Society for Gastrointestinal Endoscopy has identified the following key performance measures for screening: adenoma detection rate, cecal intubation rate, and adequate bowel preparation rate. The Quality Certificate for Colorectal Cancer Screening-which was launched as a quality assurance program on a voluntary basis by the Austrian Society of Gastroenterology and Hepatology together with the umbrella organization of Austrian social insurance carriers and the Austrian Cancer Aid for endoscopists throughout Austria-monitors these quality parameters. The aim is to achieve the highest standards of colorectal cancer screening in order to achieve the best outcomes for patients. Interest in quality-assured screening colonoscopy is also high throughout Europe: many countries, e.g., the Netherlands, Norway, and the United Kingdom, have programs to monitor and improve the quality of screening.</AbstractText><CopyrightInformation>© The Author(s) 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zessner-Spitzenberg</LastName><ForeName>Jasmin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Klinische Abteilung für Gastroenterologie und Hepatologie, Univ. Klinik für Innere Medizin III, Medizinische Universität Wien, Währinger Gürtel 18-20, 7i, 1090 Wien, Österreich.</Affiliation><Identifier Source="GRID">grid.22937.3d</Identifier><Identifier Source="ISNI">0000 0000 9259 8492</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Arbeitsgruppe Qualitätssicherung, Österreichische Gesellschaft für Gastroenterologie und Hepatologie, Wien, Österreich.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waldmann</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Klinische Abteilung für Gastroenterologie und Hepatologie, Univ. Klinik für Innere Medizin III, Medizinische Universität Wien, Währinger Gürtel 18-20, 7i, 1090 Wien, Österreich.</Affiliation><Identifier Source="GRID">grid.22937.3d</Identifier><Identifier Source="ISNI">0000 0000 9259 8492</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Arbeitsgruppe Qualitätssicherung, Österreichische Gesellschaft für Gastroenterologie und Hepatologie, Wien, Österreich.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferlitsch</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Klinische Abteilung für Gastroenterologie und Hepatologie, Univ. Klinik für Innere Medizin III, Medizinische Universität Wien, Währinger Gürtel 18-20, 7i, 1090 Wien, Österreich.</Affiliation><Identifier Source="GRID">grid.22937.3d</Identifier><Identifier Source="ISNI">0000 0000 9259 8492</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Arbeitsgruppe Qualitätssicherung, Österreichische Gesellschaft für Gastroenterologie und Hepatologie, Wien, Österreich.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Abteilung für Innere Medizin II, Gastroenterologie und Hepatologie, Evangelisches Krankenhaus Wien, Wien, Österreich.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Qualitätssicherung in der Vorsorgekoloskopie in Österreich und europaweit.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Austria</Country><MedlineTA>J Gastroenterol Hepatol Erkrank</MedlineTA><NlmUniqueID>101245359</NlmUniqueID><ISSNLinking>1728-6263</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Colonoscopy</Keyword><Keyword MajorTopicYN="N">Colorectal neoplasms</Keyword><Keyword MajorTopicYN="N">Diagnostic screening programs</Keyword><Keyword MajorTopicYN="N">Early detection of cancer</Keyword><Keyword MajorTopicYN="N">Quality assurance, health care</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>09</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320614</ArticleId><ArticleId IdType="doi">10.1007/s41971-022-00137-w</ArticleId><ArticleId IdType="pii">137</ArticleId><ArticleId IdType="pmc">PMC9610308</ArticleId></ArticleIdList><?pmcsd ?></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320608</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2214-0883</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of pharmaceutical analysis</Title><ISOAbbreviation>J Pharm Anal</ISOAbbreviation></Journal><ArticleTitle>Sensitive detection of microRNAs using polyadenine-mediated fluorescent spherical nucleic acids and a microfluidic electrokinetic signal amplification chip.</ArticleTitle><Pagination><MedlinePgn>808-813</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpha.2022.05.009</ELocationID><Abstract><AbstractText>The identification of tumor-related microRNAs (miRNAs) exhibits excellent promise for the early diagnosis of cancer and other bioanalytical applications. Therefore, we developed a sensitive and efficient biosensor using polyadenine (polyA)-mediated fluorescent spherical nucleic acid (FSNA) for miRNA analysis based on strand displacement reactions on gold nanoparticle (AuNP) surfaces and electrokinetic signal amplification (ESA) on a microfluidic chip. In this FSNA, polyA-DNA biosensor was anchored on AuNP surfaces via intrinsic affinity between adenine and Au. The upright conformational polyA-DNA recognition block hybridized with 6-carboxyfluorescein-labeled reporter-DNA, resulting in fluorescence quenching of FSNA probes induced by AuNP-based resonance energy transfer. Reporter DNA was replaced in the presence of target miRNA, leading to the recovery of reporter-DNA fluorescence. Subsequently, reporter-DNAs were accumulated and detected in the front of with Nafion membrane in the microchannel by ESA. Our method showed high selectivity and sensitivity with a limit of detection of 1.3 pM. This method could also be used to detect miRNA-21 in human serum and urine samples, with recoveries of 104.0%-113.3% and 104.9%-108.0%, respectively. Furthermore, we constructed a chip with three parallel channels for the simultaneous detection of multiple tumor-related miRNAs (miRNA-21, miRNA-141, and miRNA-375), which increased the detection efficiency. Our universal method can be applied to other DNA/RNA analyses by altering recognition sequences.</AbstractText><CopyrightInformation>© 2022 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Runhui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Haoyi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Second Clinical Medical School, Southern Medical University, Guangzhou, 510515, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khoo</LastName><ForeName>Bee Luan</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, City University of Hong Kong, Hong Kong, 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xinguo</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jincheng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Huaze</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lihong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Pharm Anal</MedlineTA><NlmUniqueID>101579451</NlmUniqueID><ISSNLinking>2214-0883</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Electrokinetic signal amplification</Keyword><Keyword MajorTopicYN="N">Gold nanoparticle</Keyword><Keyword MajorTopicYN="N">MicroRNAs</Keyword><Keyword MajorTopicYN="N">Microfluidic chip</Keyword><Keyword MajorTopicYN="N">Polyadenine-DNA</Keyword></KeywordList><CoiStatement>The authors declare that there are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>02</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>05</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>05</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320608</ArticleId><ArticleId IdType="doi">10.1016/j.jpha.2022.05.009</ArticleId><ArticleId IdType="pii">S2095-1779(22)00052-1</ArticleId><ArticleId IdType="pmc">PMC9615518</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320602</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2214-0883</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of pharmaceutical analysis</Title><ISOAbbreviation>J Pharm Anal</ISOAbbreviation></Journal><ArticleTitle>The dynamic metabolic profile of Qi-Yu-San-Long decoction in rat urine using UPLC-QTOF-MS<sup>E</sup> coupled with a post-targeted screening strategy.</ArticleTitle><Pagination><MedlinePgn>755-765</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpha.2022.05.005</ELocationID><Abstract><AbstractText>Qi-Yu-San-Long decoction (QYSLD) is a traditional Chinese medicine that has been clinically used in the treatment of non-small-cell lung cancer (NSCLC) for more than 20 years. However, to date, metabolic-related studies on QYSLD have not been performed. In this study, a post-targeted screening strategy based on ultra-performance liquid chromatography coupled with quadrupole time-of-flight full information tandem mass spectrometry (UPLC-QTOF-MS<sup>E</sup>) was developed to identify QYSLD-related xenobiotics in rat urine. The chemical compound database of QYSLD constituents was established from previous research, and metabolites related to these compounds were predicted in combination with their possible metabolic pathways. The metabolites were identified by extracted ion chromatograms using predicted <i>m</i>/<i>z</i> values as well as retention time, excimer ions, and fragmentation behavior. Overall, 85 QYSLD-related xenobiotics (20 prototype compounds and 65 metabolites) were characterized from rat urine. The main metabolic reactions and elimination features of QYSLD included oxidation, reduction, decarboxylation, hydrolysis, demethylation, glucuronidation, sulfation, methylation, deglycosylation, acetylation, and associated combination reactions. Of the identified molecules, 14 prototype compounds and 58 metabolites were slowly eliminated, thus accumulating in vivo over an extended period, while five prototypes and two metabolites were present in vivo for a short duration. Furthermore, one prototype and five metabolites underwent the process of "appearing-disappearing-reappearing" in vivo. Overall, the metabolic profile and characteristics of QYSLD in rat urine were determined, which is useful in elucidating the active components of the decoction in vivo, thus providing the basis for studying its mechanism of action.</AbstractText><CopyrightInformation>© 2022 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Key Laboratory of Xin'an Medicine, Ministry of Education, Anhui University of Chinese Medicine, Hefei, 230038, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Key Laboratory of Xin'an Medicine, Ministry of Education, Anhui University of Chinese Medicine, Hefei, 230038, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ruijuan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Key Laboratory of Xin'an Medicine, Ministry of Education, Anhui University of Chinese Medicine, Hefei, 230038, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Mengwen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Key Laboratory of Xin'an Medicine, Ministry of Education, Anhui University of Chinese Medicine, Hefei, 230038, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>An</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Key Laboratory of Xin'an Medicine, Ministry of Education, Anhui University of Chinese Medicine, Hefei, 230038, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zegeng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Key Laboratory of Xin'an Medicine, Ministry of Education, Anhui University of Chinese Medicine, Hefei, 230038, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Key Laboratory of Xin'an Medicine, Ministry of Education, Anhui University of Chinese Medicine, Hefei, 230038, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Pharm Anal</MedlineTA><NlmUniqueID>101579451</NlmUniqueID><ISSNLinking>2214-0883</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dynamic metabolic profile</Keyword><Keyword MajorTopicYN="N">Post-targeted screening strategy</Keyword><Keyword MajorTopicYN="N">Qi-Yu-San-Long decoction</Keyword><Keyword MajorTopicYN="N">UPLC-QTOF-MSE</Keyword></KeywordList><CoiStatement>The authors declare that there are no conﬂicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>04</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>05</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320602</ArticleId><ArticleId IdType="doi">10.1016/j.jpha.2022.05.005</ArticleId><ArticleId IdType="pii">S2095-1779(22)00048-X</ArticleId><ArticleId IdType="pmc">PMC9615542</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36320579</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2041-6520</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>38</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>Chemical science</Title><ISOAbbreviation>Chem Sci</ISOAbbreviation></Journal><ArticleTitle>A platinum-ruthenium hybrid prodrug with multi-enzymatic activities for chemo-catalytic therapy of hypoxic tumors.</ArticleTitle><Pagination><MedlinePgn>11360-11367</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d2sc03375e</ELocationID><Abstract><AbstractText>Regulation of tumor hypoxia and redox homeostasis is a promising strategy for cancer therapy. Nanocatalytic medicine has played more and more important roles in this field because it can cleverly convert the efficiency and selectivity of catalysis into high therapeutic efficiency. Herein, we developed a platinum(iv)-ruthenium hybrid prodrug, named as Pt-Ru, for efficient chemo-catalytic synergistic therapy of hypoxic tumors. The ruthenium hybridization endowed the Pt(iv) prodrug with multi-enzyme catalytic activity, that is, mimicking catalase (CAT) to generate O<sub>2</sub> <i>in situ</i>, mimicking peroxidase (POD) to produce reactive oxygen species, and mimicking glutathione peroxidase (GPx) to deplete GSH, thus effectively overcoming tumor hypoxia and cisplatin resistance. As a result, Pt-Ru treatment led to a superior anticancer efficacy to cisplatin both <i>in vitro</i> and <i>in vivo</i>. This work suggested redox homeostasis regulation as a tantalizing angle for developing the next generation of platinum drugs.</AbstractText><CopyrightInformation>This journal is © The Royal Society of Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Gang-Gang</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Sun Yat-Sen University Guangzhou 510275 P. R. China caoqian3@mail.sysu.edu.cn cesmzw@mail.sysu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Chemistry and Chemical Engineering, Anhui University of Technology Ma'anshan Anhui 243002 P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Xu-Xian</ForeName><Initials>XX</Initials><AffiliationInfo><Affiliation>MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Sun Yat-Sen University Guangzhou 510275 P. R. China caoqian3@mail.sysu.edu.cn cesmzw@mail.sysu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Bing-Bing</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Sun Yat-Sen University Guangzhou 510275 P. R. China caoqian3@mail.sysu.edu.cn cesmzw@mail.sysu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Zheng-Yin</ForeName><Initials>ZY</Initials><AffiliationInfo><Affiliation>MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Sun Yat-Sen University Guangzhou 510275 P. R. China caoqian3@mail.sysu.edu.cn cesmzw@mail.sysu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-2040-2942</Identifier><AffiliationInfo><Affiliation>MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Sun Yat-Sen University Guangzhou 510275 P. R. China caoqian3@mail.sysu.edu.cn cesmzw@mail.sysu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Zong-Wan</ForeName><Initials>ZW</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-7131-1154</Identifier><AffiliationInfo><Affiliation>MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Sun Yat-Sen University Guangzhou 510275 P. R. China caoqian3@mail.sysu.edu.cn cesmzw@mail.sysu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Chem Sci</MedlineTA><NlmUniqueID>101545951</NlmUniqueID><ISSNLinking>2041-6520</ISSNLinking></MedlineJournalInfo><CoiStatement>There are no conflicts to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>06</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>08</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>2</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36320579</ArticleId><ArticleId IdType="doi">10.1039/d2sc03375e</ArticleId><ArticleId IdType="pii">d2sc03375e</ArticleId><ArticleId IdType="pmc">PMC9533400</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>